Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Intraoperative radiotherapy: review of techniques and results

Identifieur interne : 004979 ( Pmc/Corpus ); précédent : 004978; suivant : 004980

Intraoperative radiotherapy: review of techniques and results

Auteurs : Avinash Pilar ; Meetakshi Gupta ; Sarbani Ghosh Laskar ; Siddhartha Laskar

Source :

RBID : PMC:5493441

Abstract

Intraoperative radiotherapy (IORT) is a technique that involves precise delivery of a large dose of ionising radiation to the tumour or tumour bed during surgery. Direct visualisation of the tumour bed and ability to space out the normal tissues from the tumour bed allows maximisation of the dose to the tumour while minimising the dose to normal tissues. This results in an improved therapeutic ratio with IORT. Although it was introduced in the 1960s, it has seen a resurgence of popularity with the introduction of self-shielding mobile linear accelerators and low-kV IORT devices, which by eliminating the logistical issues of transport of the patient during surgery for radiotherapy or building a shielded operating room, has enabled its wider use in the community.

Electrons, low-kV X-rays and HDR brachytherapy are all different methods of IORT in current clinical use. Each method has its own unique set of advantages and disadvantages, its own set of indications where one may be better suited than the other, and each requires a specific kind of expertise.

IORT has demonstrated its efficacy in a wide variety of intra-abdominal tumours, recurrent colorectal cancers, recurrent gynaecological cancers, and soft-tissue tumours. Recently, it has emerged as an attractive treatment option for selected, early-stage breast cancer, owing to the ability to complete the entire course of radiotherapy during surgery. IORT has been used in a multitude of roles across these sites, for dose escalation (retroperitoneal sarcoma), EBRT dose de-escalation (paediatric tumours), as sole radiation modality (early breast cancers) and as a re-irradiation modality (recurrent rectal and gynaecological cancers).

This article aims to provide a review of the rationale, techniques, and outcomes for IORT across different sites relevant to current clinical practice.


Url:
DOI: 10.3332/ecancer.2017.750
PubMed: 28717396
PubMed Central: 5493441

Links to Exploration step

PMC:5493441

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Intraoperative radiotherapy: review of techniques and results</title>
<author>
<name sortKey="Pilar, Avinash" sort="Pilar, Avinash" uniqKey="Pilar A" first="Avinash" last="Pilar">Avinash Pilar</name>
</author>
<author>
<name sortKey="Gupta, Meetakshi" sort="Gupta, Meetakshi" uniqKey="Gupta M" first="Meetakshi" last="Gupta">Meetakshi Gupta</name>
</author>
<author>
<name sortKey="Ghosh Laskar, Sarbani" sort="Ghosh Laskar, Sarbani" uniqKey="Ghosh Laskar S" first="Sarbani" last="Ghosh Laskar">Sarbani Ghosh Laskar</name>
</author>
<author>
<name sortKey="Laskar, Siddhartha" sort="Laskar, Siddhartha" uniqKey="Laskar S" first="Siddhartha" last="Laskar">Siddhartha Laskar</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">28717396</idno>
<idno type="pmc">5493441</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493441</idno>
<idno type="RBID">PMC:5493441</idno>
<idno type="doi">10.3332/ecancer.2017.750</idno>
<date when="2017">2017</date>
<idno type="wicri:Area/Pmc/Corpus">004979</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">004979</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Intraoperative radiotherapy: review of techniques and results</title>
<author>
<name sortKey="Pilar, Avinash" sort="Pilar, Avinash" uniqKey="Pilar A" first="Avinash" last="Pilar">Avinash Pilar</name>
</author>
<author>
<name sortKey="Gupta, Meetakshi" sort="Gupta, Meetakshi" uniqKey="Gupta M" first="Meetakshi" last="Gupta">Meetakshi Gupta</name>
</author>
<author>
<name sortKey="Ghosh Laskar, Sarbani" sort="Ghosh Laskar, Sarbani" uniqKey="Ghosh Laskar S" first="Sarbani" last="Ghosh Laskar">Sarbani Ghosh Laskar</name>
</author>
<author>
<name sortKey="Laskar, Siddhartha" sort="Laskar, Siddhartha" uniqKey="Laskar S" first="Siddhartha" last="Laskar">Siddhartha Laskar</name>
</author>
</analytic>
<series>
<title level="j">ecancermedicalscience</title>
<idno type="eISSN">1754-6605</idno>
<imprint>
<date when="2017">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>Intraoperative radiotherapy (IORT) is a technique that involves precise delivery of a large dose of ionising radiation to the tumour or tumour bed during surgery. Direct visualisation of the tumour bed and ability to space out the normal tissues from the tumour bed allows maximisation of the dose to the tumour while minimising the dose to normal tissues. This results in an improved therapeutic ratio with IORT. Although it was introduced in the 1960s, it has seen a resurgence of popularity with the introduction of self-shielding mobile linear accelerators and low-kV IORT devices, which by eliminating the logistical issues of transport of the patient during surgery for radiotherapy or building a shielded operating room, has enabled its wider use in the community.</p>
<p>Electrons, low-kV X-rays and HDR brachytherapy are all different methods of IORT in current clinical use. Each method has its own unique set of advantages and disadvantages, its own set of indications where one may be better suited than the other, and each requires a specific kind of expertise.</p>
<p>IORT has demonstrated its efficacy in a wide variety of intra-abdominal tumours, recurrent colorectal cancers, recurrent gynaecological cancers, and soft-tissue tumours. Recently, it has emerged as an attractive treatment option for selected, early-stage breast cancer, owing to the ability to complete the entire course of radiotherapy during surgery. IORT has been used in a multitude of roles across these sites, for dose escalation (retroperitoneal sarcoma), EBRT dose de-escalation (paediatric tumours), as sole radiation modality (early breast cancers) and as a re-irradiation modality (recurrent rectal and gynaecological cancers).</p>
<p>This article aims to provide a review of the rationale, techniques, and outcomes for IORT across different sites relevant to current clinical practice.</p>
</div>
</front>
<back>
<div1 type="bibliography">
<listBibl>
<biblStruct>
<analytic>
<author>
<name sortKey="Abe, M" uniqKey="Abe M">M Abe</name>
</author>
<author>
<name sortKey="Shibamoto, Y" uniqKey="Shibamoto Y">Y Shibamoto</name>
</author>
<author>
<name sortKey="Ono, K" uniqKey="Ono K">K Ono</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Abe, M" uniqKey="Abe M">M Abe</name>
</author>
<author>
<name sortKey="Takahashi, M" uniqKey="Takahashi M">M Takahashi</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Abe, Mfm" uniqKey="Abe M">MFM Abe</name>
</author>
<author>
<name sortKey="Yaniano, K" uniqKey="Yaniano K">K Yaniano</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Abe, M" uniqKey="Abe M">M Abe</name>
</author>
<author>
<name sortKey="Takahashi, M" uniqKey="Takahashi M">M Takahashi</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Goldson, A" uniqKey="Goldson A">A Goldson</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Veronesi U, Or" uniqKey="Veronesi U O">OR Veronesi U</name>
</author>
<author>
<name sortKey="Luini, A" uniqKey="Luini A">A Luini</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Harrison Lb, Ew" uniqKey="Harrison Lb E">EW Harrison LB</name>
</author>
<author>
<name sortKey="Anderson, Ll" uniqKey="Anderson L">LL Anderson</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Harrison Lb, Ew" uniqKey="Harrison Lb E">EW Harrison LB</name>
</author>
<author>
<name sortKey="Anderson, Ll" uniqKey="Anderson L">LL Anderson</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Bratengeier K, Kt" uniqKey="Bratengeier K K">KT Bratengeier K</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Huber Ft, Sr" uniqKey="Huber Ft S">SR Huber FT</name>
</author>
<author>
<name sortKey="Zimmerman, F" uniqKey="Zimmerman F">F Zimmerman</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Bernier, J" uniqKey="Bernier J">J Bernier</name>
</author>
<author>
<name sortKey="Cooper, Js" uniqKey="Cooper J">JS Cooper</name>
</author>
<author>
<name sortKey="Pajak, Tf" uniqKey="Pajak T">TF Pajak</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Bernier, J" uniqKey="Bernier J">J Bernier</name>
</author>
<author>
<name sortKey="Domenge, C" uniqKey="Domenge C">C Domenge</name>
</author>
<author>
<name sortKey="Ozsahin, M" uniqKey="Ozsahin M">M Ozsahin</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Cooper, Js" uniqKey="Cooper J">JS Cooper</name>
</author>
<author>
<name sortKey="Zhang, Q" uniqKey="Zhang Q">Q Zhang</name>
</author>
<author>
<name sortKey="Pajak, Tf" uniqKey="Pajak T">TF Pajak</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Pignon, Jp" uniqKey="Pignon J">JP Pignon</name>
</author>
<author>
<name sortKey="Bourhis, J" uniqKey="Bourhis J">J Bourhis</name>
</author>
<author>
<name sortKey="Domenge, C" uniqKey="Domenge C">C Domenge</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Janot, F" uniqKey="Janot F">F Janot</name>
</author>
<author>
<name sortKey="De Raucourt, D" uniqKey="De Raucourt D">D de Raucourt</name>
</author>
<author>
<name sortKey="Benhamou, E" uniqKey="Benhamou E">E Benhamou</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Chen, Am" uniqKey="Chen A">AM Chen</name>
</author>
<author>
<name sortKey="Bucci, Mk" uniqKey="Bucci M">MK Bucci</name>
</author>
<author>
<name sortKey="Singer, Mi" uniqKey="Singer M">MI Singer</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Nag, S" uniqKey="Nag S">S Nag</name>
</author>
<author>
<name sortKey="Schuller, De" uniqKey="Schuller D">DE Schuller</name>
</author>
<author>
<name sortKey="Martinez Monge, R" uniqKey="Martinez Monge R">R Martinez-Monge</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Perry, Dj" uniqKey="Perry D">DJ Perry</name>
</author>
<author>
<name sortKey="Chan, K" uniqKey="Chan K">K Chan</name>
</author>
<author>
<name sortKey="Wolden, S" uniqKey="Wolden S">S Wolden</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Scala, Lm" uniqKey="Scala L">LM Scala</name>
</author>
<author>
<name sortKey="Hu, K" uniqKey="Hu K">K Hu</name>
</author>
<author>
<name sortKey="Urken, Ml" uniqKey="Urken M">ML Urken</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Zeidan, Yh" uniqKey="Zeidan Y">YH Zeidan</name>
</author>
<author>
<name sortKey="Shiue, K" uniqKey="Shiue K">K Shiue</name>
</author>
<author>
<name sortKey="Weed, D" uniqKey="Weed D">D Weed</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Zeidan, Yh" uniqKey="Zeidan Y">YH Zeidan</name>
</author>
<author>
<name sortKey="Yeh, A" uniqKey="Yeh A">A Yeh</name>
</author>
<author>
<name sortKey="Weed, D" uniqKey="Weed D">D Weed</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Pinheiro, Ad" uniqKey="Pinheiro A">AD Pinheiro</name>
</author>
<author>
<name sortKey="Foote, Rl" uniqKey="Foote R">RL Foote</name>
</author>
<author>
<name sortKey="Mccaffrey, Tv" uniqKey="Mccaffrey T">TV McCaffrey</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Vaidya Js, Bm" uniqKey="Vaidya Js B">BM Vaidya JS</name>
</author>
<author>
<name sortKey="Tobias, Js" uniqKey="Tobias J">JS Tobias</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Vaidya Js, Bm" uniqKey="Vaidya Js B">BM Vaidya JS</name>
</author>
<author>
<name sortKey="Tobias, Js" uniqKey="Tobias J">JS Tobias</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Veronesi U, Or" uniqKey="Veronesi U O">OR Veronesi U</name>
</author>
<author>
<name sortKey="Luini, A" uniqKey="Luini A">A Luini</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Vaidya, Js" uniqKey="Vaidya J">JS Vaidya</name>
</author>
<author>
<name sortKey="Wenz, F" uniqKey="Wenz F">F Wenz</name>
</author>
<author>
<name sortKey="Bulsara, M" uniqKey="Bulsara M">M Bulsara</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Veronesi, U" uniqKey="Veronesi U">U Veronesi</name>
</author>
<author>
<name sortKey="Orecchia, R" uniqKey="Orecchia R">R Orecchia</name>
</author>
<author>
<name sortKey="Maisonneuve, P" uniqKey="Maisonneuve P">P Maisonneuve</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Cuzick J, Sh" uniqKey="Cuzick J S">SH Cuzick J</name>
</author>
<author>
<name sortKey="Peto, R" uniqKey="Peto R">R Peto</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Harness, Jk" uniqKey="Harness J">JK Harness</name>
</author>
<author>
<name sortKey="Silverstein, Mj" uniqKey="Silverstein M">MJ Silverstein</name>
</author>
<author>
<name sortKey="Wazer, De" uniqKey="Wazer D">DE Wazer</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Mackenzie, P" uniqKey="Mackenzie P">P Mackenzie</name>
</author>
<author>
<name sortKey="Fyles, A" uniqKey="Fyles A">A Fyles</name>
</author>
<author>
<name sortKey="Chung, C" uniqKey="Chung C">C Chung</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Yarnold, J" uniqKey="Yarnold J">J Yarnold</name>
</author>
<author>
<name sortKey="Offersen, Bv" uniqKey="Offersen B">BV Offersen</name>
</author>
<author>
<name sortKey="Olivotto, I" uniqKey="Olivotto I">I Olivotto</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Cuzick, J" uniqKey="Cuzick J">J Cuzick</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Haviland, Js" uniqKey="Haviland J">JS Haviland</name>
</author>
<author>
<name sortKey="A Hern, R" uniqKey="A Hern R">R A'Hern</name>
</author>
<author>
<name sortKey="Bentzen, Sm" uniqKey="Bentzen S">SM Bentzen</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Silverstein, Mj" uniqKey="Silverstein M">MJ Silverstein</name>
</author>
<author>
<name sortKey="Fastner, G" uniqKey="Fastner G">G Fastner</name>
</author>
<author>
<name sortKey="Maluta, S" uniqKey="Maluta S">S Maluta</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Silverstein, Mj" uniqKey="Silverstein M">MJ Silverstein</name>
</author>
<author>
<name sortKey="Fastner, G" uniqKey="Fastner G">G Fastner</name>
</author>
<author>
<name sortKey="Maluta, S" uniqKey="Maluta S">S Maluta</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Leonardi, Mc" uniqKey="Leonardi M">MC Leonardi</name>
</author>
<author>
<name sortKey="Maisonneuve, P" uniqKey="Maisonneuve P">P Maisonneuve</name>
</author>
<author>
<name sortKey="Mastropasqua, Mg" uniqKey="Mastropasqua M">MG Mastropasqua</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Leonardi, Mc" uniqKey="Leonardi M">MC Leonardi</name>
</author>
<author>
<name sortKey="Maisonneuve, P" uniqKey="Maisonneuve P">P Maisonneuve</name>
</author>
<author>
<name sortKey="Mastropasqua, Mg" uniqKey="Mastropasqua M">MG Mastropasqua</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Smith, Bd" uniqKey="Smith B">BD Smith</name>
</author>
<author>
<name sortKey="Arthur, Dw" uniqKey="Arthur D">DW Arthur</name>
</author>
<author>
<name sortKey="Buchholz, Ta" uniqKey="Buchholz T">TA Buchholz</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Polgar, C" uniqKey="Polgar C">C Polgar</name>
</author>
<author>
<name sortKey="Van Limbergen, E" uniqKey="Van Limbergen E">E Van Limbergen</name>
</author>
<author>
<name sortKey="Potter, R" uniqKey="Potter R">R Potter</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Maluta, S" uniqKey="Maluta S">S Maluta</name>
</author>
<author>
<name sortKey="Dall Oglio, S" uniqKey="Dall Oglio S">S Dall'Oglio</name>
</author>
<author>
<name sortKey="Goer, Da" uniqKey="Goer D">DA Goer</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Fastner, G" uniqKey="Fastner G">G Fastner</name>
</author>
<author>
<name sortKey="Sedlmayer, F" uniqKey="Sedlmayer F">F Sedlmayer</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Vaidya, Js" uniqKey="Vaidya J">JS Vaidya</name>
</author>
<author>
<name sortKey="Baum, M" uniqKey="Baum M">M Baum</name>
</author>
<author>
<name sortKey="Tobias, Js" uniqKey="Tobias J">JS Tobias</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Blank, E" uniqKey="Blank E">E Blank</name>
</author>
<author>
<name sortKey="Kraus Tiefenbacher, U" uniqKey="Kraus Tiefenbacher U">U Kraus-Tiefenbacher</name>
</author>
<author>
<name sortKey="Welzel, G" uniqKey="Welzel G">G Welzel</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Malter, W" uniqKey="Malter W">W Malter</name>
</author>
<author>
<name sortKey="Puppe, J" uniqKey="Puppe J">J Puppe</name>
</author>
<author>
<name sortKey="Rogee, K" uniqKey="Rogee K">K Rogee</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Malter, W" uniqKey="Malter W">W Malter</name>
</author>
<author>
<name sortKey="Kirn, V" uniqKey="Kirn V">V Kirn</name>
</author>
<author>
<name sortKey="Mallmann, P" uniqKey="Mallmann P">P Mallmann</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Braendengen, M" uniqKey="Braendengen M">M Braendengen</name>
</author>
<author>
<name sortKey="Tveit, Km" uniqKey="Tveit K">KM Tveit</name>
</author>
<author>
<name sortKey="Berglund, A" uniqKey="Berglund A">A Berglund</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Frykholm, Gj" uniqKey="Frykholm G">GJ Frykholm</name>
</author>
<author>
<name sortKey="Pahlman, L" uniqKey="Pahlman L">L Pahlman</name>
</author>
<author>
<name sortKey="Glimelius, B" uniqKey="Glimelius B">B Glimelius</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Calvo, Fa" uniqKey="Calvo F">FA Calvo</name>
</author>
<author>
<name sortKey="Gomez Espi, M" uniqKey="Gomez Espi M">M Gomez-Espi</name>
</author>
<author>
<name sortKey="Diaz Gonzalez, Ja" uniqKey="Diaz Gonzalez J">JA Diaz-Gonzalez</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Mathis, Kl" uniqKey="Mathis K">KL Mathis</name>
</author>
<author>
<name sortKey="Nelson, H" uniqKey="Nelson H">H Nelson</name>
</author>
<author>
<name sortKey="Pemberton, Jh" uniqKey="Pemberton J">JH Pemberton</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Minsky, Bd" uniqKey="Minsky B">BD Minsky</name>
</author>
<author>
<name sortKey="Cohen, Am" uniqKey="Cohen A">AM Cohen</name>
</author>
<author>
<name sortKey="Enker, We" uniqKey="Enker W">WE Enker</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Ratto, C" uniqKey="Ratto C">C Ratto</name>
</author>
<author>
<name sortKey="Valentini, V" uniqKey="Valentini V">V Valentini</name>
</author>
<author>
<name sortKey="Morganti, Ag" uniqKey="Morganti A">AG Morganti</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Sadahiro, S" uniqKey="Sadahiro S">S Sadahiro</name>
</author>
<author>
<name sortKey="Suzuki, T" uniqKey="Suzuki T">T Suzuki</name>
</author>
<author>
<name sortKey="Ishikawa, K" uniqKey="Ishikawa K">K Ishikawa</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Ferenschild, Ft" uniqKey="Ferenschild F">FT Ferenschild</name>
</author>
<author>
<name sortKey="Vermaas, M" uniqKey="Vermaas M">M Vermaas</name>
</author>
<author>
<name sortKey="Nuyttens, Jj" uniqKey="Nuyttens J">JJ Nuyttens</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Roeder, F" uniqKey="Roeder F">F Roeder</name>
</author>
<author>
<name sortKey="Treiber, M" uniqKey="Treiber M">M Treiber</name>
</author>
<author>
<name sortKey="Oertel, S" uniqKey="Oertel S">S Oertel</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Masaki, T" uniqKey="Masaki T">T Masaki</name>
</author>
<author>
<name sortKey="Takayama, M" uniqKey="Takayama M">M Takayama</name>
</author>
<author>
<name sortKey="Matsuoka, H" uniqKey="Matsuoka H">H Matsuoka</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Valentini, V" uniqKey="Valentini V">V Valentini</name>
</author>
<author>
<name sortKey="Coco, C" uniqKey="Coco C">C Coco</name>
</author>
<author>
<name sortKey="Rizzo, G" uniqKey="Rizzo G">G Rizzo</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Dubois, Jb" uniqKey="Dubois J">JB Dubois</name>
</author>
<author>
<name sortKey="Bussieres, E" uniqKey="Bussieres E">E Bussieres</name>
</author>
<author>
<name sortKey="Richaud, P" uniqKey="Richaud P">P Richaud</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Kusters, M" uniqKey="Kusters M">M Kusters</name>
</author>
<author>
<name sortKey="Valentini, V" uniqKey="Valentini V">V Valentini</name>
</author>
<author>
<name sortKey="Calvo, Fa" uniqKey="Calvo F">FA Calvo</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Sole, Cv" uniqKey="Sole C">CV Sole</name>
</author>
<author>
<name sortKey="Calvo, Fa" uniqKey="Calvo F">FA Calvo</name>
</author>
<author>
<name sortKey="Serrano, J" uniqKey="Serrano J">J Serrano</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Holman, Fa" uniqKey="Holman F">FA Holman</name>
</author>
<author>
<name sortKey="Haddock, Mg" uniqKey="Haddock M">MG Haddock</name>
</author>
<author>
<name sortKey="Gunderson, Ll" uniqKey="Gunderson L">LL Gunderson</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Willett, Cg" uniqKey="Willett C">CG Willett</name>
</author>
<author>
<name sortKey="Shellito, Pc" uniqKey="Shellito P">PC Shellito</name>
</author>
<author>
<name sortKey="Tepper, Je" uniqKey="Tepper J">JE Tepper</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Suzuki, K" uniqKey="Suzuki K">K Suzuki</name>
</author>
<author>
<name sortKey="Gunderson, Ll" uniqKey="Gunderson L">LL Gunderson</name>
</author>
<author>
<name sortKey="Devine, Rm" uniqKey="Devine R">RM Devine</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Willett, Cg" uniqKey="Willett C">CG Willett</name>
</author>
<author>
<name sortKey="Shellito, Pc" uniqKey="Shellito P">PC Shellito</name>
</author>
<author>
<name sortKey="Tepper, Je" uniqKey="Tepper J">JE Tepper</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Haddock, Mg" uniqKey="Haddock M">MG Haddock</name>
</author>
<author>
<name sortKey="Miller, Rc" uniqKey="Miller R">RC Miller</name>
</author>
<author>
<name sortKey="Nelson, H" uniqKey="Nelson H">H Nelson</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Valentini, V" uniqKey="Valentini V">V Valentini</name>
</author>
<author>
<name sortKey="Morganti, Ag" uniqKey="Morganti A">AG Morganti</name>
</author>
<author>
<name sortKey="De Franco, A" uniqKey="De Franco A">A De Franco</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Wiig, Jn" uniqKey="Wiig J">JN Wiig</name>
</author>
<author>
<name sortKey="Tveit, Km" uniqKey="Tveit K">KM Tveit</name>
</author>
<author>
<name sortKey="Poulsen, Jp" uniqKey="Poulsen J">JP Poulsen</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Calvo, Fa" uniqKey="Calvo F">FA Calvo</name>
</author>
<author>
<name sortKey="Sole, Cv" uniqKey="Sole C">CV Sole</name>
</author>
<author>
<name sortKey="Alvarez De Sierra, P" uniqKey="Alvarez De Sierra P">P Alvarez de Sierra</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Dresen, Rc" uniqKey="Dresen R">RC Dresen</name>
</author>
<author>
<name sortKey="Gosens, Mj" uniqKey="Gosens M">MJ Gosens</name>
</author>
<author>
<name sortKey="Martijn, H" uniqKey="Martijn H">H Martijn</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Roeder, F" uniqKey="Roeder F">F Roeder</name>
</author>
<author>
<name sortKey="Goetz, Jm" uniqKey="Goetz J">JM Goetz</name>
</author>
<author>
<name sortKey="Habl, G" uniqKey="Habl G">G Habl</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Holman, Fa" uniqKey="Holman F">FA Holman</name>
</author>
<author>
<name sortKey="Bosman, Sj" uniqKey="Bosman S">SJ Bosman</name>
</author>
<author>
<name sortKey="Haddock, Mg" uniqKey="Haddock M">MG Haddock</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Huber, Ft" uniqKey="Huber F">FT Huber</name>
</author>
<author>
<name sortKey="Stepan, R" uniqKey="Stepan R">R Stepan</name>
</author>
<author>
<name sortKey="Zimmermann, F" uniqKey="Zimmermann F">F Zimmermann</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Nuyttens, Jj" uniqKey="Nuyttens J">JJ Nuyttens</name>
</author>
<author>
<name sortKey="Kolkman Deurloo, Ik" uniqKey="Kolkman Deurloo I">IK Kolkman-Deurloo</name>
</author>
<author>
<name sortKey="Vermaas, M" uniqKey="Vermaas M">M Vermaas</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Mirnezami, R" uniqKey="Mirnezami R">R Mirnezami</name>
</author>
<author>
<name sortKey="Chang, Gj" uniqKey="Chang G">GJ Chang</name>
</author>
<author>
<name sortKey="Das, P" uniqKey="Das P">P Das</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Alektiar, Km" uniqKey="Alektiar K">KM Alektiar</name>
</author>
<author>
<name sortKey="Zelefsky, Mj" uniqKey="Zelefsky M">MJ Zelefsky</name>
</author>
<author>
<name sortKey="Paty, Pb" uniqKey="Paty P">PB Paty</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Lindel, K" uniqKey="Lindel K">K Lindel</name>
</author>
<author>
<name sortKey="Willett, Cg" uniqKey="Willett C">CG Willett</name>
</author>
<author>
<name sortKey="Shellito, Pc" uniqKey="Shellito P">PC Shellito</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Edmonson, Jh" uniqKey="Edmonson J">JH Edmonson</name>
</author>
<author>
<name sortKey="Petersen, Ia" uniqKey="Petersen I">IA Petersen</name>
</author>
<author>
<name sortKey="Shives, Tc" uniqKey="Shives T">TC Shives</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Azinovic, I" uniqKey="Azinovic I">I Azinovic</name>
</author>
<author>
<name sortKey="Martinez Monge, R" uniqKey="Martinez Monge R">R Martinez Monge</name>
</author>
<author>
<name sortKey="Aristu, Jj" uniqKey="Aristu J">JJ Aristu</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Kretzler, A" uniqKey="Kretzler A">A Kretzler</name>
</author>
<author>
<name sortKey="Molls, M" uniqKey="Molls M">M Molls</name>
</author>
<author>
<name sortKey="Gradinger, R" uniqKey="Gradinger R">R Gradinger</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Oertel, S" uniqKey="Oertel S">S Oertel</name>
</author>
<author>
<name sortKey="Treiber, M" uniqKey="Treiber M">M Treiber</name>
</author>
<author>
<name sortKey="Zahlten Hinguranage, A" uniqKey="Zahlten Hinguranage A">A Zahlten-Hinguranage</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Niewald, M" uniqKey="Niewald M">M Niewald</name>
</author>
<author>
<name sortKey="Fleckenstein, J" uniqKey="Fleckenstein J">J Fleckenstein</name>
</author>
<author>
<name sortKey="Licht, N" uniqKey="Licht N">N Licht</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Call, Ja" uniqKey="Call J">JA Call</name>
</author>
<author>
<name sortKey="Stafford, Sl" uniqKey="Stafford S">SL Stafford</name>
</author>
<author>
<name sortKey="Petersen, Ia" uniqKey="Petersen I">IA Petersen</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Calvo, Fa" uniqKey="Calvo F">FA Calvo</name>
</author>
<author>
<name sortKey="Sole, Cv" uniqKey="Sole C">CV Sole</name>
</author>
<author>
<name sortKey="Polo, A" uniqKey="Polo A">A Polo</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Roeder, F" uniqKey="Roeder F">F Roeder</name>
</author>
<author>
<name sortKey="Lehner, B" uniqKey="Lehner B">B Lehner</name>
</author>
<author>
<name sortKey="Schmitt, T" uniqKey="Schmitt T">T Schmitt</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Roeder, F" uniqKey="Roeder F">F Roeder</name>
</author>
<author>
<name sortKey="Lehner, B" uniqKey="Lehner B">B Lehner</name>
</author>
<author>
<name sortKey="Saleh Ebrahimi, L" uniqKey="Saleh Ebrahimi L">L Saleh-Ebrahimi</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Sindelar, Wf" uniqKey="Sindelar W">WF Sindelar</name>
</author>
<author>
<name sortKey="Kinsella, Tj" uniqKey="Kinsella T">TJ Kinsella</name>
</author>
<author>
<name sortKey="Chen, Pw" uniqKey="Chen P">PW Chen</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Alektiar, Km" uniqKey="Alektiar K">KM Alektiar</name>
</author>
<author>
<name sortKey="Hu, K" uniqKey="Hu K">K Hu</name>
</author>
<author>
<name sortKey="Anderson, L" uniqKey="Anderson L">L Anderson</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Gieschen, Hl" uniqKey="Gieschen H">HL Gieschen</name>
</author>
<author>
<name sortKey="Spiro, Ij" uniqKey="Spiro I">IJ Spiro</name>
</author>
<author>
<name sortKey="Suit, Hd" uniqKey="Suit H">HD Suit</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Petersen, Ia" uniqKey="Petersen I">IA Petersen</name>
</author>
<author>
<name sortKey="Haddock, Mg" uniqKey="Haddock M">MG Haddock</name>
</author>
<author>
<name sortKey="Donohue, Jh" uniqKey="Donohue J">JH Donohue</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Bobin, Jy" uniqKey="Bobin J">JY Bobin</name>
</author>
<author>
<name sortKey="Al Lawati, T" uniqKey="Al Lawati T">T Al-Lawati</name>
</author>
<author>
<name sortKey="Granero, Le" uniqKey="Granero L">LE Granero</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Pierie, Jp" uniqKey="Pierie J">JP Pierie</name>
</author>
<author>
<name sortKey="Betensky, Ra" uniqKey="Betensky R">RA Betensky</name>
</author>
<author>
<name sortKey="Choudry, U" uniqKey="Choudry U">U Choudry</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Krempien, R" uniqKey="Krempien R">R Krempien</name>
</author>
<author>
<name sortKey="Roeder, F" uniqKey="Roeder F">F Roeder</name>
</author>
<author>
<name sortKey="Oertel, S" uniqKey="Oertel S">S Oertel</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Pawlik, Tm" uniqKey="Pawlik T">TM Pawlik</name>
</author>
<author>
<name sortKey="Pisters, Pw" uniqKey="Pisters P">PW Pisters</name>
</author>
<author>
<name sortKey="Mikula, L" uniqKey="Mikula L">L Mikula</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Ballo, Mt" uniqKey="Ballo M">MT Ballo</name>
</author>
<author>
<name sortKey="Zagars, Gk" uniqKey="Zagars G">GK Zagars</name>
</author>
<author>
<name sortKey="Pollock, Re" uniqKey="Pollock R">RE Pollock</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Dziewirski, W" uniqKey="Dziewirski W">W Dziewirski</name>
</author>
<author>
<name sortKey="Rutkowski, P" uniqKey="Rutkowski P">P Rutkowski</name>
</author>
<author>
<name sortKey="Nowecki, Zi" uniqKey="Nowecki Z">ZI Nowecki</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Sweeting, Rs" uniqKey="Sweeting R">RS Sweeting</name>
</author>
<author>
<name sortKey="Deal, Am" uniqKey="Deal A">AM Deal</name>
</author>
<author>
<name sortKey="Llaguna, Oh" uniqKey="Llaguna O">OH Llaguna</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Roeder, F" uniqKey="Roeder F">F Roeder</name>
</author>
<author>
<name sortKey="Ulrich, A" uniqKey="Ulrich A">A Ulrich</name>
</author>
<author>
<name sortKey="Habl, G" uniqKey="Habl G">G Habl</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Stucky, Cc" uniqKey="Stucky C">CC Stucky</name>
</author>
<author>
<name sortKey="Wasif, N" uniqKey="Wasif N">N Wasif</name>
</author>
<author>
<name sortKey="Ashman, Jb" uniqKey="Ashman J">JB Ashman</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Gronchi, A" uniqKey="Gronchi A">A Gronchi</name>
</author>
<author>
<name sortKey="De Paoli, A" uniqKey="De Paoli A">A De Paoli</name>
</author>
<author>
<name sortKey="Dani, C" uniqKey="Dani C">C Dani</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Miller, Rc" uniqKey="Miller R">RC Miller</name>
</author>
<author>
<name sortKey="Haddock, Mg" uniqKey="Haddock M">MG Haddock</name>
</author>
<author>
<name sortKey="Petersen, Ia" uniqKey="Petersen I">IA Petersen</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Calvo, Fa" uniqKey="Calvo F">FA Calvo</name>
</author>
<author>
<name sortKey="Sole, Cv" uniqKey="Sole C">CV Sole</name>
</author>
<author>
<name sortKey="Cambeiro, M" uniqKey="Cambeiro M">M Cambeiro</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Haase, Gm" uniqKey="Haase G">GM Haase</name>
</author>
<author>
<name sortKey="Meagher, Dp" uniqKey="Meagher D">DP Meagher</name>
</author>
<author>
<name sortKey="Mcneely, Lk" uniqKey="Mcneely L">LK McNeely</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Oertel, S" uniqKey="Oertel S">S Oertel</name>
</author>
<author>
<name sortKey="Niethammer, Ag" uniqKey="Niethammer A">AG Niethammer</name>
</author>
<author>
<name sortKey="Krempien, R" uniqKey="Krempien R">R Krempien</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Goodman, Ka" uniqKey="Goodman K">KA Goodman</name>
</author>
<author>
<name sortKey="Wolden, Sl" uniqKey="Wolden S">SL Wolden</name>
</author>
<author>
<name sortKey="Laquaglia, Mp" uniqKey="Laquaglia M">MP LaQuaglia</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Sole, Cv" uniqKey="Sole C">CV Sole</name>
</author>
<author>
<name sortKey="Calvo, Fa" uniqKey="Calvo F">FA Calvo</name>
</author>
<author>
<name sortKey="Polo, A" uniqKey="Polo A">A Polo</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Nag, S" uniqKey="Nag S">S Nag</name>
</author>
<author>
<name sortKey="Tippin, D" uniqKey="Tippin D">D Tippin</name>
</author>
<author>
<name sortKey="Smith, S" uniqKey="Smith S">S Smith</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Stauder, Mc" uniqKey="Stauder M">MC Stauder</name>
</author>
<author>
<name sortKey="Laack, Nn" uniqKey="Laack N">NN Laack</name>
</author>
<author>
<name sortKey="Moir, Cr" uniqKey="Moir C">CR Moir</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Brunschwig, A" uniqKey="Brunschwig A">A Brunschwig</name>
</author>
<author>
<name sortKey="Barber, Hr" uniqKey="Barber H">HR Barber</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Karlen, Jr" uniqKey="Karlen J">JR Karlen</name>
</author>
<author>
<name sortKey="Piver, Ms" uniqKey="Piver M">MS Piver</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Kiselow, M" uniqKey="Kiselow M">M Kiselow</name>
</author>
<author>
<name sortKey="Butcher, Hr" uniqKey="Butcher H">HR Butcher</name>
</author>
<author>
<name sortKey="Bricker, Em" uniqKey="Bricker E">EM Bricker</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Symmonds, Re" uniqKey="Symmonds R">RE Symmonds</name>
</author>
<author>
<name sortKey="Pratt, Jh" uniqKey="Pratt J">JH Pratt</name>
</author>
<author>
<name sortKey="Webb, Mj" uniqKey="Webb M">MJ Webb</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Giorda, G" uniqKey="Giorda G">G Giorda</name>
</author>
<author>
<name sortKey="Boz, G" uniqKey="Boz G">G Boz</name>
</author>
<author>
<name sortKey="Gadducci, A" uniqKey="Gadducci A">A Gadducci</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Garton, Gr" uniqKey="Garton G">GR Garton</name>
</author>
<author>
<name sortKey="Gunderson, Ll" uniqKey="Gunderson L">LL Gunderson</name>
</author>
<author>
<name sortKey="Webb, Mj" uniqKey="Webb M">MJ Webb</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Gemignani, Ml" uniqKey="Gemignani M">ML Gemignani</name>
</author>
<author>
<name sortKey="Alektiar, Km" uniqKey="Alektiar K">KM Alektiar</name>
</author>
<author>
<name sortKey="Leitao, M" uniqKey="Leitao M">M Leitao</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Haddock, Mg" uniqKey="Haddock M">MG Haddock</name>
</author>
<author>
<name sortKey="Petersen, Ia" uniqKey="Petersen I">IA Petersen</name>
</author>
<author>
<name sortKey="Webb, Mj" uniqKey="Webb M">MJ Webb</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Martinez Monge, R" uniqKey="Martinez Monge R">R Martinez-Monge</name>
</author>
<author>
<name sortKey="Jurado, M" uniqKey="Jurado M">M Jurado</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Sole, Cv" uniqKey="Sole C">CV Sole</name>
</author>
<author>
<name sortKey="Calvo, Fa" uniqKey="Calvo F">FA Calvo</name>
</author>
<author>
<name sortKey="Lozano, Ma" uniqKey="Lozano M">MA Lozano</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Tran, Pt" uniqKey="Tran P">PT Tran</name>
</author>
<author>
<name sortKey="Su, Z" uniqKey="Su Z">Z Su</name>
</author>
<author>
<name sortKey="Hara, W" uniqKey="Hara W">W Hara</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Barney, Bm" uniqKey="Barney B">BM Barney</name>
</author>
<author>
<name sortKey="Petersen, Ia" uniqKey="Petersen I">IA Petersen</name>
</author>
<author>
<name sortKey="Dowdy, Sc" uniqKey="Dowdy S">SC Dowdy</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Calvo, Fa" uniqKey="Calvo F">FA Calvo</name>
</author>
<author>
<name sortKey="Sole, Cv" uniqKey="Sole C">CV Sole</name>
</author>
<author>
<name sortKey="Lozano, Ma" uniqKey="Lozano M">MA Lozano</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Foley, Ow" uniqKey="Foley O">OW Foley</name>
</author>
<author>
<name sortKey="Rauh Hain, Ja" uniqKey="Rauh Hain J">JA Rauh-Hain</name>
</author>
<author>
<name sortKey="Clark, Rm" uniqKey="Clark R">RM Clark</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Arians, N" uniqKey="Arians N">N Arians</name>
</author>
<author>
<name sortKey="Foerster, R" uniqKey="Foerster R">R Foerster</name>
</author>
<author>
<name sortKey="Rom, J" uniqKey="Rom J">J Rom</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Dowdy, Sc" uniqKey="Dowdy S">SC Dowdy</name>
</author>
<author>
<name sortKey="Mariani, A" uniqKey="Mariani A">A Mariani</name>
</author>
<author>
<name sortKey="Cliby, Wa" uniqKey="Cliby W">WA Cliby</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Mahe, Ma" uniqKey="Mahe M">MA Mahe</name>
</author>
<author>
<name sortKey="Gerard, Jp" uniqKey="Gerard J">JP Gerard</name>
</author>
<author>
<name sortKey="Dubois, Jb" uniqKey="Dubois J">JB Dubois</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Mahe, Ma" uniqKey="Mahe M">MA Mahe</name>
</author>
<author>
<name sortKey="Romestaing, P" uniqKey="Romestaing P">P Romestaing</name>
</author>
<author>
<name sortKey="Gerard, Jp" uniqKey="Gerard J">JP Gerard</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Del Carmen, Mg" uniqKey="Del Carmen M">MG del Carmen</name>
</author>
<author>
<name sortKey="Mcintyre, Jf" uniqKey="Mcintyre J">JF McIntyre</name>
</author>
<author>
<name sortKey="Fuller, Af" uniqKey="Fuller A">AF Fuller</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Backes, Fj" uniqKey="Backes F">FJ Backes</name>
</author>
<author>
<name sortKey="Billingsley, Cc" uniqKey="Billingsley C">CC Billingsley</name>
</author>
<author>
<name sortKey="Martin, Dd" uniqKey="Martin D">DD Martin</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Hallemeier, Cl" uniqKey="Hallemeier C">CL Hallemeier</name>
</author>
<author>
<name sortKey="Karnes, Rj" uniqKey="Karnes R">RJ Karnes</name>
</author>
<author>
<name sortKey="Pisansky, Tm" uniqKey="Pisansky T">TM Pisansky</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Hallemeier, Cl" uniqKey="Hallemeier C">CL Hallemeier</name>
</author>
<author>
<name sortKey="Choo, R" uniqKey="Choo R">R Choo</name>
</author>
<author>
<name sortKey="Davis, Bj" uniqKey="Davis B">BJ Davis</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Calvo, Fa" uniqKey="Calvo F">FA Calvo</name>
</author>
<author>
<name sortKey="Sole, Cv" uniqKey="Sole C">CV Sole</name>
</author>
<author>
<name sortKey="Martinez Monge, R" uniqKey="Martinez Monge R">R Martinez-Monge</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Eble, Mj" uniqKey="Eble M">MJ Eble</name>
</author>
<author>
<name sortKey="Staehler, G" uniqKey="Staehler G">G Staehler</name>
</author>
<author>
<name sortKey="Wannenmacher, M" uniqKey="Wannenmacher M">M Wannenmacher</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Habl, G" uniqKey="Habl G">G Habl</name>
</author>
<author>
<name sortKey="Uhl, M" uniqKey="Uhl M">M Uhl</name>
</author>
<author>
<name sortKey="Hensley, F" uniqKey="Hensley F">F Hensley</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Master, Va" uniqKey="Master V">VA Master</name>
</author>
<author>
<name sortKey="Gottschalk, Ar" uniqKey="Gottschalk A">AR Gottschalk</name>
</author>
<author>
<name sortKey="Kane, C" uniqKey="Kane C">C Kane</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Paly, Jj" uniqKey="Paly J">JJ Paly</name>
</author>
<author>
<name sortKey="Hallemeier, Cl" uniqKey="Hallemeier C">CL Hallemeier</name>
</author>
<author>
<name sortKey="Biggs, Pj" uniqKey="Biggs P">PJ Biggs</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Thompson, Im" uniqKey="Thompson I">IM Thompson</name>
</author>
<author>
<name sortKey="Valicenti, Rk" uniqKey="Valicenti R">RK Valicenti</name>
</author>
<author>
<name sortKey="Albertsen, P" uniqKey="Albertsen P">P Albertsen</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Rocco, B" uniqKey="Rocco B">B Rocco</name>
</author>
<author>
<name sortKey="Jereczek Fossa, Ba" uniqKey="Jereczek Fossa B">BA Jereczek-Fossa</name>
</author>
<author>
<name sortKey="Matei, Dv" uniqKey="Matei D">DV Matei</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Higashi, Y" uniqKey="Higashi Y">Y Higashi</name>
</author>
<author>
<name sortKey="Hyochi, N" uniqKey="Hyochi N">N Hyochi</name>
</author>
<author>
<name sortKey="Tari, K" uniqKey="Tari K">K Tari</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Kato, S" uniqKey="Kato S">S Kato</name>
</author>
<author>
<name sortKey="Sakura, M" uniqKey="Sakura M">M Sakura</name>
</author>
<author>
<name sortKey="Kazumoto, T" uniqKey="Kazumoto T">T Kazumoto</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Krengli, M" uniqKey="Krengli M">M Krengli</name>
</author>
<author>
<name sortKey="Terrone, C" uniqKey="Terrone C">C Terrone</name>
</author>
<author>
<name sortKey="Ballare, A" uniqKey="Ballare A">A Ballare</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Orecchia, R" uniqKey="Orecchia R">R Orecchia</name>
</author>
<author>
<name sortKey="Jereczek Fossa, Ba" uniqKey="Jereczek Fossa B">BA Jereczek-Fossa</name>
</author>
<author>
<name sortKey="Ciocca, M" uniqKey="Ciocca M">M Ciocca</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Saracino, B" uniqKey="Saracino B">B Saracino</name>
</author>
<author>
<name sortKey="Gallucci, M" uniqKey="Gallucci M">M Gallucci</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Wisbeck, Wm" uniqKey="Wisbeck W">WM Wisbeck</name>
</author>
<author>
<name sortKey="Becher, Em" uniqKey="Becher E">EM Becher</name>
</author>
<author>
<name sortKey="Russell, Ah" uniqKey="Russell A">AH Russell</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Gunderson, Ll" uniqKey="Gunderson L">LL Gunderson</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Macdonald, Js" uniqKey="Macdonald J">JS Macdonald</name>
</author>
<author>
<name sortKey="Smalley, Sr" uniqKey="Smalley S">SR Smalley</name>
</author>
<author>
<name sortKey="Benedetti, J" uniqKey="Benedetti J">J Benedetti</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Cunningham, D" uniqKey="Cunningham D">D Cunningham</name>
</author>
<author>
<name sortKey="Allum, Wh" uniqKey="Allum W">WH Allum</name>
</author>
<author>
<name sortKey="Stenning, Sp" uniqKey="Stenning S">SP Stenning</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Wu, Cw" uniqKey="Wu C">CW Wu</name>
</author>
<author>
<name sortKey="Hsiung, Ca" uniqKey="Hsiung C">CA Hsiung</name>
</author>
<author>
<name sortKey="Lo, Ss" uniqKey="Lo S">SS Lo</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Maruyama, K" uniqKey="Maruyama K">K Maruyama</name>
</author>
<author>
<name sortKey="Sasako, M" uniqKey="Sasako M">M Sasako</name>
</author>
<author>
<name sortKey="Kinoshita, T" uniqKey="Kinoshita T">T Kinoshita</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Fu, S" uniqKey="Fu S">S Fu</name>
</author>
<author>
<name sortKey="Lu, Jj" uniqKey="Lu J">JJ Lu</name>
</author>
<author>
<name sortKey="Zhang, Q" uniqKey="Zhang Q">Q Zhang</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Sindelar, Wf" uniqKey="Sindelar W">WF Sindelar</name>
</author>
<author>
<name sortKey="Kinsella, Tj" uniqKey="Kinsella T">TJ Kinsella</name>
</author>
<author>
<name sortKey="Tepper, Je" uniqKey="Tepper J">JE Tepper</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Zhang, Q" uniqKey="Zhang Q">Q Zhang</name>
</author>
<author>
<name sortKey="Tey, J" uniqKey="Tey J">J Tey</name>
</author>
<author>
<name sortKey="Peng, L" uniqKey="Peng L">L Peng</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Drognitz, O" uniqKey="Drognitz O">O Drognitz</name>
</author>
<author>
<name sortKey="Henne, K" uniqKey="Henne K">K Henne</name>
</author>
<author>
<name sortKey="Weissenberger, C" uniqKey="Weissenberger C">C Weissenberger</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Ogata, T" uniqKey="Ogata T">T Ogata</name>
</author>
<author>
<name sortKey="Araki, K" uniqKey="Araki K">K Araki</name>
</author>
<author>
<name sortKey="Matsuura, K" uniqKey="Matsuura K">K Matsuura</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Qin, Hl" uniqKey="Qin H">HL Qin</name>
</author>
<author>
<name sortKey="Lin, Ch" uniqKey="Lin C">CH Lin</name>
</author>
<author>
<name sortKey="Zhang, Xl" uniqKey="Zhang X">XL Zhang</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Skoropad, Vy" uniqKey="Skoropad V">VY Skoropad</name>
</author>
<author>
<name sortKey="Berdov, Ba" uniqKey="Berdov B">BA Berdov</name>
</author>
<author>
<name sortKey="Mardynski, Ys" uniqKey="Mardynski Y">YS Mardynski</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Calvo, Fa" uniqKey="Calvo F">FA Calvo</name>
</author>
<author>
<name sortKey="Sole, Cv" uniqKey="Sole C">CV Sole</name>
</author>
<author>
<name sortKey="Obregon, R" uniqKey="Obregon R">R Obregon</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Coquard, R" uniqKey="Coquard R">R Coquard</name>
</author>
<author>
<name sortKey="Ayzac, L" uniqKey="Ayzac L">L Ayzac</name>
</author>
<author>
<name sortKey="Gilly, Fn" uniqKey="Gilly F">FN Gilly</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Bacalbasa, N" uniqKey="Bacalbasa N">N Bacalbasa</name>
</author>
<author>
<name sortKey="Balescu, I" uniqKey="Balescu I">I Balescu</name>
</author>
<author>
<name sortKey="Calin, M" uniqKey="Calin M">M Calin</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Avizonis, Vn" uniqKey="Avizonis V">VN Avizonis</name>
</author>
<author>
<name sortKey="Buzydlowski, J" uniqKey="Buzydlowski J">J Buzydlowski</name>
</author>
<author>
<name sortKey="Lanciano, R" uniqKey="Lanciano R">R Lanciano</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Weese, Jl" uniqKey="Weese J">JL Weese</name>
</author>
<author>
<name sortKey="Harbison, Sp" uniqKey="Harbison S">SP Harbison</name>
</author>
<author>
<name sortKey="Stiller, Gd" uniqKey="Stiller G">GD Stiller</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Glehen, O" uniqKey="Glehen O">O Glehen</name>
</author>
<author>
<name sortKey="Peyrat, P" uniqKey="Peyrat P">P Peyrat</name>
</author>
<author>
<name sortKey="Beaujard, Ac" uniqKey="Beaujard A">AC Beaujard</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Miller, Rc" uniqKey="Miller R">RC Miller</name>
</author>
<author>
<name sortKey="Haddock, Mg" uniqKey="Haddock M">MG Haddock</name>
</author>
<author>
<name sortKey="Gunderson, Ll" uniqKey="Gunderson L">LL Gunderson</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Gourgou Bourgade, S" uniqKey="Gourgou Bourgade S">S Gourgou-Bourgade</name>
</author>
<author>
<name sortKey="Bascoul Mollevi, C" uniqKey="Bascoul Mollevi C">C Bascoul-Mollevi</name>
</author>
<author>
<name sortKey="Desseigne, F" uniqKey="Desseigne F">F Desseigne</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Hazard, L" uniqKey="Hazard L">L Hazard</name>
</author>
<author>
<name sortKey="Tward, Jd" uniqKey="Tward J">JD Tward</name>
</author>
<author>
<name sortKey="Szabo, A" uniqKey="Szabo A">A Szabo</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Von Hoff, Dd" uniqKey="Von Hoff D">DD Von Hoff</name>
</author>
<author>
<name sortKey="Ervin, T" uniqKey="Ervin T">T Ervin</name>
</author>
<author>
<name sortKey="Arena, Fp" uniqKey="Arena F">FP Arena</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Alfieri, S" uniqKey="Alfieri S">S Alfieri</name>
</author>
<author>
<name sortKey="Morganti, Ag" uniqKey="Morganti A">AG Morganti</name>
</author>
<author>
<name sortKey="Di Giorgio, A" uniqKey="Di Giorgio A">A Di Giorgio</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Calvo, Fa" uniqKey="Calvo F">FA Calvo</name>
</author>
<author>
<name sortKey="Sole, Cv" uniqKey="Sole C">CV Sole</name>
</author>
<author>
<name sortKey="Atahualpa, F" uniqKey="Atahualpa F">F Atahualpa</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Showalter, Tn" uniqKey="Showalter T">TN Showalter</name>
</author>
<author>
<name sortKey="Rao, As" uniqKey="Rao A">AS Rao</name>
</author>
<author>
<name sortKey="Anne, Pr" uniqKey="Anne P">PR Anne</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Valentini, V" uniqKey="Valentini V">V Valentini</name>
</author>
<author>
<name sortKey="Calvo, F" uniqKey="Calvo F">F Calvo</name>
</author>
<author>
<name sortKey="Reni, M" uniqKey="Reni M">M Reni</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Messick, C" uniqKey="Messick C">C Messick</name>
</author>
<author>
<name sortKey="Hardacre, Jm" uniqKey="Hardacre J">JM Hardacre</name>
</author>
<author>
<name sortKey="Mcgee, Mf" uniqKey="Mcgee M">MF McGee</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Ogawa, K" uniqKey="Ogawa K">K Ogawa</name>
</author>
<author>
<name sortKey="Karasawa, K" uniqKey="Karasawa K">K Karasawa</name>
</author>
<author>
<name sortKey="Ito, Y" uniqKey="Ito Y">Y Ito</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Valentini, V" uniqKey="Valentini V">V Valentini</name>
</author>
<author>
<name sortKey="Morganti, Ag" uniqKey="Morganti A">AG Morganti</name>
</author>
<author>
<name sortKey="Macchia, G" uniqKey="Macchia G">G Macchia</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Kokubo, M" uniqKey="Kokubo M">M Kokubo</name>
</author>
<author>
<name sortKey="Nishimura, Y" uniqKey="Nishimura Y">Y Nishimura</name>
</author>
<author>
<name sortKey="Shibamoto, Y" uniqKey="Shibamoto Y">Y Shibamoto</name>
</author>
<author>
<name sortKey="Sasai, K" uniqKey="Sasai K">K Sasai</name>
</author>
<author>
<name sortKey="Kanamori, S" uniqKey="Kanamori S">S Kanamori</name>
</author>
<author>
<name sortKey="Hosotani, R" uniqKey="Hosotani R">R Hosotani</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Reni, M" uniqKey="Reni M">M Reni</name>
</author>
<author>
<name sortKey="Panucci, Mg" uniqKey="Panucci M">MG Panucci</name>
</author>
<author>
<name sortKey="Ferreri, Aj" uniqKey="Ferreri A">AJ Ferreri</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Cai, S" uniqKey="Cai S">S Cai</name>
</author>
<author>
<name sortKey="Hong, Ts" uniqKey="Hong T">TS Hong</name>
</author>
<author>
<name sortKey="Goldberg, Si" uniqKey="Goldberg S">SI Goldberg</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Chen, Y" uniqKey="Chen Y">Y Chen</name>
</author>
<author>
<name sortKey="Che, X" uniqKey="Che X">X Che</name>
</author>
<author>
<name sortKey="Zhang, J" uniqKey="Zhang J">J Zhang</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Jingu, K" uniqKey="Jingu K">K Jingu</name>
</author>
<author>
<name sortKey="Tanabe, T" uniqKey="Tanabe T">T Tanabe</name>
</author>
<author>
<name sortKey="Nemoto, K" uniqKey="Nemoto K">K Nemoto</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Ma, Hb" uniqKey="Ma H">HB Ma</name>
</author>
<author>
<name sortKey="Di, Zl" uniqKey="Di Z">ZL Di</name>
</author>
<author>
<name sortKey="Wang, Xj" uniqKey="Wang X">XJ Wang</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Mohiuddin, M" uniqKey="Mohiuddin M">M Mohiuddin</name>
</author>
<author>
<name sortKey="Regine, Wf" uniqKey="Regine W">WF Regine</name>
</author>
<author>
<name sortKey="Stevens, J" uniqKey="Stevens J">J Stevens</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Nishimura, Y" uniqKey="Nishimura Y">Y Nishimura</name>
</author>
<author>
<name sortKey="Hosotani, R" uniqKey="Hosotani R">R Hosotani</name>
</author>
<author>
<name sortKey="Shibamoto, Y" uniqKey="Shibamoto Y">Y Shibamoto</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Willett, Cg" uniqKey="Willett C">CG Willett</name>
</author>
<author>
<name sortKey="Del Castillo, Cf" uniqKey="Del Castillo C">CF Del Castillo</name>
</author>
<author>
<name sortKey="Shih, Ha" uniqKey="Shih H">HA Shih</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Keane, Fk" uniqKey="Keane F">FK Keane</name>
</author>
<author>
<name sortKey="Wo, Jy" uniqKey="Wo J">JY Wo</name>
</author>
<author>
<name sortKey="Ferrone, Cr" uniqKey="Ferrone C">CR Ferrone</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Conroy, T" uniqKey="Conroy T">T Conroy</name>
</author>
<author>
<name sortKey="Bachet, Jb" uniqKey="Bachet J">JB Bachet</name>
</author>
<author>
<name sortKey="Ayav, A" uniqKey="Ayav A">A Ayav</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Hackert, T" uniqKey="Hackert T">T Hackert</name>
</author>
<author>
<name sortKey="Sachsenmaier, M" uniqKey="Sachsenmaier M">M Sachsenmaier</name>
</author>
<author>
<name sortKey="Hinz, U" uniqKey="Hinz U">U Hinz</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<pmc article-type="review-article">
<pmc-dir>properties open_access</pmc-dir>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Ecancermedicalscience</journal-id>
<journal-id journal-id-type="iso-abbrev">Ecancermedicalscience</journal-id>
<journal-id journal-id-type="publisher-id">ecancermedicalscience</journal-id>
<journal-title-group>
<journal-title>ecancermedicalscience</journal-title>
</journal-title-group>
<issn pub-type="epub">1754-6605</issn>
<publisher>
<publisher-name>Cancer Intelligence</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28717396</article-id>
<article-id pub-id-type="pmc">5493441</article-id>
<article-id pub-id-type="doi">10.3332/ecancer.2017.750</article-id>
<article-id pub-id-type="publisher-id">can-11-750</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Intraoperative radiotherapy: review of techniques and results</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Pilar</surname>
<given-names>Avinash</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gupta</surname>
<given-names>Meetakshi</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ghosh Laskar</surname>
<given-names>Sarbani</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Laskar</surname>
<given-names>Siddhartha</given-names>
</name>
</contrib>
<aff>Department of Radiation Oncology, Tata Memorial Hospital, Dr Ernest Borges’ Marg, Parel, Mumbai, MS, India 400012</aff>
</contrib-group>
<author-notes>
<corresp id="c1-can-11-750">
<bold>Correspondence to:</bold>
Siddhartha Laskar.
<email>laskars2000@yahoo.com</email>
</corresp>
</author-notes>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>29</day>
<month>6</month>
<year>2017</year>
</pub-date>
<volume>11</volume>
<elocation-id>750</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>1</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© the authors; licensee ecancermedicalscience.</copyright-statement>
<copyright-year>2017</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<license-p>
<pmc-comment>CREATIVE COMMONS</pmc-comment>
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0">http://creativecommons.org/licenses/by/3.0</ext-link>
), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>Intraoperative radiotherapy (IORT) is a technique that involves precise delivery of a large dose of ionising radiation to the tumour or tumour bed during surgery. Direct visualisation of the tumour bed and ability to space out the normal tissues from the tumour bed allows maximisation of the dose to the tumour while minimising the dose to normal tissues. This results in an improved therapeutic ratio with IORT. Although it was introduced in the 1960s, it has seen a resurgence of popularity with the introduction of self-shielding mobile linear accelerators and low-kV IORT devices, which by eliminating the logistical issues of transport of the patient during surgery for radiotherapy or building a shielded operating room, has enabled its wider use in the community.</p>
<p>Electrons, low-kV X-rays and HDR brachytherapy are all different methods of IORT in current clinical use. Each method has its own unique set of advantages and disadvantages, its own set of indications where one may be better suited than the other, and each requires a specific kind of expertise.</p>
<p>IORT has demonstrated its efficacy in a wide variety of intra-abdominal tumours, recurrent colorectal cancers, recurrent gynaecological cancers, and soft-tissue tumours. Recently, it has emerged as an attractive treatment option for selected, early-stage breast cancer, owing to the ability to complete the entire course of radiotherapy during surgery. IORT has been used in a multitude of roles across these sites, for dose escalation (retroperitoneal sarcoma), EBRT dose de-escalation (paediatric tumours), as sole radiation modality (early breast cancers) and as a re-irradiation modality (recurrent rectal and gynaecological cancers).</p>
<p>This article aims to provide a review of the rationale, techniques, and outcomes for IORT across different sites relevant to current clinical practice.</p>
</abstract>
<kwd-group>
<kwd>IORT</kwd>
<kwd>techniques</kwd>
<kwd>indications</kwd>
<kwd>outcomes</kwd>
<kwd>complications</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec>
<title>Background</title>
<p>Intraoperative radiation therapy (IORT) constitutes delivery of radiation to the tumour/tumour bed while the area is exposed during surgery. IORT is capable of delivering high doses of radiation, precisely to the tumour bed with minimal exposure to the surrounding healthy tissues.</p>
<p>Abe
<italic>et al.</italic>
from the University of Kyoto, Japan, were the first to introduce IORT in the early 1960s reporting its use in various intra-abdominal tumours [
<xref rid="ref1" ref-type="bibr">1</xref>
<xref rid="ref3" ref-type="bibr">3</xref>
].</p>
<p>IORT is typically used in combination with other modalities like maximal surgical resection, external beam radiotherapy (EBRT) or chemotherapy as a part of the multidisciplinary approach.</p>
<p>Efficacy of IORT has been reported in a wide variety of sites like locally advanced and recurrent rectal cancer, retroperitoneal sarcoma, pancreatic cancer, early breast cancer, and selected gynaecologic and genitourinary malignancies.</p>
</sec>
<sec>
<title>Rationale for the use of IORT</title>
<p>Traditionally, surgery is followed by EBRT in most solid tumours for the elimination of any microscopic residual disease and reducing the risk of local recurrence. However, EBRT in the post-operative setting has the following drawbacks:</p>
<list list-type="bullet">
<list-item>
<p>The usual delay between the surgical removal of the tumour and EBRT may allow repopulation of the tumour cells.</p>
</list-item>
<list-item>
<p>Difficulty in tumour bed localisation or use of larger margins, which may increase normal tissue morbidity.</p>
</list-item>
</list>
<p>Most solid tumours exhibit a dose–response relationship, the likelihood of local control improving with increasing dose; however, there are limitations to the doses that can be delivered even with conformal EBRT techniques due to the presence of dose-limiting structures adjacent to the tumour/tumour bed. Especially, in the setting of gross residual disease, doses with EBRT may never be sufficient to achieve adequate local control without causing significant morbidity.</p>
<sec>
<title>IORT allows</title>
<list list-type="bullet">
<list-item>
<p>Precise localisation of the tumour bed and targeted delivery of high-dose radiation to the tumour bed.</p>
</list-item>
<list-item>
<p>Minimal exposure of the dose-limiting normal tissues that are displaced away from the tumour bed and shielded from radiation.</p>
</list-item>
<list-item>
<p>Opportunities for dose escalation beyond that which can be achieved with EBRT.</p>
</list-item>
<list-item>
<p>Opportunities for re-irradiation especially in recurrent cancers where further irradiation with EBRT may not be possible.</p>
</list-item>
</list>
<p>Thus, IORT can deliver higher total effective dose to the tumour bed, facilitate dose escalation without significantly increasing normal tissue complications and improve therapeutic ratio compared with EBRT.</p>
<p>IORT may be used alone or in combination with conventionally fractionated EBRT. Most centres use it in combination with EBRT, as it seems to provide the best therapeutic ratio (decreased risk of late normal tissue damage due to the use of fractionation for some part of the dose).</p>
</sec>
</sec>
<sec>
<title>Methods of IORT</title>
<p>Several methods have been used to deliver IORT. Electron beams (electron IORT/IOERT), X-rays (kV IORT) and High-dose-rate brachytherapy (HDR IORT) are some of the commonly used methods for the delivery of IORT in current clinical practice.</p>
<sec>
<title>Electron IORT</title>
<p>Introduction of electron IORT (IOERT) marked the beginning of the IORT era in the early 1960s [
<xref rid="ref3" ref-type="bibr">3</xref>
,
<xref rid="ref4" ref-type="bibr">4</xref>
]. Using variable electron energies depth dose distribution could be controlled to provide uniform dose to target area. However, patients needed to be transported from the operating room (O.R) to the radiation department during surgery, posing logistical issues related to transportation and sterilisation [
<xref rid="ref2" ref-type="bibr">2</xref>
,
<xref rid="ref5" ref-type="bibr">5</xref>
]. These problems were overcome with the use of dedicated IOERT facilities, which were quite expensive because of added costs of shielding the O.R and dedicated linear accelerator requirements, limiting their use to few centres in the United States and Europe. The advent of miniaturised, self-shielded, mobile linear accelerators [
<xref rid="ref6" ref-type="bibr">6</xref>
] (Novac7, Hitesys SPA, Aprillia, Italy; 7–10 MeV and the Mobetron, IntraOp Medical Corporation, Sunnyvale, CA, USA; 4–12 MeV) in the 1990s, has brought about resurgence of IORT and allowed its use in many centres across the world while reducing the costs. Greater depth of penetration and dose homogeneity relative to HDR-IORT or kV IORT is possible with these devices. They come with applicators of different shapes and sizes, for the treatment of various sites and can deliver the treatment in a matter of minutes [
<xref rid="ref7" ref-type="bibr">7</xref>
]. However, these applicators are rigid, thus challenging to use in difficult sites (pelvis and narrow cavities) and can treat a maximum diameter of 15 cm only, larger volumes requiring multiple, closely placed fields. Abutment of fields to treat a wider area is made possible by the use of rectangular applicators or D-shaped applicators called ‘Squircle’.</p>
</sec>
<sec>
<title>HDR IORT</title>
<p>HDR brachytherapy offers distinct dosimetric advantages due to its steep dose fall off and has the ability to deliver high doses to the tumour bed while reducing doses to nearby critical structures, these characteristics of HDR brachytherapy make it well suited for the purpose of IORT. Since many centres already own a HDR after loading machine, which can be transported to the OR for IORT, it reduces the cost of dedicated system; however, like IOERT, a shielded O.R or a shielded room in the O.R complex becomes necessary for HDR IORT. HDR IORT in most centres is delivered using surface applicators like Harrison–Anderson–Mick (HAM) applicator [
<xref rid="ref8" ref-type="bibr">8</xref>
,
<xref rid="ref9" ref-type="bibr">9</xref>
] or superflab [
<xref rid="ref10" ref-type="bibr">10</xref>
,
<xref rid="ref11" ref-type="bibr">11</xref>
] applicators and prescribed at 0.5–1 cm depth. These applicators are flexible, can treat relatively uneven surfaces and come in larger sizes for larger surfaces. Disadvantages of HDR IORT are reduced depth of penetration and prolonged treatment time relative to IOERT.</p>
</sec>
<sec>
<title>KV IORT</title>
<p>With increasing use of IOERT in the 1980s, orthovoltage X-rays were attempted for use in IORT to reduce the shielding costs of the OR. However, poor uniformity, higher bone doses and prolonged treatment time quickly reduced the interest in their use. Recently, low-kV (20–50 kV) mobile IORT devices like Intrabeam, (Carl Zeiss AG, Germany) and Axxent Electronic Brachytherapy System (Xoft Inc., Fremont, California) are gaining popularity for use in IORT. They have steep dose gradients and do not require special shielding requirements. They come with spherical applicators and have a very limited depth of penetration of 0.5–1 cm. They are therefore best suited for spherically shaped target volumes as in breast cancer.</p>
<p>With a strong oncological rationale at its heart, IORT in its various forms has been tested throughout the evolution of radiotherapy and has weathered the tests of time and technology showing periodic resurgences with the advent of newer technology. The following section will focus on recently published results to describe the current role of IORT across various sites.</p>
</sec>
<sec>
<title>Search strategy and selection criteria</title>
<p>A literature search was performed through the PubMed database by using the following terms: ‘intraoperative radiotherapy/IORT’, ‘head and neck cancer’, ‘breast cancer’, ‘colorectal/rectal/colon cancers’, ‘pancreas/pancreatic cancers’, ‘gastric/stomach cancer’, ‘soft-tissue sarcoma/sarcoma’, ‘paediatric/childhood cancers’, ‘gynaecological cancer’, ‘uterine/endometrial cancer’, ‘cervical/cervix cancer’, ‘renal/kidney cancer’, “bladder cancer”, and “prostate cancer”. IORT was defined as single large dose delivered intraoperatively during surgery, articles of perioperative brachytherapy with continuous low-dose rate or pulsed dose rate or HDR with multiple small fractions, delivered over subsequent days post-surgery were not included in this review. Search was limited to articles published between 1995 and 2017. Reviews, case reports and data presented, only as an abstract at conferences were excluded. Whenever updated data from the same institute was available, earlier articles with smaller numbers were not included. For the purpose of uniformity, in the respective sections, reports combining the results of primary with recurrent colorectal cancers, extremity sarcomas with retroperitoneal sarcomas and metastatic pancreatic cancers with locally advanced pancreatic cancers together were not included in the review. A total of 123 articles were finally included in the review.</p>
</sec>
</sec>
<sec>
<title>Clinical results with IORT</title>
<sec>
<title>Head and neck cancers</title>
<p>Despite the use of multidisciplinary treatment protocols locoregional recurrences occur in more than 30% of locoregionally advanced head and neck cancers [
<xref rid="ref12" ref-type="bibr">12</xref>
<xref rid="ref15" ref-type="bibr">15</xref>
]. Outcomes are poor even after surgical salvage with high rates of local failure. Re-irradiation, in this setting, has shown to improve local control [
<xref rid="ref16" ref-type="bibr">16</xref>
]. However, persistent late sequelae from previous course of radiotherapy (RT) may hamper the chances of effective re-irradiation with EBRT. IORT is an attractive tool in this setting.</p>
<p>Many retrospective series [
<xref rid="ref17" ref-type="bibr">17</xref>
<xref rid="ref22" ref-type="bibr">22</xref>
] have demonstrated the efficacy of IORT in recurrent head and neck cancer after gross total resection (
<xref ref-type="table" rid="table1">Table 1</xref>
). Both IOERT and HDR IORT have been used to deliver IORT in recurrent head and neck cancer. Patients selected for IORT mainly consisted of recurrent or persistent cancers, who have been previously irradiated and delivery of sufficient doses of EBRT was not possible at the time of recurrence. Most studies have shown effective local control with acceptable complications [
<xref rid="ref17" ref-type="bibr">17</xref>
,
<xref rid="ref19" ref-type="bibr">19</xref>
<xref rid="ref22" ref-type="bibr">22</xref>
]. Resection status at salvage was the most important factor determining local control [
<xref rid="ref17" ref-type="bibr">17</xref>
,
<xref rid="ref19" ref-type="bibr">19</xref>
,
<xref rid="ref21" ref-type="bibr">21</xref>
]. Microscopically residual tumours did better with IORT [
<xref rid="ref23" ref-type="bibr">23</xref>
], gross residual disease however did not [
<xref rid="ref20" ref-type="bibr">20</xref>
,
<xref rid="ref23" ref-type="bibr">23</xref>
]. Adjuvant EBRT after IORT appears to further improve local control, however the small sample size of these studies precludes any definite conclusions [
<xref rid="ref20" ref-type="bibr">20</xref>
,
<xref rid="ref23" ref-type="bibr">23</xref>
]. Wound complications, osteoradionecrosis (ORN), fistulae, and neuropathy are the most common complications [
<xref rid="ref17" ref-type="bibr">17</xref>
<xref rid="ref22" ref-type="bibr">22</xref>
] after IOERT; however, these are rare with doses less than 20 Gy [
<xref rid="ref22" ref-type="bibr">22</xref>
] and no different than that of re-irradiation with EBRT [
<xref rid="ref16" ref-type="bibr">16</xref>
]. Carotid artery blow out is a rare but a fatal complication that may occur after IORT. Attempts should be made whenever possible to shield or space out the major vessels and nerves from the treatment field.</p>
</sec>
<sec>
<title>Breast cancer</title>
<p>The majority of breast cancer recurrences after breast conservation surgery and whole breast irradiation (WBI) occur in the tumour bed, questioning the need for WBI. This has led to widespread adoption of accelerated partial breast irradiation (APBI) in women with early breast cancer without adverse features. IORT has seen a growing interest in early breast cancer as a modality of delivering APBI in a single fraction.</p>
<p>Several phase-II trials [
<xref rid="ref24" ref-type="bibr">24</xref>
,
<xref rid="ref25" ref-type="bibr">25</xref>
] and prospective series [
<xref rid="ref6" ref-type="bibr">6</xref>
,
<xref rid="ref26" ref-type="bibr">26</xref>
] have shown excellent early tumour control, survival, and cosmetic outcomes. Two large phase-III studies TARGIT-A (targeted intraoperative radiotherapy) [
<xref rid="ref27" ref-type="bibr">27</xref>
] and ELIOT (intraoperative radiotherapy with electrons) [
<xref rid="ref28" ref-type="bibr">28</xref>
], have evaluated the role of IORT as single-dose, partial breast irradiation treatment compared to standard, conventionally fractionated WBI for highly selected patients with relatively low-risk early-stage invasive breast cancer.</p>
<p>
<xref ref-type="table" rid="table2">Table 2</xref>
summarises the relevant differences in the two trials with the 5-year results. Both the Eliot and TARGIT trials demonstrated significantly higher recurrence rates compared to WBI; however, the results were reported to be within the predefined statistical margin for equivalence/non-inferiority. Also, in both the trials, fewer skin side effects were seen in the IORT group compared to those in the WBI group.</p>
<p>TARGIT-A trial also reported significantly lower non-breast cancer deaths in the TARGIT group (
<italic>p</italic>
= 0.0086). This difference was attributed to fewer radiotherapy-related cardiovascular deaths in the TARGIT group; however, radiotherapy-related cardiovascular deaths may not become apparent so early in the follow-up period and these differences could have resulted due to imbalance in the treatment arms [
<xref rid="ref29" ref-type="bibr">29</xref>
<xref rid="ref32" ref-type="bibr">32</xref>
]. The TARGIT-A trial has also come in for criticism related to its statistical assumptions [
<xref rid="ref33" ref-type="bibr">33</xref>
<xref rid="ref35" ref-type="bibr">35</xref>
]. Though the trial seems to show a non-inferiority in 5-year local recurrence rates, median follow-up of all randomised patients is just 29 months which is too early to make assumptions regarding local recurrence rate at 5 years and also the authors seem to have misinterpreted the non-inferiority criterion, which require the upper confidence interval (CI) be less than the predefined non inferiority level of 2.5% [
<xref rid="ref33" ref-type="bibr">33</xref>
<xref rid="ref35" ref-type="bibr">35</xref>
].</p>
<p>To summarise the trials of single-dose IORT, both ELIOT trial (IOERT) and TARGIT trial (kV-IORT) demonstrated a higher recurrence rate compared to WBI, although within the equivalence margin [
<xref rid="ref36" ref-type="bibr">36</xref>
]. TARGIT-A (KV-IORT) also requires a longer follow-up before drawing definite conclusions and adopting it for widespread use in place of WBI [
<xref rid="ref35" ref-type="bibr">35</xref>
,
<xref rid="ref36" ref-type="bibr">36</xref>
]. It is prudent to use these techniques in a highly selected group of low-risk early-breast cancer to achieve acceptable results. Leonardi
<italic>et al</italic>
[
<xref rid="ref37" ref-type="bibr">37</xref>
,
<xref rid="ref38" ref-type="bibr">38</xref>
] used the American Society for Therapeutic Radiation Oncology (ASTRO) consensus statement [
<xref rid="ref39" ref-type="bibr">39</xref>
] and the Groupe Européen de Curiethérapie–European Society for Therapeutic Radiology and Oncology (GEC–ESTRO) recommendations [
<xref rid="ref40" ref-type="bibr">40</xref>
] for APBI patient selection, to stratify 1822 patients treated with ELIOT outside the trial into different risk groups, 16% of women met ASTRO suitable criteria and 31% were good candidates as per GEC-ESTRO recommendations, local recurrence rates were 1.5% and 1.9%, respectively. Thirty-six per cent of women who had favourable biology disease with a luminal-A subtype also showed a very low local recurrence rate of 1.7% irrespective of the risk group. Therefore, ASTRO suitable, GEC ESTRO good and luminal-A subtype identify a subset of women, who may be safely treated with single-dose IORT with acceptable results [
<xref rid="ref36" ref-type="bibr">36</xref>
<xref rid="ref38" ref-type="bibr">38</xref>
,
<xref rid="ref41" ref-type="bibr">41</xref>
].</p>
<p>Though it may not be time yet for IORT to replace WBI in early-breast cancer, IORT has been investigated as a strategy for boost in limited-stage breast cancer prior to WBI. Compared to post-operative boost, IORT boost allows precise delivery to a smaller target volume separated from skin, rather than to a volume distended or distorted by seroma, thus improving accuracy and cosmesis. Also, a single-shot boost treatment significantly reduces the duration of adjuvant RT. In a pooled analysis by the International Society of Intraoperative Radiotherapy (ISIORT), IOERT has been demonstrated to be an effective boost strategy with excellent local control rates [
<xref rid="ref42" ref-type="bibr">42</xref>
]. A total of 1109 unselected patients belonging to any of the risk groups were treated with IOERT boost (median 10 Gy) followed by WBI (50–54 Gy). At a median follow-up of 6 years, only 16 local recurrences were observed resulting in a local control rate of 99.2%. Grade was the only significant predictor of local recurrence, while none of the age groups demonstrated a higher recurrence rates. Efficacy of KV-IORT as a modality for intraoperative boost has been demonstrated in two large prospective series, an IORT boost of 18–20 Gy was followed by WBI, a local recurrence rate of 1.73% was observed in the study by Vaidya
<italic>et al</italic>
[
<xref rid="ref43" ref-type="bibr">43</xref>
], while a 3% recurrence rate was seen in the study by Blank
<italic>et al</italic>
[
<xref rid="ref44" ref-type="bibr">44</xref>
]. The TARGIT-B trial (NCT01792726), which compares EBRT boost versus an IORT boost, in patients at high risk for local recurrence who are receiving breast-conserving treatment, with standard postoperative EBRT has been launched and may provide definite answers.</p>
<p>IORT boost has emerged as an attractive option for boost in combination with oncoplastic surgery [
<xref rid="ref45" ref-type="bibr">45</xref>
]. Oncoplastic reconstruction techniques allow for a wider resection margin while maintaining the cosmetic outcome; however, an externally delivered boost, in such cases, has higher chance of partially missing the target volume due to the tissue displacement techniques used for reconstruction. IORT allows for a precise delivery of the radiation boost directly to the tumour bed during surgery and can be followed by oncoplastic reconstruction thus maintaining the oncological safety and improving cosmetic outcome, with other added advantages like avoiding seroma formation and reducing the duration of EBRT. The Breast Centre of the University Hospital of Cologne [
<xref rid="ref45" ref-type="bibr">45</xref>
,
<xref rid="ref46" ref-type="bibr">46</xref>
] has recently reported the aesthetic outcomes of X-ray IORT boost (20 Gy) combined with oncoplastic surgery in 149 patients treated since 2011, with excellent cosmetic outcomes in over 90% and seroma formation rates of 2% at 4 weeks.</p>
</sec>
<sec>
<title>Colorectal cancers</title>
<p>Locally advanced rectal cancer is best managed with aggressive multimodality treatment involving chemoradiotherapy and radical resection. Most locally advanced (T3) tumours do well with this multimodality approach and local recurrences are seen in only 5–10% of patients. However, in 15% of T4 (unresectable) tumours R0 resections may not be possible [
<xref rid="ref47" ref-type="bibr">47</xref>
,
<xref rid="ref48" ref-type="bibr">48</xref>
] and 10% of complete resections still develop local recurrences [
<xref rid="ref47" ref-type="bibr">47</xref>
,
<xref rid="ref48" ref-type="bibr">48</xref>
] after full course chemoradiotherapy. Resection status is the most important determinant of local control and survival; incomplete resections yield few long-term survivors. There may be a case for dose escalation in locally advanced/unresectable rectal cancers with incomplete resections or at high risk of local recurrence (close margins); however, gastrointestinal tolerance limits the radiation dose delivered by EBRT. With IORT, higher doses can be delivered directly to the tumour bed without significantly increasing doses to nearby structures. This high dose may be capable of sterilising the margins even after microscopic/macroscopic residual disease.</p>
<p>There is increasing evidence (
<xref ref-type="table" rid="table3">Table 3</xref>
) to suggest that inclusion of IORT in the multi-modal treatment of locally advanced rectal cancer can lead to improved local control and survival [
<xref rid="ref11" ref-type="bibr">11</xref>
,
<xref rid="ref49" ref-type="bibr">49</xref>
<xref rid="ref51" ref-type="bibr">51</xref>
] especially in the setting of R+ resection. IORT in locally advanced rectal cancer is commonly delivered as an intraoperative boost and used in combination with pre-operative or post-operative radiotherapy with or without chemotherapy [
<xref rid="ref11" ref-type="bibr">11</xref>
,
<xref rid="ref49" ref-type="bibr">49</xref>
]. Most studies have utilised IOERT and others have utilised HDR IORT for delivery of IORT in rectal cancer.</p>
<p>
<xref ref-type="table" rid="table3">Table 3</xref>
summarises various non-randomised and randomised studies of IORT in locally advanced rectal cancers. The initial non-randomised comparisons [
<xref rid="ref52" ref-type="bibr">52</xref>
<xref rid="ref54" ref-type="bibr">54</xref>
,
<xref rid="ref57" ref-type="bibr">57</xref>
,
<xref rid="ref62" ref-type="bibr">62</xref>
] showed conflicting results with IORT after complete resection (
<italic>R</italic>
0), while some studies showed equivalent local control [
<xref rid="ref54" ref-type="bibr">54</xref>
] in IORT and non IORT group
<sup>,</sup>
others showed a significant benefit in local control with IORT [
<xref rid="ref52" ref-type="bibr">52</xref>
,
<xref rid="ref57" ref-type="bibr">57</xref>
,
<xref rid="ref62" ref-type="bibr">62</xref>
]. One thing which is certain was that IORT provided significant benefit in local control and survival in patients with
<italic>R</italic>
+ resection [
<xref rid="ref54" ref-type="bibr">54</xref>
,
<xref rid="ref55" ref-type="bibr">55</xref>
,
<xref rid="ref59" ref-type="bibr">59</xref>
,
<xref rid="ref61" ref-type="bibr">61</xref>
]. The only two randomised studies [
<xref rid="ref56" ref-type="bibr">56</xref>
,
<xref rid="ref58" ref-type="bibr">58</xref>
] comparing the addition of IORT to standard treatment failed to show any benefit with addition of IORT in terms of local control or survival. The study by Dubois
<italic>et al</italic>
. [
<xref rid="ref58" ref-type="bibr">58</xref>
] had a large proportion of T3 tumours (89%), complete resection in most patients would have likely minimised the benefits of IORT, while on the other hand, the study by Masaki
<italic>et al</italic>
. [
<xref rid="ref56" ref-type="bibr">56</xref>
] was limited by small sample size and inclusion of T1/T2 patients.</p>
<p>Management of locally recurrent rectal (LRRC) cancers presents unique challenges. Prior irradiation in these patients limits the scope for further treatment of these patients with EBRT and is generally associated with poorer survival. IORT with its ability to limit the dose to critical structures serves as a reasonable technique for re-irradiation in LRRC. With the addition of IORT to gross total resection and EBRT, various initial series [
<xref rid="ref63" ref-type="bibr">63</xref>
,
<xref rid="ref64" ref-type="bibr">64</xref>
] reported a 5-year survival of over20% even without chemotherapy.</p>
<p>Non-randomised studies of IORT in LRRC (
<xref ref-type="table" rid="table4">Table 4</xref>
) have shown a significant improvement in local control with IORT and many series have also shown a survival advantage. Recent series [
<xref rid="ref65" ref-type="bibr">65</xref>
<xref rid="ref70" ref-type="bibr">70</xref>
] have also employed Re-EBRT and chemotherapy along with IORT in patients previously treated with pelvic radiotherapy and were able to achieve survival in the range of 30–40%, using these aggressive strategies. Important factors affecting outcomes in most of these studies was completeness of surgical resection [
<xref rid="ref65" ref-type="bibr">65</xref>
,
<xref rid="ref68" ref-type="bibr">68</xref>
<xref rid="ref70" ref-type="bibr">70</xref>
] and addition of IORT boost [
<xref rid="ref63" ref-type="bibr">63</xref>
,
<xref rid="ref66" ref-type="bibr">66</xref>
,
<xref rid="ref67" ref-type="bibr">67</xref>
]. EBRT during recurrent setting appears to improve the outcomes further and should be considered whenever feasible [
<xref rid="ref68" ref-type="bibr">68</xref>
,
<xref rid="ref70" ref-type="bibr">70</xref>
,
<xref rid="ref71" ref-type="bibr">71</xref>
].</p>
<p>The complication rates in these IORT studies are variable and could range anywhere between 5% and 60%. Wound complications, gastrointestinal problems, ureteric obstruction and neuropathy are some of the frequently encountered morbidities. Wound complications were most common and in some series was quite high, upwards of 40% [
<xref rid="ref50" ref-type="bibr">50</xref>
,
<xref rid="ref62" ref-type="bibr">62</xref>
,
<xref rid="ref72" ref-type="bibr">72</xref>
,
<xref rid="ref73" ref-type="bibr">73</xref>
]. Gastrointestinal fistulae and ureteric damage have an incidence ranging from 2% to 12% [
<xref rid="ref50" ref-type="bibr">50</xref>
,
<xref rid="ref62" ref-type="bibr">62</xref>
,
<xref rid="ref64" ref-type="bibr">64</xref>
,
<xref rid="ref72" ref-type="bibr">72</xref>
,
<xref rid="ref73" ref-type="bibr">73</xref>
]. Plexopathy and neuropathy are late toxicities of pelvic IORT and have shown a dose-dependent relationship after IORT [
<xref rid="ref50" ref-type="bibr">50</xref>
,
<xref rid="ref62" ref-type="bibr">62</xref>
,
<xref rid="ref64" ref-type="bibr">64</xref>
,
<xref rid="ref65" ref-type="bibr">65</xref>
,
<xref rid="ref72" ref-type="bibr">72</xref>
,
<xref rid="ref73" ref-type="bibr">73</xref>
]
<sup>.</sup>
</p>
<p>A meta-analysis [
<xref rid="ref74" ref-type="bibr">74</xref>
] of studies of IORT in locally advanced and recurrent rectal cancers together, has shown a significant benefit with addition of IORT on local control, disease-free survival and overall survival. Meta-analyses of complications did not demonstrate a significant increase in urologic or gastrointestinal complications; however, a greater number of wound complications did occur [
<xref rid="ref74" ref-type="bibr">74</xref>
].</p>
</sec>
<sec>
<title>Soft-tissue sarcomas</title>
<p>Surgery constitutes the main treatment modality for soft-tissue sarcomas; however, surgery alone cannot provide acceptable local control rates without hampering the functionality of the limb/organ in cases of large and high grade sarcomas, thus making radiation therapy an integral component of function preserving surgery. Radiation therapy used either preoperatively or postoperatively provides acceptable local control rates after an adequate surgery with negative margins. However, in cases of advanced tumours where negative margin is not possible without mutilating surgery (retroperitoneal sarcoma) or in case of recurrent tumours, optimum doses of EBRT cannot be delivered to provide acceptable local control.</p>
<p>IORT has been used in such tumours to escalate doses beyond that of conventional EBRT in an attempt to improve local control rates. In extremity sarcomas, IORT has also been used to replace external boost, reducing the dose and volumes treated with EBRT, so that tolerance of normal structures like joint space, bone, and skin can be respected.</p>
<p>
<xref ref-type="table" rid="table5">Table 5</xref>
summarises studies of IORT in extremity soft-tissue sarcomas, these studies were heterogeneous with varying proportion of recurrent tumours and incomplete resections. Use of IORT in these unfavourable patients aimed at preserving the limb while maintaining acceptable local control. IORT was mostly used in combination with function preserving surgery and moderate doses of EBRT. Recent series [
<xref rid="ref82" ref-type="bibr">82</xref>
<xref rid="ref85" ref-type="bibr">85</xref>
] of IORT demonstrate excellent LC rates and functional outcomes, comparable to the series of EBRT alone, despite including higher proportion of tumours with unfavourable factors. Dose of IORT was dependant on resection status, volume and dose of EBRT. While
<italic>R</italic>
+ disease fared equally well as
<italic>R</italic>
0 disease in the series by Call
<italic>et al</italic>
and Kretzler
<italic>et al</italic>
[
<xref rid="ref79" ref-type="bibr">79</xref>
,
<xref rid="ref82" ref-type="bibr">82</xref>
], studies by Niewald
<italic>et al</italic>
and Kretzler
<italic>et al</italic>
[
<xref rid="ref79" ref-type="bibr">79</xref>
,
<xref rid="ref81" ref-type="bibr">81</xref>
] reported equivalent outcomes in recurrent as well as primary disease. However, in some of the larger series, [
<xref rid="ref82" ref-type="bibr">82</xref>
<xref rid="ref85" ref-type="bibr">85</xref>
] resection status and recurrent disease were the most important factors determining local control. Limb preservation was achievable in most patients even with recurrent disease. The complications of neuropathy, contracture, and lymphedema were low, wound complications were the most common complications, and were not much different from that with EBRT [
<xref rid="ref79" ref-type="bibr">79</xref>
<xref rid="ref82" ref-type="bibr">82</xref>
].</p>
<p>Soft-tissue sarcomas in the retro peritoneum are difficult to remove with adequate margins due to their large size, advanced stage, and difficult location with multiple critical organs in close vicinity. Therefore, surgery is often combined with radiotherapy in order to improve the local control rate. However, the proximity of normal organs, such as viscera and neurovascular structures, has made the delivery of therapeutic doses of postoperative EBRT problematic, with higher rates of gastrointestinal complications, including disabling chronic enteritis and fistulae. These difficulties have led to adoption of IORT in the treatment regimen for retroperitoneal sarcoma since the late 1980s.</p>
<p>A randomised trial at the NCI [
<xref rid="ref86" ref-type="bibr">86</xref>
], at a median follow-up of 8 years, showed a significantly better local control with IOERT and low-dose post-operative EBRT compared to high-dose post-operative EBRT alone (60% vs. 20%,
<italic>p</italic>
< 0.05). The IOERT arm experienced significantly more peripheral neuropathy attributed in part to use of concurrent radio-sensitisers (60% vs. 5%,
<italic>p</italic>
< 0.05), while the EBRT only arm had significantly higher GI complications. Experience from other series, summarised in
<xref ref-type="table" rid="table6">Table 6</xref>
, has also shown encouraging results with a favourable toxicity profile.</p>
<p>IORT in combination with pre-operative or post-operative RT has shown encouraging results [
<xref rid="ref87" ref-type="bibr">87</xref>
<xref rid="ref94" ref-type="bibr">94</xref>
,
<xref rid="ref97" ref-type="bibr">97</xref>
,
<xref rid="ref99" ref-type="bibr">99</xref>
]. While initial reports [
<xref rid="ref87" ref-type="bibr">87</xref>
,
<xref rid="ref89" ref-type="bibr">89</xref>
,
<xref rid="ref90" ref-type="bibr">90</xref>
,
<xref rid="ref92" ref-type="bibr">92</xref>
] had higher proportion of patients receiving post-operative RT, recent series [
<xref rid="ref88" ref-type="bibr">88</xref>
,
<xref rid="ref91" ref-type="bibr">91</xref>
,
<xref rid="ref93" ref-type="bibr">93</xref>
,
<xref rid="ref97" ref-type="bibr">97</xref>
<xref rid="ref99" ref-type="bibr">99</xref>
] mostly use pre-operative RT because of the smaller volumes that are required with reduced rates of complications. Combination of pre-operative RT, gross total resection and IORT has demonstrated improved local control [
<xref rid="ref91" ref-type="bibr">91</xref>
,
<xref rid="ref98" ref-type="bibr">98</xref>
] as well as survival [
<xref rid="ref88" ref-type="bibr">88</xref>
,
<xref rid="ref91" ref-type="bibr">91</xref>
] compared to the non-IORT regimens in some of the recent non-randomised comparisons. Resection status and recurrent disease were the most important determinants for local control [
<xref rid="ref89" ref-type="bibr">89</xref>
,
<xref rid="ref92" ref-type="bibr">92</xref>
,
<xref rid="ref94" ref-type="bibr">94</xref>
,
<xref rid="ref97" ref-type="bibr">97</xref>
]. GI toxicities, neuropathy and ureteric stenosis are the most common complications with reported rates of 10–35%. They may be dose-dependent, high single dose resulting in greater risk of complications [
<xref rid="ref65" ref-type="bibr">65</xref>
,
<xref rid="ref86" ref-type="bibr">86</xref>
,
<xref rid="ref100" ref-type="bibr">100</xref>
].</p>
<p>Most studies of IORT shown in
<xref ref-type="table" rid="table5">Tables 5</xref>
and
<xref ref-type="table" rid="table6">6</xref>
had a large proportion of recurrent tumours, emphasising the fact that IORT plays a pivotal role in the management of these locally recurrent sarcomas. In a multi-centric, long-term outcomes analysis by the Spanish Cooperative Initiative [
<xref rid="ref101" ref-type="bibr">101</xref>
] for Intraoperative electron radiotherapy, 103 patients were investigated to analyse long-term outcomes of locally recurrent soft-tissue sarcoma (LR-STS) patients treated with a multidisciplinary approach. The 5-year IORT in-field control, disease-free survival (DFS), and overall survival were 73%, 43%, and 52%, respectively. Not combining EBRT with surgical resection and IOERT in patients with LR-STS was associated with a significantly increased probability of LR and IOERT in-field relapse. They concluded that low rate of severe toxic events suggests that a multimodality approach with re-resection and IOERT is feasible without prohibitive long-term side effects.</p>
</sec>
<sec>
<title>Paediatric tumours</title>
<p>Most paediatric tumours are radiosensitive and radiotherapy constitutes an integral component in their management schema, more so for the unresectable and recurrent tumours, where outcomes remain dismal with chemotherapy alone. However, the use of radiotherapy, especially EBRT in the paediatric population is fraught with late effects like retarded bone and soft tissue growth, abnormal organ development and the risk of second malignancies due to the sensitive nature of these maturing tissues. Thus, there is a narrow therapeutic window within which local control and late effects, which needs to be balanced. The goal of IORT for paediatric tumours is to improve the therapeutic ratio by increasing local control while limiting these late toxicities.</p>
<p>
<xref ref-type="table" rid="table7">Table 7</xref>
summarises various studies of IORT in paediatric tumours, though the numbers are small, IORT has been used across a wide variety of sites and histologies, as a sole radiation modality for radio-sensitive tumours like neuroblastoma [
<xref rid="ref102" ref-type="bibr">102</xref>
] or in combination with EBRT for dose escalation to improve local control in sarcomas [
<xref rid="ref103" ref-type="bibr">103</xref>
] or for dose de-escalation in RMS with low-dose EBRT. Oertel [
<xref rid="ref103" ref-type="bibr">103</xref>
], Goodman [
<xref rid="ref104" ref-type="bibr">104</xref>
] and Sole [
<xref rid="ref105" ref-type="bibr">105</xref>
]
<italic>et al</italic>
included quite a number of recurrent tumours. Use of IORT in combination with surgery and EBRT provided excellent local control across most studies with acceptable toxicity.</p>
<p>In a study by Sole [
<xref rid="ref105" ref-type="bibr">105</xref>
]
<italic>et al</italic>
, after a median follow-up of 72 months (range, 4–10 months), 10-year LC, disease-free survival, and OS was 74%, 57%, and 68%, respectively. In multivariate analysis after adjustment for other covariates, disease status (
<italic>p</italic>
= 0.04 and
<italic>p</italic>
= 0.05) and resection margin status (
<italic>p</italic>
< 0.01 and
<italic>p</italic>
= 0.04) remained significantly associated with LC and OS.</p>
<p>IOERT can be considered as an effective option as a part of multimodality regimen for paediatric solid malignancies, especially for patients with recurrent tumours and abdominopelvic malignancies.</p>
</sec>
<sec>
<title>Gynaecological cancers</title>
<p>Recurrent gynaecological malignancies are associated with poor survival due to lack of effective salvage options. Survival rates of locally recurrent cervical cancer after prior radiation therapy are dismal. Most recurrences especially those involving the pelvic sidewall are not resectable and when resection is possible (as in central recurrences), extensive procedures like pelvic exenteration are required, which are associated with a high rate of complications and operative mortality of over 10% [
<xref rid="ref108" ref-type="bibr">108</xref>
<xref rid="ref111" ref-type="bibr">111</xref>
]. Introduction of IORT has widened the scope of patients who may be offered surgery and patients who have been previously treated with non-surgical modalities can be offered radical resection when combined with IORT. In resectable recurrences, IORT given after gross total resection can improve local control rates.</p>
<p>IORT has been used to treat locally advanced primary cervical cancers also; however, these series [
<xref rid="ref112" ref-type="bibr">112</xref>
] are small and most of the experience comes from recurrent cancers (
<xref ref-type="table" rid="table8">Table 8</xref>
). IORT has shown to improve local control and thus survival in locally recurrent cancers [
<xref rid="ref113" ref-type="bibr">113</xref>
<xref rid="ref121" ref-type="bibr">121</xref>
] of the uterine cervix and endometrium, limited locoregional recurrences from endometrial cancers doing much better than recurrences from cervical cancers [
<xref rid="ref119" ref-type="bibr">119</xref>
,
<xref rid="ref122" ref-type="bibr">122</xref>
<xref rid="ref124" ref-type="bibr">124</xref>
]. The benefit of IORT is seen much more in patients with microscopic residual disease than in those with gross residual disease [
<xref rid="ref113" ref-type="bibr">113</xref>
<xref rid="ref115" ref-type="bibr">115</xref>
,
<xref rid="ref121" ref-type="bibr">121</xref>
]. Patient selection based on resection status and volume of recurrence are the most important factors determining outcome after IORT. Previously, irradiated patients when adjusted for resection status and volume of recurrence appear to fare as well as previously un-irradiated patients [
<xref rid="ref115" ref-type="bibr">115</xref>
] and addition of EBRT to IORT regimen further improves the control rates [
<xref rid="ref117" ref-type="bibr">117</xref>
,
<xref rid="ref119" ref-type="bibr">119</xref>
,
<xref rid="ref120" ref-type="bibr">120</xref>
,
<xref rid="ref123" ref-type="bibr">123</xref>
]. IORT does not seem to increase the rate of acute complications following surgery. Neuropathy and gastrointestinal toxicity are the most common IORT-related toxicities and occur in 5–30% of patients.</p>
</sec>
<sec>
<title>Genitourinary cancers</title>
<sec>
<title>Bladder cancer</title>
<p>Although multiple reports of perioperative brachytherapy in bladder cancer are available with encouraging results, there is limited data on IORT in bladder cancer, with only one small retrospective series in recurrent bladder cancer meeting our search and selection criteria. Recurrent bladder tumours after a cystectomy are associated with dismal survival rates, owing to the fact that adequate surgery is often not feasible and salvage with high doses of EBRT is difficult due to the tolerance of adjacent organs. IORT is used to deliver high doses to the tumour in an effort to improve local control. Hallemeier
<italic>et al</italic>
[
<xref rid="ref128" ref-type="bibr">128</xref>
] reported the use of IOERT in 17 patients after maximal resection of disease. Pre- or post-operative EBRT was used in 94% of patients. Encouraging 2-year local control and survival was seen, completely resected tumours were associated with a significant improvement in survival compared to gross residual disease.</p>
</sec>
<sec>
<title>Renal cancer</title>
<p>Radical surgery forms the mainstay of treatment in patients with renal cell carcinoma (RCC). However, in patients with recurrent and advanced tumours, achieving complete resection with wide margins may be difficult due to proximity to the critical structures and this effects not only the local control but survival as well [
<xref rid="ref129" ref-type="bibr">129</xref>
]. Adjuvant EBRT in this setting may improve local control; however, the doses achievable with EBRT is limited due to low tolerance of the surrounding structures like stomach, small bowel, contralateral kidney, liver, and spinal cord. IORT offers an attractive treatment option to escalate doses to the tumour bed, especially in cases with positive resection margins. Studies evaluating the role of IORT in the management of locally advanced and recurrent RCC are summarised in
<xref ref-type="table" rid="table9">Table 9</xref>
[
<xref rid="ref129" ref-type="bibr">129</xref>
<xref rid="ref134" ref-type="bibr">134</xref>
].</p>
<p>Habl
<italic>et al</italic>
[
<xref rid="ref132" ref-type="bibr">132</xref>
] reported outcomes with IOERT after complete surgical resection in a cohort of 17 patients with locally recurrent RCC. Although R0 resection could be achieved in only one-third of the patients, most patients failed distally, with only two local recurrences. None of the patients suffered from any acute or late radiation toxicities. One of the largest series of IOERT in RCC has been reported by Paly
<italic>et al</italic>
in a multi-institutional cohort of 98 patients. Twenty-eight per cent patients had advanced disease at presentation and 72% had recurrent disease. More than 50% had residual disease after resection. Sixty-two per cent received additional pre-operative or post-operative EBRT. An excellent local control of 72% at 5 years was demonstrated with grade 3 toxicity in 5% of patients. Higher IORT dose was associated with improved survival (
<italic>p</italic>
< 0.001). Thus, studies of IORT in RCC, though retrospective in nature demonstrate a consistently high local control rate in recurrent/advanced RCC with acceptable toxicity rates.</p>
</sec>
<sec>
<title>Prostate cancer</title>
<p>Locally advanced/high-risk prostate cancer is associated with significant risk of relapse when treated with radical prostatectomy alone, risk being the highest when the margins are positive. Adjuvant radiotherapy in this setting reduces the risk of relapse significantly [
<xref rid="ref135" ref-type="bibr">135</xref>
]. IORT has been explored in high-risk prostate cancers in combination with radical prostatectomy and post-operative EBRT to improve local control via dose escalation. IORT has the added radiobiological advantage of high single dose of radiation, which improves the therapeutic gain due to low α/β of prostate. It also helps limit doses to the rectum and has been shown to have low gastrointestinal (GI) morbidity even in combination with EBRT [
<xref rid="ref136" ref-type="bibr">136</xref>
]. Several small prospective series (
<xref ref-type="table" rid="table10">Table 10</xref>
[
<xref rid="ref136" ref-type="bibr">136</xref>
<xref rid="ref141" ref-type="bibr">141</xref>
]) have evaluated the feasibility of this multi-modality approach in patients with non-metastatic, node-negative disease with probability of LN involvement being less than 15%. Encouraging local control and acceptable toxicity has been demonstrated even though significant proportion of patients had margin positive disease in these series [
<xref rid="ref136" ref-type="bibr">136</xref>
,
<xref rid="ref139" ref-type="bibr">139</xref>
,
<xref rid="ref141" ref-type="bibr">141</xref>
]; however, long-term results are awaited.</p>
</sec>
</sec>
<sec>
<title>Upper gastro-intestinal tumours</title>
<sec>
<title>Gastric cancers</title>
<p>Curative resection is the mainstay of treatment for gastric cancer; however, high incidence of locoregional and systemic failures, makes outcomes dismal, especially in cases with gastric serosal involvement and/or nodal involvement [
<xref rid="ref142" ref-type="bibr">142</xref>
,
<xref rid="ref143" ref-type="bibr">143</xref>
]. Attempts to improve locoregional control and survival include addition of adjuvant radiotherapy/chemoradiation [
<xref rid="ref144" ref-type="bibr">144</xref>
], perioperative chemotherapy [
<xref rid="ref145" ref-type="bibr">145</xref>
] and extensive surgeries including D2/D3 resections [
<xref rid="ref146" ref-type="bibr">146</xref>
,
<xref rid="ref147" ref-type="bibr">147</xref>
]. Despite significant improvements in disease control and survival with adjuvant chemoradiotherapy, local and regional recurrences remain high at 19% and 65%, respectively, after tri-modality therapy [
<xref rid="ref144" ref-type="bibr">144</xref>
]. Therefore, there may be a case for dose escalation with IORT in advanced gastric carcinomas (especially serosal/nodal involvement) to improve local/regional control. IORT in gastric cancer involves boosting the tumour bed, remaining lymphatic networks, and nodal basins to control residual microscopic disease and improve locoregional control.</p>
<p>Role of IORT in gastric cancer after curative resection has been evaluated in multiple studies (retrospective, prospective, and randomised control), which have shown an improvement in locoregional control [
<xref rid="ref148" ref-type="bibr">148</xref>
,
<xref rid="ref150" ref-type="bibr">150</xref>
] and survival with IORT, especially in patients with stage-II/stage-III and node-positive disease (
<xref ref-type="table" rid="table11">Table 11</xref>
) [
<xref rid="ref1" ref-type="bibr">1</xref>
,
<xref rid="ref148" ref-type="bibr">148</xref>
,
<xref rid="ref150" ref-type="bibr">150</xref>
<xref rid="ref154" ref-type="bibr">154</xref>
]. While initial studies of IORT involved less aggressive surgeries (D1) and infrequent use of adjuvant radiotherapy recent studies [
<xref rid="ref148" ref-type="bibr">148</xref>
,
<xref rid="ref150" ref-type="bibr">150</xref>
,
<xref rid="ref153" ref-type="bibr">153</xref>
] have demonstrated a consistent benefit with IORT, even in combination with D2 resections and post-operative CTRT. Extended resections like D3 may reduce the benefit with IORT [
<xref rid="ref153" ref-type="bibr">153</xref>
], however, IORT combined with a limited lymph node dissection (D1) may be associated with survival similar to extended dissection (D2/3), with lesser post-operative mortality [
<xref rid="ref156" ref-type="bibr">156</xref>
]. While most studies did not show an increase in complications with the use of IORT, Drognitz
<italic>et al</italic>
[
<xref rid="ref151" ref-type="bibr">151</xref>
] have demonstrated a significant increase in surgical complications with the use of IORT (44% vs. 20%,
<italic>p</italic>
< 0.05). They also did not show a benefit with addition of IORT to surgical resection. Complication rates need to be carefully weighed against improvement in locoregional control to maximise benefits with IORT [
<xref rid="ref157" ref-type="bibr">157</xref>
].</p>
</sec>
<sec>
<title>Pancreatic cancer</title>
<p>Pancreatic cancer is associated with dismal survival rates even in completely resected patients. Significant proportion of patients either develop locoregional recurrence or systemic metastases. Multi-modality treatment approaches combining chemotherapy and radiotherapy in addition to surgery have resulted in some improvement in locoregional control and survival [
<xref rid="ref162" ref-type="bibr">162</xref>
<xref rid="ref164" ref-type="bibr">164</xref>
]. Attempts at radiotherapy dose escalation with EBRT have been limited due to the location of tumour. IORT can result in delivery of higher doses to the tumour bed and may improve local control and survival in resected pancreatic cancers. In unresectable tumours, IORT alone or in combination with EBRT can provide some local control along with effective palliation of symptoms.</p>
<p>Studies of IORT in resectable pancreatic cancers are summarised in
<xref ref-type="table" rid="table12">Table 12</xref>
[
<xref rid="ref165" ref-type="bibr">165</xref>
<xref rid="ref171" ref-type="bibr">171</xref>
], though heterogeneous in proportion of
<italic>R</italic>
1 resections and use of adjuvant EBRT and/or chemotherapy, they have been consistent in showing an improvement in locoregional control [
<xref rid="ref165" ref-type="bibr">165</xref>
<xref rid="ref168" ref-type="bibr">168</xref>
]. Some studies have also shown an improvement in survival [
<xref rid="ref165" ref-type="bibr">165</xref>
,
<xref rid="ref168" ref-type="bibr">168</xref>
,
<xref rid="ref172" ref-type="bibr">172</xref>
,
<xref rid="ref173" ref-type="bibr">173</xref>
]. Addition of IORT to standard treatment did not result in any increase in perioperative morbidity or late toxicity rates [
<xref rid="ref165" ref-type="bibr">165</xref>
,
<xref rid="ref167" ref-type="bibr">167</xref>
<xref rid="ref169" ref-type="bibr">169</xref>
,
<xref rid="ref173" ref-type="bibr">173</xref>
]. Stage [
<xref rid="ref172" ref-type="bibr">172</xref>
,
<xref rid="ref173" ref-type="bibr">173</xref>
],
<italic>R</italic>
0 resection [
<xref rid="ref166" ref-type="bibr">166</xref>
], chemotherapy [
<xref rid="ref170" ref-type="bibr">170</xref>
], and pre-operative treatment [
<xref rid="ref168" ref-type="bibr">168</xref>
] were other important determinants of survival in these studies. A systematic review also agreed with observations from these non-randomised studies and suggested a survival benefit with IORT in resected pancreatic patients.</p>
<p>Studies of IORT in unresectable pancreatic cancer (
<xref ref-type="table" rid="table12">Table 12</xref>
[
<xref rid="ref174" ref-type="bibr">174</xref>
<xref rid="ref180" ref-type="bibr">180</xref>
]) on the other hand, have failed to demonstrate a survival benefit with the addition of IORT, though an improved local control was seen [
<xref rid="ref174" ref-type="bibr">174</xref>
<xref rid="ref176" ref-type="bibr">176</xref>
,
<xref rid="ref178" ref-type="bibr">178</xref>
,
<xref rid="ref181" ref-type="bibr">181</xref>
]. IORT also resulted in significant pain relief and palliation of symptoms [
<xref rid="ref175" ref-type="bibr">175</xref>
,
<xref rid="ref177" ref-type="bibr">177</xref>
<xref rid="ref179" ref-type="bibr">179</xref>
] with no additional morbidity or toxicity [
<xref rid="ref175" ref-type="bibr">175</xref>
,
<xref rid="ref177" ref-type="bibr">177</xref>
,
<xref rid="ref181" ref-type="bibr">181</xref>
]. Tumour size [
<xref rid="ref17" ref-type="bibr">17</xref>
,
<xref rid="ref174" ref-type="bibr">174</xref>
,
<xref rid="ref176" ref-type="bibr">176</xref>
,
<xref rid="ref180" ref-type="bibr">180</xref>
], metastasis [
<xref rid="ref179" ref-type="bibr">179</xref>
], and chemotherapy [
<xref rid="ref17" ref-type="bibr">17</xref>
,
<xref rid="ref174" ref-type="bibr">174</xref>
,
<xref rid="ref176" ref-type="bibr">176</xref>
] were predictors of survival in these studies of unresectable pancreatic cancer. Most of these studies included patients treated before the year 2000 and utilised post-operative radiotherapy and chemotherapy with older regimes. In the current era, pre-operative chemotherapy (± radiotherapy) with novel systemic agents (like FOLFIRINOX and nab-Paclitaxel) has shown to improve resectablity rates and survival in unresectable pancreatic cancers [
<xref rid="ref182" ref-type="bibr">182</xref>
,
<xref rid="ref183" ref-type="bibr">183</xref>
]. Keane
<italic>et al</italic>
[
<xref rid="ref181" ref-type="bibr">181</xref>
], evaluated the role of IORT in combination with intensive neoadjuvant chemoradiotherapy regimens and demonstrated encouraging survival rates in patients with close/positive margins and unresectable disease with no increase in toxicity. Further studies are required to better define the role of IORT in the management of pancreatic cancers, in the current era especially with the advent of novel systemic agents.</p>
</sec>
</sec>
</sec>
<sec>
<title>Conclusion</title>
<p>Intraoperative radiation therapy is an attractive treatment option for patients with colorectal, gynaecological, intra-abdominal, head and neck, and most recently, breast cancers. IORT has been used in a multitude of roles across these sites, for dose escalation, EBRT dose de-escalation, as sole radiation modality in early-breast cancers and as a Re-irradiation modality in recurrent cancers. IORT serves its role best in combination with gross total resection and moderate doses of EBRT. Utility of IORT has been tested in the setting of a randomised control trial in early breast, retroperitoneum, gastric and colorectal cancers, the results of which support the use of IORT as a management option in these settings. However, appropriate technique and patient selection is the key to success with IORT. IORT has the potential to improve outcomes in recurrent cancers of the pelvis, head and neck and colorectum and can be considered as a supplement to gross total resection. In paediatric tumours, IORT serves to decrease late toxicities associated with EBRT. In appropriately selected patients, complication rates associated with IORT are low.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="ref1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shibamoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ono</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiation therapy for carcinoma of the stomach and pancreas</article-title>
<source>Front Radiat Ther Oncol</source>
<year>1991</year>
<volume>25</volume>
<fpage>258</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="doi">10.1159/000429597</pub-id>
<pub-id pub-id-type="pmid">1908417</pub-id>
</element-citation>
</ref>
<ref id="ref2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Intraoperative radiotherapy: the Japanese experience</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>1981</year>
<volume>7</volume>
<issue>7</issue>
<fpage>863</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/0360-3016(81)90001-8</pub-id>
<pub-id pub-id-type="pmid">7198109</pub-id>
</element-citation>
</ref>
<ref id="ref3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abe</surname>
<given-names>MFM</given-names>
</name>
<name>
<surname>Yaniano</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative irradiation in abdominal and cerebral tumours</article-title>
<source>Acta Radiol</source>
<year>1971</year>
<volume>10</volume>
<fpage>408</fpage>
<lpage>16</lpage>
</element-citation>
</ref>
<ref id="ref4">
<label>4.</label>
<element-citation publication-type="book">
<collab>Intraoperative radiation therapy</collab>
<person-group person-group-type="editor">
<name>
<surname>Abe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Proceedings of the third international symposium on intraoperative radiation therapy</article-title>
<year>1991</year>
</element-citation>
</ref>
<ref id="ref5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldson</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Past, present and prospects of intraoperative radiotherapy (IOR)</article-title>
<source>Semin Oncol</source>
<year>1981</year>
</element-citation>
</ref>
<ref id="ref6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veronesi U</surname>
<given-names>OR</given-names>
</name>
<name>
<surname>Luini</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A preliminary report of intraoperative radiotherapy (IORT) in limited-stage breast cancers that are conservatively treated</article-title>
<source>Eur J Cancer</source>
<year>2001</year>
<volume>2001</volume>
<issue>37</issue>
<fpage>2178</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="doi">10.1016/S0959-8049(01)00285-4</pub-id>
</element-citation>
</ref>
<ref id="ref7">
<label>7.</label>
<element-citation publication-type="journal">
<collab>Vaeth JMea</collab>
<article-title>Intraoperative radiation therapy in the treatment of cancer</article-title>
<source>Front Radiat Ther Oncol</source>
<year>1996</year>
<volume>31</volume>
<fpage>65</fpage>
<lpage>7</lpage>
</element-citation>
</ref>
<ref id="ref8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harrison LB</surname>
<given-names>EW</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>LL</given-names>
</name>
</person-group>
<article-title>High dose rate intraoperative radiation therapy for colorectal cancer</article-title>
<source>I Oncol</source>
<year>1995</year>
<volume>9</volume>
<fpage>679</fpage>
<lpage>83</lpage>
</element-citation>
</ref>
<ref id="ref9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harrison LB</surname>
<given-names>EW</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>LL</given-names>
</name>
</person-group>
<article-title>High-dose rate intraoperative radiation therapy for colorectal cancer: II</article-title>
<source>Oncol</source>
<year>1995</year>
<volume>9</volume>
<fpage>737</fpage>
<lpage>41</lpage>
</element-citation>
</ref>
<ref id="ref10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bratengeier K</surname>
<given-names>KT</given-names>
</name>
</person-group>
<article-title>Homogeneous Ir-192 afterloading-flab irradiation of plane surfaces</article-title>
<source>Z Med Phys</source>
<year>2002</year>
<volume>12</volume>
<issue>230–7</issue>
<pub-id pub-id-type="doi">10.1016/S0939-3889(15)70477-0</pub-id>
</element-citation>
</ref>
<ref id="ref11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huber FT</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Locally advanced rectal cancer: resection and intraoperative radiotherapy using the flab method combined with preoperative or postoperative radiochemotherapy</article-title>
<source>Dis Colon Rectum</source>
<year>1996</year>
<volume>39</volume>
<issue>774–9</issue>
<pub-id pub-id-type="doi">10.1007/BF02054443</pub-id>
<pub-id pub-id-type="pmid">8674370</pub-id>
</element-citation>
</ref>
<ref id="ref12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernier</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Pajak</surname>
<given-names>TF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)</article-title>
<source>Head Neck</source>
<year>2005</year>
<volume>27</volume>
<issue>10</issue>
<fpage>843</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1002/hed.20279</pub-id>
<pub-id pub-id-type="pmid">16161069</pub-id>
</element-citation>
</ref>
<ref id="ref13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernier</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Domenge</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ozsahin</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer</article-title>
<source>N Engl J Med</source>
<year>2004</year>
<volume>350</volume>
<issue>19</issue>
<fpage>1945</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa032641</pub-id>
<pub-id pub-id-type="pmid">15128894</pub-id>
</element-citation>
</ref>
<ref id="ref14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cooper</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Pajak</surname>
<given-names>TF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2012</year>
<volume>84</volume>
<issue>5</issue>
<fpage>1198</fpage>
<lpage>205</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2012.05.008</pub-id>
<pmc-comment>3465463</pmc-comment>
<pub-id pub-id-type="pmid">22749632</pub-id>
</element-citation>
</ref>
<ref id="ref15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pignon</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Bourhis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Domenge</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data MACH-NC collaborative group Meta-analysis of chemotherapy on head and neck cancer</article-title>
<source>Lancet</source>
<year>2000</year>
<volume>355</volume>
<issue>9208</issue>
<fpage>949</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(00)90011-4</pub-id>
<pub-id pub-id-type="pmid">10768432</pub-id>
</element-citation>
</ref>
<ref id="ref16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janot</surname>
<given-names>F</given-names>
</name>
<name>
<surname>de Raucourt</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Benhamou</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma</article-title>
<source>J Clin Oncol</source>
<year>2008</year>
<volume>26</volume>
<issue>34</issue>
<fpage>5518</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1200/JCO.2007.15.0102</pub-id>
<pub-id pub-id-type="pmid">18936479</pub-id>
</element-citation>
</ref>
<ref id="ref17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Bucci</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Singer</surname>
<given-names>MI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiation therapy for recurrent head-and-neck cancer: the UCSF experience</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2007</year>
<volume>67</volume>
<issue>1</issue>
<fpage>122</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2006.08.038</pub-id>
<pub-id pub-id-type="pmid">17084543</pub-id>
</element-citation>
</ref>
<ref id="ref18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nag</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schuller</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Martinez-Monge</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative electron beam radiotherapy for previously irradiated advanced head and neck malignancies</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>1998</year>
<volume>42</volume>
<issue>5</issue>
<fpage>1085</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/S0360-3016(98)00289-2</pub-id>
<pub-id pub-id-type="pmid">9869233</pub-id>
</element-citation>
</ref>
<ref id="ref19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perry</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wolden</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High-dose-rate intraoperative radiation therapy for recurrent head-and-neck cancer</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2010</year>
<volume>76</volume>
<issue>4</issue>
<fpage>1140</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2009.03.025</pub-id>
<pub-id pub-id-type="pmid">19560882</pub-id>
</element-citation>
</ref>
<ref id="ref20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scala</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Urken</surname>
<given-names>ML</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative high-dose-rate radiotherapy in the management of locoregionally recurrent head and neck cancer</article-title>
<source>Head Neck</source>
<year>2013</year>
<volume>35</volume>
<issue>4</issue>
<fpage>485</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1002/hed.23007</pub-id>
<pub-id pub-id-type="pmid">23460243</pub-id>
</element-citation>
</ref>
<ref id="ref21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeidan</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Shiue</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Weed</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiotherapy for parotid cancer: a single-institution experience</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2012</year>
<volume>82</volume>
<issue>5</issue>
<fpage>1831</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2011.02.033</pub-id>
<pub-id pub-id-type="pmid">21514074</pub-id>
</element-citation>
</ref>
<ref id="ref22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeidan</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Weed</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiation therapy for advanced cervical metastasis: a single institution experience</article-title>
<source>Radiat Oncol</source>
<year>2011</year>
<volume>6</volume>
<fpage>72</fpage>
<pub-id pub-id-type="doi">10.1186/1748-717X-6-72</pub-id>
<pmc-comment>3141525</pmc-comment>
<pub-id pub-id-type="pmid">21676211</pub-id>
</element-citation>
</ref>
<ref id="ref23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinheiro</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Foote</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>McCaffrey</surname>
<given-names>TV</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiotherapy for head and neck and skull base cancer</article-title>
<source>Head Neck</source>
<year>2003</year>
<volume>25</volume>
<issue>3</issue>
<fpage>217</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="doi">10.1002/hed.10203</pub-id>
<pub-id pub-id-type="pmid">12599289</pub-id>
</element-citation>
</ref>
<ref id="ref24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vaidya JS</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Tobias</surname>
<given-names>JS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Targeted intra-operative radiotherapy (Targit): an innovative method of treatment for early breast cancer</article-title>
<source>Ann Oncol</source>
<year>2001</year>
<volume>12</volume>
<pub-id pub-id-type="doi">10.1023/A:1011609401132</pub-id>
<pub-id pub-id-type="pmid">11583188</pub-id>
</element-citation>
</ref>
<ref id="ref25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vaidya JS</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Tobias</surname>
<given-names>JS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Targeted intraoperative radiotherapy (TARGIT) yields very low recurrence rates when given as a boost</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2006</year>
<volume>66</volume>
<fpage>1335</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2006.07.1378</pub-id>
<pub-id pub-id-type="pmid">17084562</pub-id>
</element-citation>
</ref>
<ref id="ref26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veronesi U</surname>
<given-names>OR</given-names>
</name>
<name>
<surname>Luini</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons</article-title>
<source>Breast Cancer Res Treat</source>
<year>2010</year>
<volume>124</volume>
<fpage>141</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="doi">10.1007/s10549-010-1115-5</pub-id>
<pub-id pub-id-type="pmid">20711810</pub-id>
</element-citation>
</ref>
<ref id="ref27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vaidya</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Wenz</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bulsara</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial</article-title>
<source>Lancet</source>
<year>2014</year>
<volume>383</volume>
<issue>9917</issue>
<fpage>603</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(13)61950-9</pub-id>
<pub-id pub-id-type="pmid">24224997</pub-id>
</element-citation>
</ref>
<ref id="ref28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veronesi</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Orecchia</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Maisonneuve</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial</article-title>
<source>Lancet Oncol</source>
<year>2013</year>
<volume>14</volume>
<issue>13</issue>
<fpage>1269</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1016/S1470-2045(13)70497-2</pub-id>
<pub-id pub-id-type="pmid">24225155</pub-id>
</element-citation>
</ref>
<ref id="ref29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cuzick J</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Peto</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer</article-title>
<source>Cancer Treat Rep</source>
<year>1987</year>
<volume>71</volume>
<fpage>15</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="pmid">2856861</pub-id>
</element-citation>
</ref>
<ref id="ref30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harness</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Silverstein</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Wazer</surname>
<given-names>DE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Radiotherapy for breast cancer, the TARGIT-A trial</article-title>
<source>Lancet</source>
<year>2014</year>
<volume>383</volume>
<issue>9930</issue>
<fpage>1718</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(14)60829-1</pub-id>
<pub-id pub-id-type="pmid">24835612</pub-id>
</element-citation>
</ref>
<ref id="ref31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mackenzie</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fyles</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Radiotherapy for breast cancer, the TARGIT-A trial</article-title>
<source>Lancet</source>
<year>2014</year>
<volume>383</volume>
<issue>9930</issue>
<fpage>1717</fpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(14)60827-8</pub-id>
<pub-id pub-id-type="pmid">24835610</pub-id>
</element-citation>
</ref>
<ref id="ref32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yarnold</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Offersen</surname>
<given-names>BV</given-names>
</name>
<name>
<surname>Olivotto</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Radiotherapy for breast cancer, the TARGIT-A trial</article-title>
<source>Lancet</source>
<year>2014</year>
<volume>383</volume>
<issue>9930</issue>
<fpage>1717</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(14)60828-X</pub-id>
<pub-id pub-id-type="pmid">24835611</pub-id>
</element-citation>
</ref>
<ref id="ref33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cuzick</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Radiotherapy for breast cancer, the TARGIT-A trial</article-title>
<source>Lancet</source>
<year>2014</year>
<volume>383</volume>
<issue>9930</issue>
<fpage>1716</fpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(14)60825-4</pub-id>
<pub-id pub-id-type="pmid">24835608</pub-id>
</element-citation>
</ref>
<ref id="ref34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haviland</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>A'Hern</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bentzen</surname>
<given-names>SM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Radiotherapy for breast cancer, the TARGIT-A trial</article-title>
<source>Lancet</source>
<year>2014</year>
<volume>383</volume>
<issue>9930</issue>
<fpage>1716</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(14)60826-6</pub-id>
<pub-id pub-id-type="pmid">24835609</pub-id>
</element-citation>
</ref>
<ref id="ref35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silverstein</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Fastner</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Maluta</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiation therapy: a critical analysis of the ELIOT and TARGIT trials Part 2–TARGIT</article-title>
<source>Ann Surg Oncol</source>
<year>2014</year>
<volume>21</volume>
<issue>12</issue>
<fpage>3793</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1245/s10434-014-3999-5</pub-id>
<pmc-comment>4189006</pmc-comment>
<pub-id pub-id-type="pmid">25138079</pub-id>
</element-citation>
</ref>
<ref id="ref36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silverstein</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Fastner</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Maluta</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiation therapy: a critical analysis of the ELIOT and TARGIT trials Part 1–ELIOT</article-title>
<source>Ann Surg Oncol</source>
<year>2014</year>
<volume>21</volume>
<issue>12</issue>
<fpage>3787</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1245/s10434-014-3998-6</pub-id>
<pmc-comment>4189005</pmc-comment>
<pub-id pub-id-type="pmid">25160734</pub-id>
</element-citation>
</ref>
<ref id="ref37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leonardi</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Maisonneuve</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mastropasqua</surname>
<given-names>MG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Accelerated partial breast irradiation with intraoperative electrons: using GEC-ESTRO recommendations as guidance for patient selection</article-title>
<source>Radiother Oncol</source>
<year>2013</year>
<volume>106</volume>
<issue>1</issue>
<fpage>21</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1016/j.radonc.2012.10.018</pub-id>
<pub-id pub-id-type="pmid">23218711</pub-id>
</element-citation>
</ref>
<ref id="ref38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leonardi</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Maisonneuve</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mastropasqua</surname>
<given-names>MG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>How do the ASTRO consensus statement guidelines for the application of accelerated partial breast irradiation fit intraoperative radiotherapy? A retrospective analysis of patients treated at the European Institute of Oncology</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2012</year>
<volume>83</volume>
<issue>3</issue>
<fpage>806</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2011.08.014</pub-id>
<pub-id pub-id-type="pmid">22245196</pub-id>
</element-citation>
</ref>
<ref id="ref39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Arthur</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Buchholz</surname>
<given-names>TA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO)</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2009</year>
<volume>74</volume>
<issue>4</issue>
<fpage>987</fpage>
<lpage>1001</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2009.02.031</pub-id>
<pub-id pub-id-type="pmid">19545784</pub-id>
</element-citation>
</ref>
<ref id="ref40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polgar</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Van Limbergen</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Potter</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Europeen de Curietherapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009)</article-title>
<source>Radiother Oncol</source>
<year>2010</year>
<volume>94</volume>
<issue>3</issue>
<fpage>264</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="doi">10.1016/j.radonc.2010.01.014</pub-id>
<pub-id pub-id-type="pmid">20181402</pub-id>
</element-citation>
</ref>
<ref id="ref41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maluta</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dall'Oglio</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Goer</surname>
<given-names>DA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative electron radiotherapy (IOERT) as an alternative to standard whole breast irradiation: only for low-risk subgroups?</article-title>
<source>Breast care</source>
<year>2014</year>
<volume>9</volume>
<issue>2</issue>
<fpage>102</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1159/000362392</pub-id>
<pmc-comment>4038312</pmc-comment>
<pub-id pub-id-type="pmid">24944552</pub-id>
</element-citation>
</ref>
<ref id="ref42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fastner</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sedlmayer</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>IORT with electrons as boost strategy during breast conserving therapy in limited stage breast cancer: long term results of an ISIORT pooled analysis</article-title>
<source>Radiother Oncol</source>
<year>2013</year>
<volume>108</volume>
<issue>2</issue>
<fpage>279</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="doi">10.1016/j.radonc.2013.05.031</pub-id>
<pub-id pub-id-type="pmid">23830467</pub-id>
</element-citation>
</ref>
<ref id="ref43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vaidya</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Baum</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tobias</surname>
<given-names>JS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term results of targeted intraoperative radiotherapy (Targit) boost during breast-conserving surgery</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2011</year>
<volume>81</volume>
<issue>4</issue>
<fpage>1091</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2010.07.1996</pub-id>
<pub-id pub-id-type="pmid">20951505</pub-id>
</element-citation>
</ref>
<ref id="ref44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blank</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kraus-Tiefenbacher</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Welzel</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Single-center long-term follow-up after intraoperative radiotherapy as a boost during breast-conserving surgery using low-kilovoltage x-rays</article-title>
<source>Ann Surg Oncol</source>
<year>2010</year>
<volume>17</volume>
<issue>Suppl 3</issue>
<fpage>352</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1245/s10434-010-1265-z</pub-id>
<pub-id pub-id-type="pmid">20853058</pub-id>
</element-citation>
</ref>
<ref id="ref45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malter</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Puppe</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rogee</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Single center experiences with intraoperative radiotherapy as a boost during oncoplastic breast-conserving surgery</article-title>
<source>Eur J Cancer</source>
<year>2012</year>
<volume>48</volume>
<fpage>S219</fpage>
<pub-id pub-id-type="doi">10.1016/S0959-8049(12)70663-9</pub-id>
</element-citation>
</ref>
<ref id="ref46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malter</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kirn</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Mallmann</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oncoplastic breast reconstruction after IORT</article-title>
<source>Transla Cancer Res</source>
<year>2014</year>
<volume>3</volume>
<issue>1</issue>
<fpage>74</fpage>
<lpage>82</lpage>
</element-citation>
</ref>
<ref id="ref47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braendengen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tveit</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Berglund</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer</article-title>
<source>J Clin Oncol</source>
<year>2008</year>
<volume>26</volume>
<issue>22</issue>
<fpage>3687</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1200/JCO.2007.15.3858</pub-id>
<pub-id pub-id-type="pmid">18669453</pub-id>
</element-citation>
</ref>
<ref id="ref48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frykholm</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Pahlman</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Glimelius</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Combined chemo- and radiotherapy vs. radiotherapy alone in the treatment of primary, nonresectable adenocarcinoma of the rectum</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2001</year>
<volume>50</volume>
<issue>2</issue>
<fpage>427</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1016/S0360-3016(01)01479-1</pub-id>
<pub-id pub-id-type="pmid">11380230</pub-id>
</element-citation>
</ref>
<ref id="ref49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calvo</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Gomez-Espi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Diaz-Gonzalez</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative presacral electron boost following preoperative chemoradiation in T3-4Nx rectal cancer: initial local effects and clinical outcome analysis</article-title>
<source>Radiother Oncol</source>
<year>2002</year>
<volume>62</volume>
<issue>2</issue>
<fpage>201</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1016/S0167-8140(01)00477-7</pub-id>
<pub-id pub-id-type="pmid">11937247</pub-id>
</element-citation>
</ref>
<ref id="ref50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mathis</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Pemberton</surname>
<given-names>JH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Unresectable colorectal cancer can be cured with multimodality therapy</article-title>
<source>Ann Surg</source>
<year>2008</year>
<volume>248</volume>
<issue>4</issue>
<fpage>592</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">18936572</pub-id>
</element-citation>
</ref>
<ref id="ref51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minsky</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Enker</surname>
<given-names>WE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Radiation therapy for unresectable rectal cancer</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<volume>21</volume>
<issue>5</issue>
<fpage>1283</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">1938525</pub-id>
</element-citation>
</ref>
<ref id="ref52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ratto</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Valentini</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Morganti</surname>
<given-names>AG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Combined-modality therapy in locally advanced primary rectal cancer</article-title>
<source>Dis Colon Rectum</source>
<year>2003</year>
<volume>46</volume>
<issue>1</issue>
<fpage>59</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1007/s10350-004-6497-1</pub-id>
<pub-id pub-id-type="pmid">12544523</pub-id>
</element-citation>
</ref>
<ref id="ref53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sadahiro</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ishikawa</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Preoperative radio/chemo-radiotherapy in combination with intraoperative radiotherapy for T3-4Nx rectal cancer</article-title>
<source>Eur J Surg Oncol</source>
<year>2004</year>
<volume>30</volume>
<issue>7</issue>
<fpage>750</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejso.2004.04.012</pub-id>
<pub-id pub-id-type="pmid">15296989</pub-id>
</element-citation>
</ref>
<ref id="ref54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferenschild</surname>
<given-names>FT</given-names>
</name>
<name>
<surname>Vermaas</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nuyttens</surname>
<given-names>JJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Value of intraoperative radiotherapy in locally advanced rectal cancer</article-title>
<source>Dis Colon Rectum</source>
<year>2006</year>
<volume>49</volume>
<issue>9</issue>
<fpage>1257</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="doi">10.1007/s10350-006-0651-x</pub-id>
<pub-id pub-id-type="pmid">16912909</pub-id>
</element-citation>
</ref>
<ref id="ref55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roeder</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Treiber</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Oertel</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Patterns of failure and local control after intraoperative electron boost radiotherapy to the presacral space in combination with total mesorectal excision in patients with locally advanced rectal cancer</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2007</year>
<volume>67</volume>
<issue>5</issue>
<fpage>1381</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2006.11.039</pub-id>
<pub-id pub-id-type="pmid">17275208</pub-id>
</element-citation>
</ref>
<ref id="ref56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takayama</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Matsuoka</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiotherapy for oncological and function-preserving surgery in patients with advanced lower rectal cancer</article-title>
<source>Langenbecks Arch Surg</source>
<year>2008</year>
<volume>393</volume>
<issue>2</issue>
<fpage>173</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1007/s00423-007-0260-8</pub-id>
<pub-id pub-id-type="pmid">18172677</pub-id>
</element-citation>
</ref>
<ref id="ref57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valentini</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Coco</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rizzo</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Outcomes of clinical T4M0 extra-peritoneal rectal cancer treated with preoperative radiochemotherapy and surgery: a prospective evaluation of a single institutional experience</article-title>
<source>Surgery</source>
<year>2009</year>
<volume>145</volume>
<issue>5</issue>
<fpage>486</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1016/j.surg.2009.01.007</pub-id>
<pub-id pub-id-type="pmid">19375606</pub-id>
</element-citation>
</ref>
<ref id="ref58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dubois</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Bussieres</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Richaud</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intra-operative radiotherapy of rectal cancer: results of the French multi-institutional randomized study</article-title>
<source>Radiother Oncol</source>
<year>2011</year>
<volume>98</volume>
<issue>3</issue>
<fpage>298</fpage>
<lpage>303</lpage>
<pub-id pub-id-type="doi">10.1016/j.radonc.2011.01.017</pub-id>
<pub-id pub-id-type="pmid">21339010</pub-id>
</element-citation>
</ref>
<ref id="ref59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kusters</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Valentini</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Calvo</surname>
<given-names>FA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Results of European pooled analysis of IORT-containing multimodality treatment for locally advanced rectal cancer: adjuvant chemotherapy prevents local recurrence rather than distant metastases</article-title>
<source>Ann Oncol</source>
<year>2010</year>
<volume>21</volume>
<issue>6</issue>
<fpage>1279</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="doi">10.1093/annonc/mdp501</pub-id>
<pub-id pub-id-type="pmid">19889621</pub-id>
</element-citation>
</ref>
<ref id="ref60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sole</surname>
<given-names>CV</given-names>
</name>
<name>
<surname>Calvo</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Serrano</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Post-chemoradiation intraoperative electron-beam radiation therapy boost in resected locally advanced rectal cancer: long-term results focused on topographic pattern of locoregional relapse</article-title>
<source>Radiother Oncol</source>
<year>2014</year>
<volume>112</volume>
<issue>1</issue>
<fpage>52</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/j.radonc.2014.05.012</pub-id>
<pub-id pub-id-type="pmid">24997989</pub-id>
</element-citation>
</ref>
<ref id="ref61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holman</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Haddock</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Gunderson</surname>
<given-names>LL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Results of intraoperative electron beam radiotherapy containing multimodality treatment for locally unresectable T4 rectal cancer: a pooled analysis of the Mayo Clinic Rochester and Catharina Hospital Eindhoven</article-title>
<source>J Gastrointest Oncol</source>
<year>2016</year>
<volume>7</volume>
<issue>6</issue>
<fpage>903</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.21037/jgo.2016.07.01</pub-id>
<pub-id pub-id-type="pmid">28078113</pub-id>
</element-citation>
</ref>
<ref id="ref62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willett</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Shellito</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Tepper</surname>
<given-names>JE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative electron beam radiation therapy for primary locally advanced rectal and rectosigmoid carcinoma</article-title>
<source>J Clin Oncol</source>
<year>1991</year>
<volume>9</volume>
<issue>5</issue>
<fpage>843</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1200/JCO.1991.9.5.843</pub-id>
<pub-id pub-id-type="pmid">2016628</pub-id>
</element-citation>
</ref>
<ref id="ref63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gunderson</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Devine</surname>
<given-names>RM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative irradiation after palliative surgery for locally recurrent rectal cancer</article-title>
<source>Cancer</source>
<year>1995</year>
<volume>75</volume>
<issue>4</issue>
<fpage>939</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">7531113</pub-id>
</element-citation>
</ref>
<ref id="ref64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willett</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Shellito</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Tepper</surname>
<given-names>JE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative electron beam radiation therapy for recurrent locally advanced rectal or rectosigmoid carcinoma</article-title>
<source>Cancer</source>
<year>1991</year>
<volume>67</volume>
<issue>6</issue>
<fpage>1504</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">2001537</pub-id>
</element-citation>
</ref>
<ref id="ref65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haddock</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Combined modality therapy including intraoperative electron irradiation for locally recurrent colorectal cancer</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2011</year>
<volume>79</volume>
<issue>1</issue>
<fpage>143</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2009.10.046</pub-id>
<pub-id pub-id-type="pmid">20395067</pub-id>
</element-citation>
</ref>
<ref id="ref66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valentini</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Morganti</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>De Franco</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chemoradiation with or without intraoperative radiation therapy in patients with locally recurrent rectal carcinoma: prognostic factors and long term outcome</article-title>
<source>Cancer</source>
<year>1999</year>
<volume>86</volume>
<issue>12</issue>
<fpage>2612</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="pmid">10594856</pub-id>
</element-citation>
</ref>
<ref id="ref67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiig</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Tveit</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Poulsen</surname>
<given-names>JP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Preoperative irradiation and surgery for recurrent rectal cancer. Will intraoperative radiotherapy (IORT) be of additional benefit? A prospective study</article-title>
<source>Radiother Oncol</source>
<year>2002</year>
<volume>62</volume>
<issue>2</issue>
<fpage>207</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="doi">10.1016/S0167-8140(01)00486-8</pub-id>
<pub-id pub-id-type="pmid">11937248</pub-id>
</element-citation>
</ref>
<ref id="ref68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calvo</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Sole</surname>
<given-names>CV</given-names>
</name>
<name>
<surname>Alvarez de Sierra</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prognostic impact of external beam radiation therapy in patients treated with and without extended surgery and intraoperative electrons for locally recurrent rectal cancer: 16-year experience in a single institution</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2013</year>
<volume>86</volume>
<issue>5</issue>
<fpage>892</fpage>
<lpage>900</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2013.04.008</pub-id>
<pub-id pub-id-type="pmid">23845842</pub-id>
</element-citation>
</ref>
<ref id="ref69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dresen</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Gosens</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Martijn</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Radical resection after IORT-containing multimodality treatment is the most important determinant for outcome in patients treated for locally recurrent rectal cancer</article-title>
<source>Ann Surg Oncol</source>
<year>2008</year>
<volume>15</volume>
<issue>7</issue>
<fpage>1937</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="doi">10.1245/s10434-008-9896-z</pub-id>
<pmc-comment>2467498</pmc-comment>
<pub-id pub-id-type="pmid">18389321</pub-id>
</element-citation>
</ref>
<ref id="ref70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roeder</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Goetz</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Habl</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative electron radiation therapy (IOERT) in the management of locally recurrent rectal cancer</article-title>
<source>BMC Cancer</source>
<year>2012</year>
<volume>12</volume>
<fpage>592</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2407-12-592</pub-id>
<pmc-comment>3557137</pmc-comment>
<pub-id pub-id-type="pmid">23231663</pub-id>
</element-citation>
</ref>
<ref id="ref71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holman</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Bosman</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Haddock</surname>
<given-names>MG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Results of a pooled analysis of IOERT containing multimodality treatment for locally recurrent rectal cancer: results of 565 patients of two major treatment centres</article-title>
<source>Eur J Surg Oncol</source>
<year>2017</year>
<volume>43</volume>
<issue>1</issue>
<fpage>107</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejso.2016.08.015</pub-id>
<pub-id pub-id-type="pmid">27659000</pub-id>
</element-citation>
</ref>
<ref id="ref72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huber</surname>
<given-names>FT</given-names>
</name>
<name>
<surname>Stepan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zimmermann</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Locally advanced rectal cancer: resection and intraoperative radiotherapy using the flab method combined with preoperative or postoperative radiochemotherapy</article-title>
<source>Dis Colon Rectum</source>
<year>1996</year>
<volume>39</volume>
<issue>7</issue>
<fpage>774</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1007/BF02054443</pub-id>
<pub-id pub-id-type="pmid">8674370</pub-id>
</element-citation>
</ref>
<ref id="ref73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nuyttens</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Kolkman-Deurloo</surname>
<given-names>IK</given-names>
</name>
<name>
<surname>Vermaas</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High-dose-rate intraoperative radiotherapy for close or positive margins in patients with locally advanced or recurrent rectal cancer</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2004</year>
<volume>58</volume>
<issue>1</issue>
<fpage>106</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1016/S0360-3016(03)01494-9</pub-id>
<pub-id pub-id-type="pmid">14697427</pub-id>
</element-citation>
</ref>
<ref id="ref74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mirnezami</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiotherapy in colorectal cancer: systematic review and meta-analysis of techniques, long-term outcomes, and complications</article-title>
<source>Surg Oncol</source>
<year>2013</year>
<volume>22</volume>
<issue>1</issue>
<fpage>22</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1016/j.suronc.2012.11.001</pub-id>
<pub-id pub-id-type="pmid">23270946</pub-id>
</element-citation>
</ref>
<ref id="ref75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alektiar</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Zelefsky</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Paty</surname>
<given-names>PB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2000</year>
<volume>48</volume>
<issue>1</issue>
<fpage>219</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1016/S0360-3016(00)00634-9</pub-id>
<pub-id pub-id-type="pmid">10924992</pub-id>
</element-citation>
</ref>
<ref id="ref76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindel</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Willett</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Shellito</surname>
<given-names>PC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer</article-title>
<source>Radiother Oncol</source>
<year>2001</year>
<volume>58</volume>
<issue>1</issue>
<fpage>83</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1016/S0167-8140(00)00309-1</pub-id>
<pub-id pub-id-type="pmid">11165686</pub-id>
</element-citation>
</ref>
<ref id="ref77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edmonson</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Petersen</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Shives</surname>
<given-names>TC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor</article-title>
<source>Cancer</source>
<year>2002</year>
<volume>94</volume>
<issue>3</issue>
<fpage>786</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1002/cncr.10259</pub-id>
<pub-id pub-id-type="pmid">11857314</pub-id>
</element-citation>
</ref>
<ref id="ref78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Azinovic</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Martinez Monge</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Aristu</surname>
<given-names>JJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiotherapy electron boost followed by moderate doses of external beam radiotherapy in resected soft-tissue sarcoma of the extremities</article-title>
<source>Radiother Oncol</source>
<year>2003</year>
<volume>67</volume>
<issue>3</issue>
<fpage>331</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1016/S0167-8140(03)00163-4</pub-id>
<pub-id pub-id-type="pmid">12865183</pub-id>
</element-citation>
</ref>
<ref id="ref79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kretzler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Molls</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gradinger</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiotherapy of soft tissue sarcoma of the extremity</article-title>
<source>Strahlenther Onkol</source>
<year>2004</year>
<volume>180</volume>
<issue>6</issue>
<fpage>365</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="doi">10.1007/s00066-004-1191-8</pub-id>
<pub-id pub-id-type="pmid">15175871</pub-id>
</element-citation>
</ref>
<ref id="ref80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oertel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Treiber</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zahlten-Hinguranage</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative electron boost radiation followed by moderate doses of external beam radiotherapy in limb-sparing treatment of patients with extremity soft-tissue sarcoma</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2006</year>
<volume>64</volume>
<issue>5</issue>
<fpage>1416</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2005.10.009</pub-id>
<pub-id pub-id-type="pmid">16413697</pub-id>
</element-citation>
</ref>
<ref id="ref81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niewald</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fleckenstein</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Licht</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiotherapy (IORT) combined with external beam radiotherapy (EBRT) for soft-tissue sarcomas—a retrospective evaluation of the Homburg experience in the years 1995–2007</article-title>
<source>Radiat Oncol</source>
<year>2009</year>
<volume>4</volume>
<fpage>32</fpage>
<pub-id pub-id-type="doi">10.1186/1748-717X-4-32</pub-id>
<pub-id pub-id-type="pmid">19709420</pub-id>
</element-citation>
</ref>
<ref id="ref82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Call</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Stafford</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Petersen</surname>
<given-names>IA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Use of intraoperative radiotherapy for upper-extremity soft-tissue sarcomas: analysis of disease outcomes and toxicity</article-title>
<source>Am J Clin Oncol</source>
<year>2014</year>
<volume>37</volume>
<issue>1</issue>
<fpage>81</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1097/COC.0b013e31826b9b3d</pub-id>
<pub-id pub-id-type="pmid">23111357</pub-id>
</element-citation>
</ref>
<ref id="ref83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calvo</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Sole</surname>
<given-names>CV</given-names>
</name>
<name>
<surname>Polo</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Limb-sparing management with surgical resection, external-beam and intraoperative electron-beam radiation therapy boost for patients with primary soft tissue sarcoma of the extremity: a multicentric pooled analysis of long-term outcomes</article-title>
<source>Strahlenther Onkol</source>
<year>2014</year>
<volume>190</volume>
<issue>10</issue>
<fpage>891</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1007/s00066-014-0640-2</pub-id>
<pub-id pub-id-type="pmid">24715241</pub-id>
</element-citation>
</ref>
<ref id="ref84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roeder</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lehner</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial</article-title>
<source>BMC Cancer</source>
<year>2014</year>
<volume>14</volume>
<fpage>350</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2407-14-350</pub-id>
<pmc-comment>4032585</pmc-comment>
<pub-id pub-id-type="pmid">24885755</pub-id>
</element-citation>
</ref>
<ref id="ref85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roeder</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lehner</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Saleh-Ebrahimi</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative electron radiation therapy combined with external beam radiation therapy and limb sparing surgery in extremity soft tissue sarcoma: a retrospective single center analysis of 183 cases</article-title>
<source>Radiother Oncol</source>
<year>2016</year>
<volume>119</volume>
<issue>1</issue>
<fpage>22</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.radonc.2015.11.014</pub-id>
<pub-id pub-id-type="pmid">26651593</pub-id>
</element-citation>
</ref>
<ref id="ref86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sindelar</surname>
<given-names>WF</given-names>
</name>
<name>
<surname>Kinsella</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>PW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial</article-title>
<source>Arch Surg</source>
<year>1993</year>
<volume>128</volume>
<issue>4</issue>
<fpage>402</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1001/archsurg.1993.01420160040005</pub-id>
<pub-id pub-id-type="pmid">8457152</pub-id>
</element-citation>
</ref>
<ref id="ref87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alektiar</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2000</year>
<volume>47</volume>
<issue>1</issue>
<fpage>157</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="doi">10.1016/S0360-3016(99)00546-5</pub-id>
<pub-id pub-id-type="pmid">10758318</pub-id>
</element-citation>
</ref>
<ref id="ref88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gieschen</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Spiro</surname>
<given-names>IJ</given-names>
</name>
<name>
<surname>Suit</surname>
<given-names>HD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2001</year>
<volume>50</volume>
<issue>1</issue>
<fpage>127</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1016/S0360-3016(00)01589-3</pub-id>
<pub-id pub-id-type="pmid">11316555</pub-id>
</element-citation>
</ref>
<ref id="ref89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petersen</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Haddock</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Donohue</surname>
<given-names>JH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2002</year>
<volume>52</volume>
<issue>2</issue>
<fpage>469</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="doi">10.1016/S0360-3016(01)02595-0</pub-id>
<pub-id pub-id-type="pmid">11872294</pub-id>
</element-citation>
</ref>
<ref id="ref90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bobin</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Al-Lawati</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Granero</surname>
<given-names>LE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Surgical management of retroperitoneal sarcomas associated with external and intraoperative electron beam radiotherapy</article-title>
<source>Eur J Surg Oncol</source>
<year>2003</year>
<volume>29</volume>
<issue>8</issue>
<fpage>676</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1016/S0748-7983(03)00139-2</pub-id>
<pub-id pub-id-type="pmid">14511617</pub-id>
</element-citation>
</ref>
<ref id="ref91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pierie</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Betensky</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Choudry</surname>
<given-names>U</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Outcomes in a series of 103 retroperitoneal sarcomas</article-title>
<source>Eur J Surg Oncol</source>
<year>2006</year>
<volume>32</volume>
<issue>10</issue>
<fpage>1235</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejso.2006.07.002</pub-id>
<pub-id pub-id-type="pmid">16919908</pub-id>
</element-citation>
</ref>
<ref id="ref92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krempien</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Roeder</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Oertel</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative electron-beam therapy for primary and recurrent retroperitoneal soft-tissue sarcoma</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2006</year>
<volume>65</volume>
<issue>3</issue>
<fpage>773</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2006.01.028</pub-id>
<pub-id pub-id-type="pmid">16682152</pub-id>
</element-citation>
</ref>
<ref id="ref93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pawlik</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Pisters</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Mikula</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma</article-title>
<source>Ann Surg Oncol</source>
<year>2006</year>
<volume>13</volume>
<issue>4</issue>
<fpage>508</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1245/ASO.2006.05.035</pub-id>
<pub-id pub-id-type="pmid">16491338</pub-id>
</element-citation>
</ref>
<ref id="ref94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ballo</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Zagars</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Pollock</surname>
<given-names>RE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2007</year>
<volume>67</volume>
<issue>1</issue>
<fpage>158</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2006.08.025</pub-id>
<pub-id pub-id-type="pmid">17084545</pub-id>
</element-citation>
</ref>
<ref id="ref95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dziewirski</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Rutkowski</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nowecki</surname>
<given-names>ZI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Surgery combined with intraoperative brachytherapy in the treatment of retroperitoneal sarcomas</article-title>
<source>Ann Surg Oncol</source>
<year>2006</year>
<volume>13</volume>
<issue>2</issue>
<fpage>245</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="doi">10.1245/ASO.2006.03.026</pub-id>
<pub-id pub-id-type="pmid">16411144</pub-id>
</element-citation>
</ref>
<ref id="ref96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sweeting</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Deal</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Llaguna</surname>
<given-names>OH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative electron radiation therapy as an important treatment modality in retroperitoneal sarcoma</article-title>
<source>J Surg Res</source>
<year>2013</year>
<volume>185</volume>
<issue>1</issue>
<fpage>245</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.jss.2013.05.015</pub-id>
<pmc-comment>4166614</pmc-comment>
<pub-id pub-id-type="pmid">23769633</pub-id>
</element-citation>
</ref>
<ref id="ref97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roeder</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ulrich</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Habl</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma: interim analysis</article-title>
<source>BMC Cancer</source>
<year>2014</year>
<volume>14</volume>
<fpage>617</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2407-14-617</pub-id>
<pmc-comment>4156610</pmc-comment>
<pub-id pub-id-type="pmid">25163595</pub-id>
</element-citation>
</ref>
<ref id="ref98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stucky</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Wasif</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ashman</surname>
<given-names>JB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Excellent local control with preoperative radiation therapy, surgical resection, and intra-operative electron radiation therapy for retroperitoneal sarcoma</article-title>
<source>J Surg Oncol</source>
<year>2014</year>
<volume>109</volume>
<issue>8</issue>
<fpage>798</fpage>
<lpage>803</lpage>
<pub-id pub-id-type="doi">10.1002/jso.23576</pub-id>
<pub-id pub-id-type="pmid">24862926</pub-id>
</element-citation>
</ref>
<ref id="ref99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gronchi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>De Paoli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dani</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group</article-title>
<source>Eur J Cancer</source>
<year>2014</year>
<volume>50</volume>
<issue>4</issue>
<fpage>784</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejca.2013.11.021</pub-id>
<pub-id pub-id-type="pmid">24316063</pub-id>
</element-citation>
</ref>
<ref id="ref100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Haddock</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Petersen</surname>
<given-names>IA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative electron-beam radiotherapy and ureteral obstruction</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2006</year>
<volume>64</volume>
<issue>3</issue>
<fpage>792</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2005.08.019</pub-id>
<pub-id pub-id-type="pmid">16243445</pub-id>
</element-citation>
</ref>
<ref id="ref101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calvo</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Sole</surname>
<given-names>CV</given-names>
</name>
<name>
<surname>Cambeiro</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prognostic value of external beam radiation therapy in patients treated with surgical resection and intraoperative electron beam radiation therapy for locally recurrent soft tissue sarcoma: a multicentric long-term outcome analysis</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2014</year>
<volume>88</volume>
<issue>1</issue>
<fpage>143</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2013.10.021</pub-id>
<pub-id pub-id-type="pmid">24331661</pub-id>
</element-citation>
</ref>
<ref id="ref102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haase</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Meagher</surname>
<given-names>DP</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>McNeely</surname>
<given-names>LK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Electron beam intraoperative radiation therapy for pediatric neoplasms</article-title>
<source>Cancer</source>
<year>1994</year>
<volume>74</volume>
<issue>2</issue>
<fpage>740</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">8033056</pub-id>
</element-citation>
</ref>
<ref id="ref103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oertel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Niethammer</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Krempien</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Combination of external-beam radiotherapy with intraoperative electron-beam therapy is effective in incompletely resected pediatric malignancies</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2006</year>
<volume>64</volume>
<issue>1</issue>
<fpage>235</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2005.06.038</pub-id>
<pub-id pub-id-type="pmid">16257132</pub-id>
</element-citation>
</ref>
<ref id="ref104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodman</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Wolden</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>LaQuaglia</surname>
<given-names>MP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative high-dose-rate brachytherapy for pediatric solid tumors: a 10-year experience</article-title>
<source>Brachytherapy</source>
<year>2003</year>
<volume>2</volume>
<issue>3</issue>
<fpage>139</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="doi">10.1016/S1538-4721(03)00135-1</pub-id>
<pub-id pub-id-type="pmid">15062136</pub-id>
</element-citation>
</ref>
<ref id="ref105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sole</surname>
<given-names>CV</given-names>
</name>
<name>
<surname>Calvo</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Polo</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative electron-beam radiation therapy for pediatric Ewing sarcomas and rhabdomyosarcomas: long-term outcomes</article-title>
<source>Int J Radiat Oncol Biol, Phys</source>
<year>2015</year>
<volume>92</volume>
<issue>5</issue>
<fpage>1069</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2015.04.048</pub-id>
<pub-id pub-id-type="pmid">26194682</pub-id>
</element-citation>
</ref>
<ref id="ref106">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nag</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tippin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative electron beam treatment for pediatric malignancies: The Ohio State University experience</article-title>
<source>Med Pediatr Oncol</source>
<year>2003</year>
<volume>40</volume>
<issue>6</issue>
<fpage>360</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1002/mpo.10296</pub-id>
<pub-id pub-id-type="pmid">12692803</pub-id>
</element-citation>
</ref>
<ref id="ref107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stauder</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Laack</surname>
<given-names>NN</given-names>
</name>
<name>
<surname>Moir</surname>
<given-names>CR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Excellent local control and survival after intraoperative and external beam radiotherapy for pediatric solid tumors: long-term follow-up of the Mayo Clinic experience</article-title>
<source>J Pediatr Hematol/Oncol</source>
<year>2011</year>
<volume>33</volume>
<issue>5</issue>
<fpage>350</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1097/MPH.0b013e3182148dad</pub-id>
</element-citation>
</ref>
<ref id="ref108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brunschwig</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Barber</surname>
<given-names>HR</given-names>
</name>
</person-group>
<article-title>Extended pelvic exenteration for advanced cancer of the cervix. long survivals following added resection of involved small bowel</article-title>
<source>Cancer</source>
<year>1964</year>
<volume>17</volume>
<fpage>1267</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="pmid">14236759</pub-id>
</element-citation>
</ref>
<ref id="ref109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karlen</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Piver</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>Reduction of mortality and morbidity associated with pelvic exenteration</article-title>
<source>Gynecol Oncol</source>
<year>1975</year>
<volume>3</volume>
<issue>2</issue>
<fpage>164</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1016/0090-8258(75)90076-1</pub-id>
<pub-id pub-id-type="pmid">1183867</pub-id>
</element-citation>
</ref>
<ref id="ref110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kiselow</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Butcher</surname>
<given-names>HR</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Bricker</surname>
<given-names>EM</given-names>
</name>
</person-group>
<article-title>Results of the radical surgical treatment of advanced pelvic cancer: a fifteen-year study</article-title>
<source>Ann Surg</source>
<year>1967</year>
<volume>166</volume>
<issue>3</issue>
<fpage>428</fpage>
<lpage>36</lpage>
<pmc-comment>1477392</pmc-comment>
<pub-id pub-id-type="pmid">6039602</pub-id>
</element-citation>
</ref>
<ref id="ref111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Symmonds</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Pratt</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Webb</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Exenterative operations: experience with 198 patients</article-title>
<source>Am J Obstet Gynecol</source>
<year>1975</year>
<volume>121</volume>
<issue>7</issue>
<fpage>907</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1016/0002-9378(75)90908-4</pub-id>
<pub-id pub-id-type="pmid">1115180</pub-id>
</element-citation>
</ref>
<ref id="ref112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giorda</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Boz</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gadducci</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Multimodality approach in extra cervical locally advanced cervical cancer: chemoradiation, surgery and intra-operative radiation therapy A phase II trial</article-title>
<source>Eur J Surg Oncol</source>
<year>2011</year>
<volume>37</volume>
<issue>5</issue>
<fpage>442</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejso.2011.02.011</pub-id>
<pub-id pub-id-type="pmid">21492777</pub-id>
</element-citation>
</ref>
<ref id="ref113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garton</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Gunderson</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Webb</surname>
<given-names>MJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiation therapy in gynecologic cancer: update of the experience at a single institution</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>1997</year>
<volume>37</volume>
<issue>4</issue>
<fpage>839</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="doi">10.1016/S0360-3016(96)00546-9</pub-id>
<pub-id pub-id-type="pmid">9128960</pub-id>
</element-citation>
</ref>
<ref id="ref114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gemignani</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Alektiar</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Leitao</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Radical surgical resection and high-dose intraoperative radiation therapy (HDR-IORT) in patients with recurrent gynecologic cancers</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2001</year>
<volume>50</volume>
<issue>3</issue>
<fpage>687</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1016/S0360-3016(01)01507-3</pub-id>
<pub-id pub-id-type="pmid">11395237</pub-id>
</element-citation>
</ref>
<ref id="ref115">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haddock</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Petersen</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Webb</surname>
<given-names>MJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>IORT for locally advanced gynecological malignancies</article-title>
<source>Front Radiat Ther Oncol</source>
<year>1997</year>
<volume>31</volume>
<fpage>256</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1159/000061131</pub-id>
<pub-id pub-id-type="pmid">9263836</pub-id>
</element-citation>
</ref>
<ref id="ref116">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez-Monge</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jurado</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative electron beam radiotherapy during radical surgery for locally advanced and recurrent cervical cancer</article-title>
<source>Gynecol Oncol</source>
<year>2001</year>
<volume>82</volume>
<issue>3</issue>
<fpage>538</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="doi">10.1006/gyno.2001.6329</pub-id>
<pub-id pub-id-type="pmid">11520152</pub-id>
</element-citation>
</ref>
<ref id="ref117">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sole</surname>
<given-names>CV</given-names>
</name>
<name>
<surname>Calvo</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>MA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>External-beam radiation therapy after surgical resection and intraoperative electron-beam radiation therapy for oligorecurrent gynecological cancer Long-term outcome</article-title>
<source>Strahlenther Onkol</source>
<year>2014</year>
<volume>190</volume>
<issue>2</issue>
<fpage>171</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1007/s00066-013-0472-5</pub-id>
<pub-id pub-id-type="pmid">24306064</pub-id>
</element-citation>
</ref>
<ref id="ref118">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tran</surname>
<given-names>PT</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Hara</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2007</year>
<volume>69</volume>
<issue>2</issue>
<fpage>504</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2007.03.021</pub-id>
<pub-id pub-id-type="pmid">17560736</pub-id>
</element-citation>
</ref>
<ref id="ref119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barney</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Petersen</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Dowdy</surname>
<given-names>SC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative electron beam radiotherapy (IOERT) in the management of locally advanced or recurrent cervical cancer</article-title>
<source>Radiat Oncol</source>
<year>2013</year>
<volume>8</volume>
<fpage>80</fpage>
<pub-id pub-id-type="doi">10.1186/1748-717X-8-80</pub-id>
<pmc-comment>3641982</pmc-comment>
<pub-id pub-id-type="pmid">23566444</pub-id>
</element-citation>
</ref>
<ref id="ref120">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calvo</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Sole</surname>
<given-names>CV</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>MA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative electron beam radiotherapy and extended surgical resection for gynecological pelvic recurrent malignancies with and without external beam radiation therapy: long-term outcomes</article-title>
<source>Gynecol Oncol</source>
<year>2013</year>
<volume>130</volume>
<issue>3</issue>
<fpage>537</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1016/j.ygyno.2013.05.016</pub-id>
<pub-id pub-id-type="pmid">23707668</pub-id>
</element-citation>
</ref>
<ref id="ref121">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foley</surname>
<given-names>OW</given-names>
</name>
<name>
<surname>Rauh-Hain</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>RM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiation therapy in the management of gynecologic malignancies</article-title>
<source>Am J Clin Oncol</source>
<year>2016</year>
<volume>39</volume>
<issue>4</issue>
<fpage>329</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1097/COC.0000000000000063</pub-id>
<pub-id pub-id-type="pmid">24685883</pub-id>
</element-citation>
</ref>
<ref id="ref122">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arians</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Foerster</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rom</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Outcome of patients with local recurrent gynecologic malignancies after resection combined with intraoperative electron radiation therapy (IOERT)</article-title>
<source>Radiat Oncol</source>
<year>2016</year>
<volume>11</volume>
<fpage>44</fpage>
<pub-id pub-id-type="doi">10.1186/s13014-016-0622-x</pub-id>
<pmc-comment>4797348</pmc-comment>
<pub-id pub-id-type="pmid">26988089</pub-id>
</element-citation>
</ref>
<ref id="ref123">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dowdy</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Mariani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cliby</surname>
<given-names>WA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes</article-title>
<source>Gynecol Oncol</source>
<year>2006</year>
<volume>101</volume>
<issue>2</issue>
<fpage>280</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1016/j.ygyno.2005.10.018</pub-id>
<pub-id pub-id-type="pmid">16321431</pub-id>
</element-citation>
</ref>
<ref id="ref124">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahe</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Gerard</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Dubois</surname>
<given-names>JB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiation therapy in recurrent carcinoma of the uterine cervix: report of the French intraoperative group on 70 patients</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>1996</year>
<volume>34</volume>
<issue>1</issue>
<fpage>21</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1016/0360-3016(95)02089-6</pub-id>
<pub-id pub-id-type="pmid">12118553</pub-id>
</element-citation>
</ref>
<ref id="ref125">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahe</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Romestaing</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gerard</surname>
<given-names>JP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prognostic factors for local control in recurrent cervical carcinoma treated with IORT: report of the French IORT Group</article-title>
<source>Front Radiat Ther Oncol</source>
<year>1997</year>
<volume>31</volume>
<fpage>267</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="doi">10.1159/000061190</pub-id>
<pub-id pub-id-type="pmid">9263839</pub-id>
</element-citation>
</ref>
<ref id="ref126">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>del Carmen</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>McIntyre</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Fuller</surname>
<given-names>AF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiation therapy in the treatment of pelvic gynecologic malignancies: a review of fifteen cases</article-title>
<source>Gynecol Oncol</source>
<year>2000</year>
<volume>79</volume>
<issue>3</issue>
<fpage>457</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="doi">10.1006/gyno.2000.6002</pub-id>
<pub-id pub-id-type="pmid">11104619</pub-id>
</element-citation>
</ref>
<ref id="ref127">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Backes</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Billingsley</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>DD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?</article-title>
<source>Gynecol Oncol</source>
<year>2014</year>
<volume>135</volume>
<issue>1</issue>
<fpage>95</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.ygyno.2014.07.093</pub-id>
<pub-id pub-id-type="pmid">25084510</pub-id>
</element-citation>
</ref>
<ref id="ref128">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hallemeier</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Karnes</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Pisansky</surname>
<given-names>TM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Multimodality therapy including surgical resection and intraoperative electron radiotherapy for recurrent or advanced primary carcinoma of the urinary bladder or ureter</article-title>
<source>Am J Clin Oncol</source>
<year>2013</year>
<volume>36</volume>
<issue>6</issue>
<fpage>596</fpage>
<lpage>600</lpage>
<pub-id pub-id-type="doi">10.1097/COC.0b013e31825d52f7</pub-id>
<pub-id pub-id-type="pmid">22868244</pub-id>
</element-citation>
</ref>
<ref id="ref129">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hallemeier</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Choo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>BJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term outcomes after maximal surgical resection and intraoperative electron radiotherapy for locoregionally recurrent or locoregionally advanced primary renal cell carcinoma</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2012</year>
<fpage>82</fpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2011.02.026</pub-id>
</element-citation>
</ref>
<ref id="ref130">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calvo</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Sole</surname>
<given-names>CV</given-names>
</name>
<name>
<surname>Martinez-Monge</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative EBRT and resection for renal cell carcinoma: twenty-year outcomes</article-title>
<source>Strahlentherapie Onkol</source>
<year>2013</year>
<volume>189</volume>
</element-citation>
</ref>
<ref id="ref131">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eble</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Staehler</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wannenmacher</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The intraoperative radiotherapy (IORT) of locally spread and recurrent renal-cell carcinomas</article-title>
<source>Strahlentherapie Onkol</source>
<year>1998</year>
<volume>174</volume>
<issue>1</issue>
<fpage>30</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1007/BF03038225</pub-id>
</element-citation>
</ref>
<ref id="ref132">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Habl</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Uhl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hensley</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative electron radiation therapy (IOERT) in patients with locally recurrent renal cell carcinoma</article-title>
<source>Radiat Oncol</source>
<year>2013</year>
<volume>8</volume>
<issue>1</issue>
<fpage>282</fpage>
<pub-id pub-id-type="doi">10.1186/1748-717X-8-282</pub-id>
<pmc-comment>3922867</pmc-comment>
<pub-id pub-id-type="pmid">24295293</pub-id>
</element-citation>
</ref>
<ref id="ref133">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Master</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Gottschalk</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Kane</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Management of isolated renal fossa recurrence following radical nephrectomy</article-title>
<source>J Urol</source>
<year>2005</year>
<volume>174</volume>
<pub-id pub-id-type="doi">10.1097/01.ju.0000165574.62188.d0</pub-id>
</element-citation>
</ref>
<ref id="ref134">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paly</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Hallemeier</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Biggs</surname>
<given-names>PJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Outcomes for a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma [abstract]</article-title>
<source>Int J Oncol Biol Phys</source>
<year>2012</year>
<volume>84</volume>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2012.07.1123</pub-id>
</element-citation>
</ref>
<ref id="ref135">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thompson</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Valicenti</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Albertsen</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline</article-title>
<source>J Urol</source>
<year>2013</year>
<volume>190</volume>
<issue>2</issue>
<fpage>441</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.juro.2013.05.032</pub-id>
<pub-id pub-id-type="pmid">23707439</pub-id>
</element-citation>
</ref>
<ref id="ref136">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rocco</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Jereczek-Fossa</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Matei</surname>
<given-names>DV</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiotherapy during radical prostatectomy for intermediate-risk to locally advanced prostate cancer: treatment technique and evaluation of perioperative and functional outcome vs standard radical prostatectomy, in a matched-pair analysis</article-title>
<source>BJU Int</source>
<year>2009</year>
<volume>104</volume>
<issue>11</issue>
<fpage>1624</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1111/j.1464-410X.2009.08668.x</pub-id>
<pub-id pub-id-type="pmid">19624597</pub-id>
</element-citation>
</ref>
<ref id="ref137">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Higashi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hyochi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tari</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Intraoperative radiotherapy combined with external beam radiation for prostate cancer without metastasis</article-title>
<source>Nihon Rinsho</source>
<year>1998</year>
<volume>56</volume>
<issue>8</issue>
<fpage>2177</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="pmid">9750530</pub-id>
</element-citation>
</ref>
<ref id="ref138">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kato</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sakura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kazumoto</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiation therapy for locally advanced prostate cancer</article-title>
<source>J JASTRO</source>
<year>1998</year>
<volume>10</volume>
<issue>3</issue>
<fpage>241</fpage>
<lpage>8</lpage>
</element-citation>
</ref>
<ref id="ref139">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krengli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Terrone</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ballare</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiotherapy during radical prostatectomy for locally advanced prostate cancer: technical and dosimetric aspects</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2010</year>
<volume>76</volume>
<issue>4</issue>
<fpage>1073</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2009.03.037</pub-id>
<pub-id pub-id-type="pmid">19625135</pub-id>
</element-citation>
</ref>
<ref id="ref140">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orecchia</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jereczek-Fossa</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Ciocca</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiotherapy for locally advanced prostate cancer: treatment technique and ultrasound-based analysis of dose distribution</article-title>
<source>Anticancer Res</source>
<year>2007</year>
<volume>27</volume>
<issue>5b</issue>
<fpage>3471</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">17972503</pub-id>
</element-citation>
</ref>
<ref id="ref141">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saracino</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gallucci</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phase I-II study of intraoperative radiation therapy (IORT) after radical prostatectomy for prostate cancer</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2008</year>
<volume>71</volume>
<issue>4</issue>
<fpage>1049</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2007.11.076</pub-id>
<pub-id pub-id-type="pmid">18325679</pub-id>
</element-citation>
</ref>
<ref id="ref142">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wisbeck</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Becher</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>AH</given-names>
</name>
</person-group>
<article-title>Adenocarcinoma of the stomach: autopsy observations with therapeutic implications for the radiation oncologist</article-title>
<source>Radiother Oncol</source>
<year>1986</year>
<volume>7</volume>
<issue>1</issue>
<fpage>13</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/S0167-8140(86)80120-7</pub-id>
<pub-id pub-id-type="pmid">3775075</pub-id>
</element-citation>
</ref>
<ref id="ref143">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gunderson</surname>
<given-names>LL</given-names>
</name>
</person-group>
<article-title>Gastric cancer—patterns of relapse after surgical resection</article-title>
<source>Semin Radiat Oncol</source>
<year>2002</year>
<volume>12</volume>
<issue>2</issue>
<fpage>150</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.1053/srao.2002.30817</pub-id>
<pub-id pub-id-type="pmid">11979416</pub-id>
</element-citation>
</ref>
<ref id="ref144">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Macdonald</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Smalley</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Benedetti</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction</article-title>
<source>N Engl J Med</source>
<year>2001</year>
<volume>345</volume>
<issue>10</issue>
<fpage>725</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa010187</pub-id>
<pub-id pub-id-type="pmid">11547741</pub-id>
</element-citation>
</ref>
<ref id="ref145">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cunningham</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Allum</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Stenning</surname>
<given-names>SP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer</article-title>
<source>New Engl J Med</source>
<year>2006</year>
<volume>355</volume>
<issue>1</issue>
<fpage>11</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa055531</pub-id>
<pub-id pub-id-type="pmid">16822992</pub-id>
</element-citation>
</ref>
<ref id="ref146">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Hsiung</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>SS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nodal dissection for patients with gastric cancer: a randomised controlled trial</article-title>
<source>Lancet Oncol</source>
<year>2006</year>
<volume>7</volume>
<issue>4</issue>
<fpage>309</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1016/S1470-2045(06)70623-4</pub-id>
<pub-id pub-id-type="pmid">16574546</pub-id>
</element-citation>
</ref>
<ref id="ref147">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maruyama</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sasako</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kinoshita</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pancreas-preserving total gastrectomy for proximal gastric cancer</article-title>
<source>World J Surg</source>
<year>1995</year>
<volume>19</volume>
<issue>4</issue>
<fpage>532</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1007/BF00294714</pub-id>
<pub-id pub-id-type="pmid">7676695</pub-id>
</element-citation>
</ref>
<ref id="ref148">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiotherapy combined with adjuvant chemoradiotherapy for locally advanced gastric adenocarcinoma</article-title>
<source>Int J Radiat Oncol, Biol, Phys</source>
<year>2008</year>
<volume>72</volume>
<issue>5</issue>
<fpage>1488</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2008.03.012</pub-id>
<pub-id pub-id-type="pmid">18538489</pub-id>
</element-citation>
</ref>
<ref id="ref149">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sindelar</surname>
<given-names>WF</given-names>
</name>
<name>
<surname>Kinsella</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Tepper</surname>
<given-names>JE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Randomized trial of intraoperative radiotherapy in carcinoma of the stomach</article-title>
<source>Am J Surg</source>
<year>1993</year>
<volume>165</volume>
<issue>1</issue>
<fpage>178</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="doi">10.1016/S0002-9610(05)80423-4</pub-id>
<pub-id pub-id-type="pmid">8418695</pub-id>
</element-citation>
</ref>
<ref id="ref150">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Tey</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Adjuvant chemoradiotherapy with or without intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma</article-title>
<source>Radiother Oncol</source>
<year>2012</year>
<volume>102</volume>
<issue>1</issue>
<fpage>51</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1016/j.radonc.2011.10.008</pub-id>
<pub-id pub-id-type="pmid">22178689</pub-id>
</element-citation>
</ref>
<ref id="ref151">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drognitz</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Henne</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Weissenberger</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term results after intraoperative radiation therapy for gastric cancer</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2008</year>
<volume>70</volume>
<issue>3</issue>
<fpage>715</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2007.07.2331</pub-id>
<pub-id pub-id-type="pmid">18164840</pub-id>
</element-citation>
</ref>
<ref id="ref152">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogata</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Araki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Matsuura</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A 10-year experience of intraoperative radiotherapy for gastric carcinoma and a new surgical method of creating a wider irradiation field for cases of total gastrectomy patients</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>1995</year>
<volume>32</volume>
<issue>2</issue>
<fpage>341</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1016/0360-3016(94)00479-5</pub-id>
<pub-id pub-id-type="pmid">7751175</pub-id>
</element-citation>
</ref>
<ref id="ref153">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>XL</given-names>
</name>
</person-group>
<article-title>Evaluation of intraoperative radiotherapy for gastric carcinoma with D2 and D3 surgical resection</article-title>
<source>World J Gastroenterol</source>
<year>2006</year>
<volume>12</volume>
<issue>43</issue>
<fpage>7033</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.3748/wjg.v12.i43.7033</pub-id>
<pmc-comment>4087350</pmc-comment>
<pub-id pub-id-type="pmid">17109501</pub-id>
</element-citation>
</ref>
<ref id="ref154">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skoropad</surname>
<given-names>VY</given-names>
</name>
<name>
<surname>Berdov</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Mardynski</surname>
<given-names>YS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A prospective, randomized trial of pre-operative and intraoperative radiotherapy versus surgery alone in resectable gastric cancer</article-title>
<source>Eur J Surg Oncol</source>
<year>2000</year>
<volume>26</volume>
<issue>8</issue>
<fpage>773</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1053/ejso.2000.1002</pub-id>
<pub-id pub-id-type="pmid">11087644</pub-id>
</element-citation>
</ref>
<ref id="ref155">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calvo</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Sole</surname>
<given-names>CV</given-names>
</name>
<name>
<surname>Obregon</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma: topography of locoregional recurrences and long-term outcomes.</article-title>
<source>Clin Transl Oncol</source>
<year>2013</year>
<volume>15</volume>
<issue>6</issue>
<fpage>443</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1007/s12094-012-0949-1</pub-id>
<pub-id pub-id-type="pmid">23143948</pub-id>
</element-citation>
</ref>
<ref id="ref156">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coquard</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ayzac</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gilly</surname>
<given-names>FN</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiation therapy combined with limited lymph node resection in gastric cancer: an alternative to extended dissection?</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>1997</year>
<volume>39</volume>
<issue>5</issue>
<fpage>1093</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/S0360-3016(97)00386-6</pub-id>
<pub-id pub-id-type="pmid">9392549</pub-id>
</element-citation>
</ref>
<ref id="ref157">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bacalbasa</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Balescu</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Calin</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiation therapy in gastric cancer</article-title>
<source>J Med life</source>
<year>2014</year>
<volume>7</volume>
<issue>2</issue>
<fpage>128</fpage>
<lpage>31</lpage>
<pmc-comment>4197496</pmc-comment>
<pub-id pub-id-type="pmid">25408715</pub-id>
</element-citation>
</ref>
<ref id="ref158">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Avizonis</surname>
<given-names>VN</given-names>
</name>
<name>
<surname>Buzydlowski</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lanciano</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Treatment of adenocarcinoma of the stomach with resection, intraoperative radiotherapy, and adjuvant external beam radiation: a phase II study from Radiation Therapy Oncology Group 85-04</article-title>
<source>Ann Surg Oncol</source>
<year>1995</year>
<volume>2</volume>
<issue>4</issue>
<fpage>295</fpage>
<lpage>302</lpage>
<pub-id pub-id-type="doi">10.1007/BF02307060</pub-id>
<pub-id pub-id-type="pmid">7552617</pub-id>
</element-citation>
</ref>
<ref id="ref159">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weese</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Harbison</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Stiller</surname>
<given-names>GD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): improved treatment for gastric adenocarcinoma</article-title>
<source>Surgery</source>
<year>2000</year>
<volume>128</volume>
<issue>4</issue>
<fpage>564</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="doi">10.1067/msy.2000.108420</pub-id>
<pub-id pub-id-type="pmid">11015089</pub-id>
</element-citation>
</ref>
<ref id="ref160">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glehen</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Peyrat</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Beaujard</surname>
<given-names>AC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pattern of failures in gastric cancer patients with lymph node involvement treated by surgery, intraoperative and external beam radiotherapy</article-title>
<source>Radiother Oncol</source>
<year>2003</year>
<volume>67</volume>
<issue>2</issue>
<fpage>171</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="doi">10.1016/S0167-8140(02)00344-4</pub-id>
<pub-id pub-id-type="pmid">12812847</pub-id>
</element-citation>
</ref>
<ref id="ref161">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Haddock</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Gunderson</surname>
<given-names>LL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiotherapy for treatment of locally advanced and recurrent esophageal and gastric adenocarcinomas</article-title>
<source>Dis Esophagus</source>
<year>2006</year>
<volume>19</volume>
<issue>6</issue>
<fpage>487</fpage>
<lpage>95.</lpage>
<pub-id pub-id-type="doi">10.1111/j.1442-2050.2006.00626.x</pub-id>
<pub-id pub-id-type="pmid">17069594</pub-id>
</element-citation>
</ref>
<ref id="ref162">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gourgou-Bourgade</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bascoul-Mollevi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Desseigne</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial</article-title>
<source>J Clin Oncol</source>
<year>2013</year>
<volume>31</volume>
<issue>1</issue>
<fpage>23</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1200/JCO.2012.44.4869</pub-id>
<pub-id pub-id-type="pmid">23213101</pub-id>
</element-citation>
</ref>
<ref id="ref163">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hazard</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Tward</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Szabo</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data</article-title>
<source>Cancer</source>
<year>2007</year>
<volume>110</volume>
<issue>10</issue>
<fpage>2191</fpage>
<lpage>201</lpage>
<pub-id pub-id-type="doi">10.1002/cncr.23047</pub-id>
<pub-id pub-id-type="pmid">17918259</pub-id>
</element-citation>
</ref>
<ref id="ref164">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Von Hoff</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Ervin</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Arena</surname>
<given-names>FP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine</article-title>
<source>N Engl J Med</source>
<year>2013</year>
<volume>369</volume>
<issue>18</issue>
<fpage>1691</fpage>
<lpage>703</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1304369</pub-id>
<pmc-comment>4631139</pmc-comment>
<pub-id pub-id-type="pmid">24131140</pub-id>
</element-citation>
</ref>
<ref id="ref165">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alfieri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Morganti</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Di Giorgio</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Improved survival and local control after intraoperative radiation therapy and postoperative radiotherapy: a multivariate analysis of 46 patients undergoing surgery for pancreatic head cancer</article-title>
<source>Arch Surg</source>
<year>2001</year>
<volume>136</volume>
<issue>3</issue>
<fpage>343</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1001/archsurg.136.3.343</pub-id>
<pub-id pub-id-type="pmid">11231859</pub-id>
</element-citation>
</ref>
<ref id="ref166">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calvo</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Sole</surname>
<given-names>CV</given-names>
</name>
<name>
<surname>Atahualpa</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chemoradiation for resected pancreatic adenocarcinoma with or without intraoperative radiation therapy boost: long-term outcomes</article-title>
<source>Pancreatology</source>
<year>2013</year>
<volume>13</volume>
<issue>6</issue>
<fpage>576</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1016/j.pan.2013.09.002</pub-id>
<pub-id pub-id-type="pmid">24280572</pub-id>
</element-citation>
</ref>
<ref id="ref167">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Showalter</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Anne</surname>
<given-names>PR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Does intraoperative radiation therapy improve local tumor control in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma? A propensity score analysis</article-title>
<source>Ann Surg Oncol</source>
<year>2009</year>
<volume>16</volume>
<issue>8</issue>
<fpage>2116</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1245/s10434-009-0498-1</pub-id>
<pub-id pub-id-type="pmid">19437078</pub-id>
</element-citation>
</ref>
<ref id="ref168">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valentini</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Calvo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Reni</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intra-operative radiotherapy (IORT) in pancreatic cancer: joint analysis of the ISIORT-Europe experience</article-title>
<source>Radiother Oncol</source>
<year>2009</year>
<volume>91</volume>
<issue>1</issue>
<fpage>54</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.radonc.2008.07.020</pub-id>
<pub-id pub-id-type="pmid">18762346</pub-id>
</element-citation>
</ref>
<ref id="ref169">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Messick</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hardacre</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>McGee</surname>
<given-names>MF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Early experience with intraoperative radiotherapy in patients with resected pancreatic adenocarcinoma</article-title>
<source>Am J Surg</source>
<year>2008</year>
<volume>195</volume>
<issue>3</issue>
<fpage>308</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="doi">10.1016/j.amjsurg.2007.12.024</pub-id>
<pub-id pub-id-type="pmid">18207129</pub-id>
</element-citation>
</ref>
<ref id="ref170">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Karasawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiotherapy for resected pancreatic cancer: a multi-institutional retrospective analysis of 210 patients</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2010</year>
<volume>77</volume>
<issue>3</issue>
<fpage>734</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2009.09.010</pub-id>
<pub-id pub-id-type="pmid">20207498</pub-id>
</element-citation>
</ref>
<ref id="ref171">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valentini</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Morganti</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Macchia</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiation therapy in resected pancreatic carcinoma: long-term analysis</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2008</year>
<volume>70</volume>
<issue>4</issue>
<fpage>1094</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2007.07.2346</pub-id>
<pub-id pub-id-type="pmid">18313525</pub-id>
</element-citation>
</ref>
<ref id="ref172">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kokubo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shibamoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sasai</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kanamori</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hosotani</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Analysis of the clinical benefit of intraoperative radiotherapy in patients undergoing macroscopically curative resection for pancreatic cancer</article-title>
<source>International journal of radiation oncology, biology, physics</source>
<year>2000</year>
<volume>48</volume>
<issue>4</issue>
<fpage>1081</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1016/S0360-3016(00)00673-8</pub-id>
<pub-id pub-id-type="pmid">11072166</pub-id>
</element-citation>
</ref>
<ref id="ref173">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reni</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Panucci</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Ferreri</surname>
<given-names>AJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2001</year>
<volume>50</volume>
<issue>3</issue>
<fpage>651</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1016/S0360-3016(01)01470-5</pub-id>
<pub-id pub-id-type="pmid">11395232</pub-id>
</element-citation>
</ref>
<ref id="ref174">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>SI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010</article-title>
<source>Cancer</source>
<year>2013</year>
<volume>119</volume>
<issue>23</issue>
<fpage>4196</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1002/cncr.28329</pub-id>
<pmc-comment>4403862</pmc-comment>
<pub-id pub-id-type="pmid">24006012</pub-id>
</element-citation>
</ref>
<ref id="ref175">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Che</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term results of intraoperative electron beam radiation therapy for nonmetastatic locally advanced pancreatic cancer: retrospective cohort study, 7-year experience with 247 patients at the National Cancer Center in China</article-title>
<source>Medicine</source>
<year>2016</year>
<volume>95</volume>
<issue>38</issue>
<fpage>e4861</fpage>
<pub-id pub-id-type="doi">10.1097/MD.0000000000004861</pub-id>
<pmc-comment>5044898</pmc-comment>
<pub-id pub-id-type="pmid">27661028</pub-id>
</element-citation>
</ref>
<ref id="ref176">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jingu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tanabe</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nemoto</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiotherapy for pancreatic cancer: 30-year experience in a single institution in Japan</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<year>2012</year>
<volume>83</volume>
<issue>4</issue>
<fpage>e507</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2012.01.024</pub-id>
<pub-id pub-id-type="pmid">22445002</pub-id>
</element-citation>
</ref>
<ref id="ref177">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Di</surname>
<given-names>ZL</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>XJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of intraoperative radiotherapy combined with external beam radiotherapy following internal drainage for advanced pancreatic carcinoma</article-title>
<source>World J Gastroenterol</source>
<year>2004</year>
<volume>10</volume>
<issue>11</issue>
<fpage>1669</fpage>
<lpage>771</lpage>
<pub-id pub-id-type="doi">10.3748/wjg.v10.i11.1669</pub-id>
<pmc-comment>4572777</pmc-comment>
<pub-id pub-id-type="pmid">15162548</pub-id>
</element-citation>
</ref>
<ref id="ref178">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohiuddin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Regine</surname>
<given-names>WF</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas</article-title>
<source>J Clin Oncol</source>
<year>1995</year>
<volume>13</volume>
<issue>11</issue>
<fpage>2764</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1200/JCO.1995.13.11.2764</pub-id>
<pub-id pub-id-type="pmid">7595736</pub-id>
</element-citation>
</ref>
<ref id="ref179">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishimura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hosotani</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shibamoto</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>External and intraoperative radiotherapy for resectable and unresectable pancreatic cancer: analysis of survival rates and complications</article-title>
<source>Int J Radiat Oncol, Biol, Phys</source>
<year>1997</year>
<volume>39</volume>
<issue>1</issue>
<fpage>39</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="doi">10.1016/S0360-3016(97)00295-2</pub-id>
<pub-id pub-id-type="pmid">9300738</pub-id>
</element-citation>
</ref>
<ref id="ref180">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willett</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Del Castillo</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Shih</surname>
<given-names>HA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer</article-title>
<source>Ann Surg</source>
<year>2005</year>
<volume>241</volume>
<issue>2</issue>
<fpage>295</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1097/01.sla.0000152016.40331.bb</pub-id>
<pmc-comment>1356915</pmc-comment>
<pub-id pub-id-type="pmid">15650640</pub-id>
</element-citation>
</ref>
<ref id="ref181">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keane</surname>
<given-names>FK</given-names>
</name>
<name>
<surname>Wo</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Ferrone</surname>
<given-names>CR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intraoperative radiotherapy in the era of intensive neoadjuvant chemotherapy and chemoradiotherapy for pancreatic adenocarcinoma</article-title>
<source>Am J Clin Oncol</source>
<fpage>9000</fpage>
</element-citation>
</ref>
<ref id="ref182">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conroy</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bachet</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Ayav</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Current standards and new innovative approaches for treatment of pancreatic cancer</article-title>
<source>Eur J Cancer</source>
<year>2016</year>
<volume>57</volume>
<fpage>10</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejca.2015.12.026</pub-id>
<pub-id pub-id-type="pmid">26851397</pub-id>
</element-citation>
</ref>
<ref id="ref183">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hackert</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sachsenmaier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hinz</surname>
<given-names>U</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients</article-title>
<source>Ann Surg</source>
<year>2016</year>
<volume>264</volume>
<issue>3</issue>
<fpage>457</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="doi">10.1097/SLA.0000000000001850</pub-id>
<pub-id pub-id-type="pmid">27355262</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<table-wrap id="table1" position="float">
<label>Table 1.</label>
<caption>
<title>Studies of IORT in recurrent head and neck cancer after gross total resection.</title>
</caption>
<table frame="border" rules="all">
<thead>
<tr>
<th align="center" valign="top" rowspan="1" colspan="1">Author/Year</th>
<th align="center" valign="top" rowspan="1" colspan="1">Sample size</th>
<th align="center" valign="top" rowspan="1" colspan="1">Study design</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT type</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT dose (Gy)</th>
<th align="center" valign="top" rowspan="1" colspan="1">Prior RT (%)</th>
<th align="center" valign="top" rowspan="1" colspan="1">Adj. RT (%)</th>
<th align="center" valign="top" rowspan="1" colspan="1">Median follow-up</th>
<th align="center" valign="top" rowspan="1" colspan="1">LC (%)</th>
<th align="center" valign="top" rowspan="1" colspan="1">OS (%)</th>
<th align="center" valign="top" rowspan="1" colspan="1">Toxicity grade 3 or ></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Scala
<italic>et al</italic>
2013 [
<xref rid="ref20" ref-type="bibr">20</xref>
]</td>
<td align="left" valign="top" rowspan="1" colspan="1">76 (100% recurrent)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">HDR IORT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–17.5</td>
<td align="left" valign="top" rowspan="1" colspan="1">71</td>
<td align="left" valign="top" rowspan="1" colspan="1">24</td>
<td align="left" valign="top" rowspan="1" colspan="1">11</td>
<td align="left" valign="top" rowspan="1" colspan="1">62 (2yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">42 (2yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total -6%
<break></break>
Neuropathy-1
<xref ref-type="table-fn" rid="table1-fn1">
<sup>*</sup>
</xref>
<break></break>
Wound-1
<xref ref-type="table-fn" rid="table1-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Ziedan
<italic>et al</italic>
2012 [
<xref rid="ref21" ref-type="bibr">21</xref>
]</td>
<td align="left" valign="top" rowspan="1" colspan="1">96 (48% recurrent)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective (parotid cancers)</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">15–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">55</td>
<td align="left" valign="top" rowspan="1" colspan="1">57</td>
<td align="left" valign="top" rowspan="1" colspan="1">67</td>
<td align="left" valign="top" rowspan="1" colspan="1">68.5 (3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">66.1 (3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total -27%
<break></break>
Fistula-4
<xref ref-type="table-fn" rid="table1-fn1">
<sup>*</sup>
</xref>
<break></break>
ORN-4
<xref ref-type="table-fn" rid="table1-fn1">
<sup>*</sup>
</xref>
<break></break>
Neuropathy-1
<xref ref-type="table-fn" rid="table1-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Ziedan
<italic>et al</italic>
2011 [
<xref rid="ref22" ref-type="bibr">22</xref>
]</td>
<td align="left" valign="top" rowspan="1" colspan="1">231 (89% recurrent)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">15–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">81</td>
<td align="left" valign="top" rowspan="1" colspan="1">21</td>
<td align="left" valign="top" rowspan="1" colspan="1">12</td>
<td align="left" valign="top" rowspan="1" colspan="1">55 (3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">34 (3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-27%
<break></break>
ORN-8
<xref ref-type="table-fn" rid="table1-fn1">
<sup>*</sup>
</xref>
<break></break>
Neuropathy-8
<xref ref-type="table-fn" rid="table1-fn1">
<sup>*</sup>
</xref>
<break></break>
Fistulas-20
<xref ref-type="table-fn" rid="table1-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Perry
<italic>et al</italic>
2010 [
<xref rid="ref19" ref-type="bibr">19</xref>
]</td>
<td align="left" valign="top" rowspan="1" colspan="1">34(100% recurrent)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">HDR IORT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">15</td>
<td align="left" valign="top" rowspan="1" colspan="1">23</td>
<td align="left" valign="top" rowspan="1" colspan="1">56 (2yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">55 (2yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-29%
<break></break>
Wound-3
<xref ref-type="table-fn" rid="table1-fn1">
<sup>*</sup>
</xref>
<break></break>
ORN-1
<xref ref-type="table-fn" rid="table1-fn1">
<sup>*</sup>
</xref>
<break></break>
Neuropathy-1
<xref ref-type="table-fn" rid="table1-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Chen
<italic>et al</italic>
2007 [
<xref rid="ref17" ref-type="bibr">17</xref>
]</td>
<td align="left" valign="top" rowspan="1" colspan="1">137 (100% recurrent)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–18</td>
<td align="left" valign="top" rowspan="1" colspan="1">83</td>
<td align="left" valign="top" rowspan="1" colspan="1">26</td>
<td align="left" valign="top" rowspan="1" colspan="1">41</td>
<td align="left" valign="top" rowspan="1" colspan="1">61 (3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">36 (3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-6%
<break></break>
Wound-4
<xref ref-type="table-fn" rid="table1-fn1">
<sup>*</sup>
</xref>
<break></break>
Fistula-2
<xref ref-type="table-fn" rid="table1-fn1">
<sup>*</sup>
</xref>
<break></break>
Neuropathy-1
<xref ref-type="table-fn" rid="table1-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Pinheiro
<italic>et al</italic>
2002 [
<xref rid="ref23" ref-type="bibr">23</xref>
]</td>
<td align="left" valign="top" rowspan="1" colspan="1">34- SCC 10- non-SCC</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">12.5–22.5</td>
<td align="left" valign="top" rowspan="1" colspan="1">64</td>
<td align="left" valign="top" rowspan="1" colspan="1">36</td>
<td align="left" valign="top" rowspan="1" colspan="1">75.6 for living
<break></break>
patients</td>
<td align="left" valign="top" rowspan="1" colspan="1">46 52 (2yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">32 50 (2yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-7%
<break></break>
Fistula-1
<xref ref-type="table-fn" rid="table1-fn1">
<sup>*</sup>
</xref>
<break></break>
Neuropathy-1
<xref ref-type="table-fn" rid="table1-fn1">
<sup>*</sup>
</xref>
<break></break>
Carotid blowout-1
<xref ref-type="table-fn" rid="table1-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Nag
<italic>et al</italic>
1998 [
<xref rid="ref18" ref-type="bibr">18</xref>
]</td>
<td align="left" valign="top" rowspan="1" colspan="1">38 (100% recurrent)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">15–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">0</td>
<td align="left" valign="top" rowspan="1" colspan="1">30</td>
<td align="left" valign="top" rowspan="1" colspan="1">19 (1yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">21% (1yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total -16%
<break></break>
Fistula-2
<xref ref-type="table-fn" rid="table1-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>Adj. RT: Adjuvant post-IORT RT, LC: local control, OS: overall Survival,</p>
<fn id="table1-fn1">
<label>*</label>
<p>Number of patients.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2" position="float">
<label>Table 2.</label>
<caption>
<title>Randomised control trials of IORT versus WBI in early-breast cancer.</title>
</caption>
<table frame="border" rules="all">
<thead>
<tr>
<th align="center" valign="top" rowspan="1" colspan="1">Trial name</th>
<th align="center" valign="top" rowspan="1" colspan="1">Sample size</th>
<th align="center" valign="top" rowspan="1" colspan="1">Age</th>
<th align="center" valign="top" rowspan="1" colspan="1">Inclusion criteria</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT type</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT dose</th>
<th align="center" valign="top" rowspan="1" colspan="1">Trial design</th>
<th align="center" valign="top" rowspan="1" colspan="1">Local recurrence (5yr)</th>
<th align="center" valign="top" rowspan="1" colspan="1">Overall survival/mortality (5yr)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">ELIOT [
<xref rid="ref28" ref-type="bibr">28</xref>
]</td>
<td align="left" valign="top" rowspan="1" colspan="1">1305 median follow-up: 5.8 years</td>
<td align="left" valign="top" rowspan="1" colspan="1">> 48 years</td>
<td align="left" valign="top" rowspan="1" colspan="1">any invasive cancer < 2.5 cm</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">ELIOT:21 Gy/1# to tumour bed with 6–9 MeV electrons
<break></break>
WBI:50 Gy/25# + 10 Gy/5# boost</td>
<td align="left" valign="top" rowspan="1" colspan="1">Equivalence trial:
<break></break>
Statistical margin was local recurrence of 7.5% in the IORT group</td>
<td align="left" valign="top" rowspan="1" colspan="1">ELIOT:4.4% (95% C.I: 2.7–6.1)
<break></break>
WBI: 0.4%
<break></break>
<italic>p</italic>
< 0.0001</td>
<td align="left" valign="top" rowspan="1" colspan="1">ELIOT:96.8%
<break></break>
WBI: 96.9%
<break></break>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">TARGIT-A [
<xref rid="ref27" ref-type="bibr">27</xref>
]
<break></break>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">3451 Median follow-up:
<break></break>
2.5 years</td>
<td align="left" valign="top" rowspan="1" colspan="1">> 45years</td>
<td align="left" valign="top" rowspan="1" colspan="1">T1-2, N0, 1 IDC < 3.5 cm
<break></break>
(If EIC or ILC on final histology,
<break></break>
add whole breast RT)</td>
<td align="left" valign="top" rowspan="1" colspan="1">X-ray IORT (50 kv X-ray)</td>
<td align="left" valign="top" rowspan="1" colspan="1">TARGIT: 20 Gy to tumour bed
<break></break>
5–7 Gy at 1 cm depth
<break></break>
WBI: 40–56 Gy with or without boost 10–16 Gy</td>
<td align="left" valign="top" rowspan="1" colspan="1">Non-inferiority trial:
<break></break>
Statistical margin was 2.5% difference in local recurrence at 5 years</td>
<td align="left" valign="top" rowspan="1" colspan="1">TARGIT:3.3% (95% CI: 2.1–5.1)
<break></break>
WBI:1.3%
<break></break>
(95% CI: 0.7–2.5)
<break></break>
<italic>p</italic>
= 0.042</td>
<td align="left" valign="top" rowspan="1" colspan="1">TARGIT:3.9%
<break></break>
WBI: 5.3
<break></break>
<italic>p</italic>
= 0.009
<break></break>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>EIC: extensive intraductal component, ILC: invasive lobular cancer, WBI: whole breast RT.</p>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3" position="float">
<label>Table 3.</label>
<caption>
<title>Studies of IORT in locally advanced colorectal cancer after gross total resection.</title>
</caption>
<table frame="border" rules="all">
<thead>
<tr>
<th align="center" valign="top" rowspan="1" colspan="1">Author/Year</th>
<th align="center" valign="top" rowspan="1" colspan="1">Sample size</th>
<th align="center" valign="top" rowspan="1" colspan="1">Study design</th>
<th align="center" valign="top" rowspan="1" colspan="1">T4 %</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT type</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT dose (Gy)</th>
<th align="center" valign="top" rowspan="1" colspan="1">EBRT %</th>
<th align="center" valign="top" rowspan="1" colspan="1">Median F/U</th>
<th align="center" valign="top" rowspan="1" colspan="1">LC 5 year (%)</th>
<th align="center" valign="top" rowspan="1" colspan="1">OS 5 year (%)</th>
<th align="center" valign="top" rowspan="1" colspan="1">Toxicity grade 3 or ></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Ratto
<italic>et al</italic>
. [
<xref rid="ref52" ref-type="bibr">52</xref>
] 2003</td>
<td align="left" valign="top" rowspan="1" colspan="1">43
<break></break>
IORT-19
<break></break>
No IORT-24</td>
<td align="left" valign="top" rowspan="1" colspan="1">NRC</td>
<td align="left" valign="top" rowspan="1" colspan="1">93</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">74</td>
<td align="left" valign="top" rowspan="1" colspan="1">Sx + IORT: 91
<break></break>
Sx − 57
<break></break>
<italic>p</italic>
= 0.035</td>
<td align="left" valign="top" rowspan="1" colspan="1">61</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR for IORT patients</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Sadahiro
<italic>et al</italic>
. [
<xref rid="ref53" ref-type="bibr">53</xref>
] 2004</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT-99
<break></break>
No IORT-68</td>
<td align="left" valign="top" rowspan="1" colspan="1">NRC</td>
<td align="left" valign="top" rowspan="1" colspan="1">12</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">15–25</td>
<td align="left" valign="top" rowspan="1" colspan="1">100 (20 Gy only)</td>
<td align="left" valign="top" rowspan="1" colspan="1">67
<break></break>
83</td>
<td align="left" valign="top" rowspan="1" colspan="1">Sx + IORT-98
<break></break>
Sx- 84
<break></break>
<italic>p</italic>
= 0.002</td>
<td align="left" valign="top" rowspan="1" colspan="1">Sx + IORT- 79
<break></break>
Sx- 58
<break></break>
<italic>p</italic>
= 0.002</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR for IORT patients</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Ferenschild
<italic>et al</italic>
. [
<xref rid="ref54" ref-type="bibr">54</xref>
] 2006</td>
<td align="left" valign="top" rowspan="1" colspan="1">123
<break></break>
IORT-30
<break></break>
No IORT-93</td>
<td align="left" valign="top" rowspan="1" colspan="1">NRC</td>
<td align="left" valign="top" rowspan="1" colspan="1">25</td>
<td align="left" valign="top" rowspan="1" colspan="1">HDR-IORT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">25</td>
<td align="left" valign="top" rowspan="1" colspan="1">R0+IORT:72
<break></break>
R0:71 (N.S diff)
<break></break>
<italic>R</italic>
<sup>(+)</sup>
+ IORT:58
<break></break>
<italic>R</italic>
<sup>(+)</sup>
:0 (
<italic>p</italic>
= 0.016)</td>
<td align="left" valign="top" rowspan="1" colspan="1">R0+IORT:56
<break></break>
R0:66 (N.s diff)
<break></break>
<italic>R</italic>
+ ( + ) IORT:38
<break></break>
<italic>R</italic>
+:0 (
<italic>p=</italic>
0.026)</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR for IORT patients</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Roeder
<italic>et al</italic>
. [
<xref rid="ref55" ref-type="bibr">55</xref>
] 2007</td>
<td align="left" valign="top" rowspan="1" colspan="1">243</td>
<td align="left" valign="top" rowspan="1" colspan="1">RC</td>
<td align="left" valign="top" rowspan="1" colspan="1">20</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">86</td>
<td align="left" valign="top" rowspan="1" colspan="1">59</td>
<td align="left" valign="top" rowspan="1" colspan="1">R0 + IORT- 94
<break></break>
<italic>R</italic>
<sup>(+)</sup>
+ IORT-72</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-10%
<break></break>
Proctitis-8
<break></break>
Fistula-7
<break></break>
Bowel stenosis-8</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Mathis
<italic>et al</italic>
. [
<xref rid="ref50" ref-type="bibr">50</xref>
] 2008</td>
<td align="left" valign="top" rowspan="1" colspan="1">146</td>
<td align="left" valign="top" rowspan="1" colspan="1">PC</td>
<td align="left" valign="top" rowspan="1" colspan="1">64</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">7.5–25</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">44</td>
<td align="left" valign="top" rowspan="1" colspan="1">86</td>
<td align="left" valign="top" rowspan="1" colspan="1">52</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total- 22%
<break></break>
Neuropathy-3
<xref ref-type="table-fn" rid="table3-fn1">
<sup>*</sup>
</xref>
<break></break>
GI/GU-23
<xref ref-type="table-fn" rid="table3-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Masaki
<italic>et al</italic>
. [
<xref rid="ref56" ref-type="bibr">56</xref>
] 2008</td>
<td align="left" valign="top" rowspan="1" colspan="1">44
<break></break>
IORT-19
<break></break>
No IORT-25</td>
<td align="left" valign="top" rowspan="1" colspan="1">RCT</td>
<td align="left" valign="top" rowspan="1" colspan="1">0</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">18–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">No</td>
<td align="left" valign="top" rowspan="1" colspan="1">34</td>
<td align="left" valign="top" rowspan="1" colspan="1">Sx+IORT-94.7
<break></break>
Sx-95.5%</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<italic>p =</italic>
0.344
<break></break>
N.s diff</td>
<td align="left" valign="top" rowspan="1" colspan="1">Urinary catheter indwelling 29% vs. 3%,
<break></break>
Rest- N.s diff</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Valentini
<italic>et al</italic>
. [
<xref rid="ref57" ref-type="bibr">57</xref>
] 2009</td>
<td align="left" valign="top" rowspan="1" colspan="1">100
<break></break>
IORT-29
<break></break>
No IORT-71</td>
<td align="left" valign="top" rowspan="1" colspan="1">NRC</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">31</td>
<td align="left" valign="top" rowspan="1" colspan="1">R0+IORT:100
<break></break>
R0:81
<break></break>
<italic>p</italic>
= 0.014</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR for IORT patients</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Dubois
<italic>et al</italic>
[
<xref rid="ref58" ref-type="bibr">58</xref>
] 2008</td>
<td align="left" valign="top" rowspan="1" colspan="1">142
<break></break>
IORT-73
<break></break>
No IORT-69</td>
<td align="left" valign="top" rowspan="1" colspan="1">RCT</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">15–18</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">60</td>
<td align="left" valign="top" rowspan="1" colspan="1">Sx + IORT- 91.8
<break></break>
Sx- 92.8
<break></break>
<italic>p</italic>
= 0.6018</td>
<td align="left" valign="top" rowspan="1" colspan="1">Sx + IORT - 69.8
<break></break>
Sx- 74.8
<break></break>
<italic>p</italic>
=0.25</td>
<td align="left" valign="top" rowspan="1" colspan="1">No difference in toxicity
<italic>p</italic>
=0.15</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Kusters
<italic>et al</italic>
[
<xref rid="ref59" ref-type="bibr">59</xref>
] 2010</td>
<td align="left" valign="top" rowspan="1" colspan="1">605</td>
<td align="left" valign="top" rowspan="1" colspan="1">PC
<break></break>
Pooled analysis</td>
<td align="left" valign="top" rowspan="1" colspan="1">29</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–12.5</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1">R0+IORT- 90.5
<break></break>
<italic>R</italic>
<sup>(+)</sup>
+ IORT-55
<break></break>
<italic>p</italic>
< 0.001</td>
<td align="left" valign="top" rowspan="1" colspan="1">67</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Sole
<italic>et al</italic>
. [
<xref rid="ref60" ref-type="bibr">60</xref>
] 2014</td>
<td align="left" valign="top" rowspan="1" colspan="1">335</td>
<td align="left" valign="top" rowspan="1" colspan="1">PC</td>
<td align="left" valign="top" rowspan="1" colspan="1">16</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">72.6</td>
<td align="left" valign="top" rowspan="1" colspan="1">92</td>
<td align="left" valign="top" rowspan="1" colspan="1">75</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-10%
<break></break>
GI-19
<xref ref-type="table-fn" rid="table3-fn1">
<sup>*</sup>
</xref>
<break></break>
GU-8
<xref ref-type="table-fn" rid="table3-fn1">
<sup>*</sup>
</xref>
<break></break>
Neuropathy-7
<xref ref-type="table-fn" rid="table3-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Holman
<italic>et al</italic>
[
<xref rid="ref61" ref-type="bibr">61</xref>
] 2016</td>
<td align="left" valign="top" rowspan="1" colspan="1">417</td>
<td align="left" valign="top" rowspan="1" colspan="1">PC
<break></break>
Pooled analysis</td>
<td align="left" valign="top" rowspan="1" colspan="1">100%
<break></break>
T4</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–12.5</td>
<td align="left" valign="top" rowspan="1" colspan="1">97</td>
<td align="left" valign="top" rowspan="1" colspan="1">52</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<italic>R</italic>
0 + IORT- 87
<break></break>
<italic>R</italic>
1 + IORT- 60
<break></break>
<italic>R</italic>
2 + IORT- 57
<break></break>
<italic>p</italic>
< 0.001</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<italic>R</italic>
0 + IORT-65
<break></break>
<italic>R</italic>
1 + IORT- 34
<break></break>
<italic>R</italic>
2 + IORT- 14
<break></break>
<italic>p</italic>
< 0.001</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>NRC: non randomised comparison, RCT: randomised controlled trial, PC: prospective cohort, RC: retrospective cohort, F/U: follow-up, Sx: surgery,
<italic>R</italic>
<sup>(+)</sup>
: residual after surgery, LC:-local control, OS:-overall Survival, NR: not reported,</p>
<fn id="table3-fn1">
<label>*</label>
<p>Number of patients,</p>
</fn>
<p>N.s diff: Non significant difference.</p>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table4" position="float">
<label>Table 4.</label>
<caption>
<title>studies of IORT in locally recurrent colorectal cancers.</title>
</caption>
<table frame="border" rules="all">
<thead>
<tr>
<th align="center" valign="top" rowspan="1" colspan="1">Author/Year</th>
<th align="center" valign="top" rowspan="1" colspan="1">Sample size</th>
<th align="center" valign="top" rowspan="1" colspan="1">Study design</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT type</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT dose (Gy)</th>
<th align="center" valign="top" rowspan="1" colspan="1">Prior EBRT %</th>
<th align="center" valign="top" rowspan="1" colspan="1">Adj. EBRT %</th>
<th align="center" valign="top" rowspan="1" colspan="1">Median Follow up</th>
<th align="center" valign="top" rowspan="1" colspan="1">LC 5year (%)</th>
<th align="center" valign="top" rowspan="1" colspan="1">OS 5year (%)</th>
<th align="center" valign="top" rowspan="1" colspan="1">Toxicity grade 3 or ></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Suzuki
<italic>et al</italic>
. [
<xref rid="ref63" ref-type="bibr">63</xref>
] 1995</td>
<td align="left" valign="top" rowspan="1" colspan="1">106
<break></break>
Sx+IORT:42
<break></break>
Sx:64</td>
<td align="left" valign="top" rowspan="1" colspan="1">NRC</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–30</td>
<td align="left" valign="top" rowspan="1" colspan="1">25</td>
<td align="left" valign="top" rowspan="1" colspan="1">98</td>
<td align="left" valign="top" rowspan="1" colspan="1">44</td>
<td align="left" valign="top" rowspan="1" colspan="1">Sx+IORT:60%
<break></break>
Sx:7%
<break></break>
at 3years</td>
<td align="left" valign="top" rowspan="1" colspan="1">Sx+IORT:19
<break></break>
Sx: 7%
<break></break>
P=0.0006</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-36%
<break></break>
Abcess-5
<break></break>
GI/GU-9
<break></break>
wound-3</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Valentini
<italic>et al</italic>
. [
<xref rid="ref66" ref-type="bibr">66</xref>
] 1999</td>
<td align="left" valign="top" rowspan="1" colspan="1">47
<break></break>
Sx+IORT:11
<break></break>
Sx:14</td>
<td align="left" valign="top" rowspan="1" colspan="1">NRC</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">28</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">80</td>
<td align="left" valign="top" rowspan="1" colspan="1">Sx+IORT:80
<break></break>
Sx:24
<break></break>
<italic>p</italic>
< 0.05</td>
<td align="left" valign="top" rowspan="1" colspan="1">Sx+IORT:41
<break></break>
Sx:16
<break></break>
N.S diff</td>
<td align="left" valign="top" rowspan="1" colspan="1">Hydronephrosis-1
<break></break>
Neuropathy-0
<xref ref-type="table-fn" rid="table4-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Alektiar
<italic>et al</italic>
. [
<xref rid="ref75" ref-type="bibr">75</xref>
] 2000</td>
<td align="left" valign="top" rowspan="1" colspan="1">74</td>
<td align="left" valign="top" rowspan="1" colspan="1">RC</td>
<td align="left" valign="top" rowspan="1" colspan="1">HDR-IORT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–18</td>
<td align="left" valign="top" rowspan="1" colspan="1">53</td>
<td align="left" valign="top" rowspan="1" colspan="1">39</td>
<td align="left" valign="top" rowspan="1" colspan="1">22</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<italic>R</italic>
0+IORT- 43
<break></break>
<italic>R</italic>
<sup>(+)</sup>
+IORT-26
<break></break>
<italic>p</italic>
= 0.02</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<italic>R</italic>
0+IORT-36
<break></break>
<italic>R</italic>
<sup>(+)</sup>
+IORT-11
<break></break>
<italic>p</italic>
= 0.04</td>
<td align="left" valign="top" rowspan="1" colspan="1">Fistula-8
<xref ref-type="table-fn" rid="table4-fn1">
<sup>*</sup>
</xref>
<break></break>
Neuropathy-1
<xref ref-type="table-fn" rid="table4-fn1">
<sup>*</sup>
</xref>
<break></break>
Ureter-10
<xref ref-type="table-fn" rid="table4-fn1">
<sup>*</sup>
</xref>
<break></break>
Wound-5
<xref ref-type="table-fn" rid="table4-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Lindel
<italic>et al</italic>
. [
<xref rid="ref76" ref-type="bibr">76</xref>
] 2001</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT-49
<break></break>
No IORT-20</td>
<td align="left" valign="top" rowspan="1" colspan="1">NRC</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">14</td>
<td align="left" valign="top" rowspan="1" colspan="1">94</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<italic>R</italic>
0 + IORT-56
<break></break>
<italic>R</italic>
<sup>(+)</sup>
+IORT-14
<break></break>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<italic>R</italic>
0 + IORT-40
<break></break>
<italic>R</italic>
<sup>(+)</sup>
+IORT-17
<break></break>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">Wound complication-4
<xref ref-type="table-fn" rid="table4-fn1">
<sup>*</sup>
</xref>
<break></break>
Neuropathy-4
<xref ref-type="table-fn" rid="table4-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Wiig
<italic>et al</italic>
. [
<xref rid="ref67" ref-type="bibr">67</xref>
] 2002</td>
<td align="left" valign="top" rowspan="1" colspan="1">107
<break></break>
Sx+IORT:59
<break></break>
Sx:48</td>
<td align="left" valign="top" rowspan="1" colspan="1">NRC</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">15–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">0</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">Sx+IORT:50
<break></break>
Sx: 30
<break></break>
N.S diff</td>
<td align="left" valign="top" rowspan="1" colspan="1">Sx+IORT:30
<break></break>
Sx: 30%
<break></break>
N.S diff</td>
<td align="left" valign="top" rowspan="1" colspan="1">late toxicity: NR
<break></break>
Acute complication: N.s diff</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Dresen
<italic>et al</italic>
[
<xref rid="ref69" ref-type="bibr">69</xref>
]. 2008</td>
<td align="left" valign="top" rowspan="1" colspan="1">147</td>
<td align="left" valign="top" rowspan="1" colspan="1">RC</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10.–17.5</td>
<td align="left" valign="top" rowspan="1" colspan="1">53</td>
<td align="left" valign="top" rowspan="1" colspan="1">84</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<italic>R</italic>
0 + IORT-69
<break></break>
<italic>R</italic>
1 + IORT-29
<break></break>
<italic>R</italic>
2 + IORT-28
<italic>p</italic>
< 0.001(3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<italic>R</italic>
0 + IORT-59
<break></break>
<italic>R</italic>
1 + IORT-27
<break></break>
<italic>R</italic>
2 + IORT-24
<break></break>
<italic>p</italic>
< 0.001(3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Neuropathy-16
<xref ref-type="table-fn" rid="table4-fn1">
<sup>*</sup>
</xref>
<break></break>
Ureter stenosis-4
<xref ref-type="table-fn" rid="table4-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Haddock
<italic>et al</italic>
. [
<xref rid="ref65" ref-type="bibr">65</xref>
] 2011</td>
<td align="left" valign="top" rowspan="1" colspan="1">607</td>
<td align="left" valign="top" rowspan="1" colspan="1">PC</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">7.5–30</td>
<td align="left" valign="top" rowspan="1" colspan="1">45</td>
<td align="left" valign="top" rowspan="1" colspan="1">96</td>
<td align="left" valign="top" rowspan="1" colspan="1">44</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<italic>R</italic>
0 + IORT-79
<break></break>
<italic>R</italic>
1 + IORT-56
<break></break>
<italic>R</italic>
2 + IORT-49
<break></break>
<italic>p</italic>
< 0.001</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<italic>R</italic>
0 + IORT-46
<break></break>
<italic>R</italic>
1 + IORT-27
<break></break>
<italic>R</italic>
2 + IORT-16
<break></break>
<italic>p</italic>
< 0.001</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-11%
<break></break>
Wound-42
<xref ref-type="table-fn" rid="table4-fn1">
<sup>*</sup>
</xref>
<break></break>
Neropathy-18
<xref ref-type="table-fn" rid="table4-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Roeder
<italic>et al</italic>
.[
<xref rid="ref70" ref-type="bibr">70</xref>
] 2012</td>
<td align="left" valign="top" rowspan="1" colspan="1">97</td>
<td align="left" valign="top" rowspan="1" colspan="1">PC</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">44</td>
<td align="left" valign="top" rowspan="1" colspan="1">52</td>
<td align="left" valign="top" rowspan="1" colspan="1">33</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<italic>R</italic>
0 + IORT-82
<break></break>
<italic>R</italic>
1 + IORT-41
<break></break>
<italic>R</italic>
2 + IORT-18
<break></break>
<italic>p</italic>
< 0.001(3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<italic>R</italic>
0 + IORT-80
<break></break>
<italic>R</italic>
1 + IORT-37
<break></break>
<italic>R</italic>
2 + IORT-35
<break></break>
<italic>p</italic>
< 0.001(3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Acute:
<break></break>
Abscess /fistula-16
<break></break>
Late:
<break></break>
Neuropathy-8
<xref ref-type="table-fn" rid="table4-fn1">
<sup>*</sup>
</xref>
<break></break>
Ureter stenosis-3
<xref ref-type="table-fn" rid="table4-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Calvo
<italic>et al</italic>
. [
<xref rid="ref68" ref-type="bibr">68</xref>
] 2013</td>
<td align="left" valign="top" rowspan="1" colspan="1">60</td>
<td align="left" valign="top" rowspan="1" colspan="1">RC</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">50</td>
<td align="left" valign="top" rowspan="1" colspan="1">47</td>
<td align="left" valign="top" rowspan="1" colspan="1">36</td>
<td align="left" valign="top" rowspan="1" colspan="1">44
<break></break>
<italic>R</italic>
0 vs
<italic>R</italic>
1: HR-2.09,
<italic>p</italic>
= 0.05</td>
<td align="left" valign="top" rowspan="1" colspan="1">43
<break></break>
<italic>R</italic>
0 vs R1:HR-2.9,
<italic>p</italic>
= 0.05</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total:42%
<break></break>
Fistula-4
<xref ref-type="table-fn" rid="table4-fn1">
<sup>*</sup>
</xref>
<break></break>
Neuropathy-4
<xref ref-type="table-fn" rid="table4-fn1">
<sup>*</sup>
</xref>
<break></break>
GI-4
<xref ref-type="table-fn" rid="table4-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Holman
<italic>et al</italic>
. [
<xref rid="ref71" ref-type="bibr">71</xref>
] 2017</td>
<td align="left" valign="top" rowspan="1" colspan="1">565</td>
<td align="left" valign="top" rowspan="1" colspan="1">PC pooled analysis</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">46</td>
<td align="left" valign="top" rowspan="1" colspan="1">95</td>
<td align="left" valign="top" rowspan="1" colspan="1">40 months
<break></break>
In survivors</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<italic>R</italic>
0 + IORT-72
<break></break>
<italic>R</italic>
1 + IORT-36
<break></break>
<italic>R</italic>
2 + IORT-39
<break></break>
<italic>p</italic>
< 0.0001</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<italic>R</italic>
0 + IORT-48
<break></break>
<italic>R</italic>
1 + IORT-25
<break></break>
<italic>R</italic>
2 + IORT-17
<break></break>
<italic>p</italic>
< 0.0001</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>NRC: non randomised comparison, RCT: randomised controlled trial, PC: prospective cohort, RC: retrospective cohort, Sx: surgery,
<italic>R</italic>
<sup>(+)</sup>
: residual after surgery,
<italic>R</italic>
0: no residual after surgery, LC: local control, OS: overall survival, NR: not reported,</p>
<fn id="table4-fn1">
<label>*</label>
<p>Number of patients,</p>
</fn>
<p>N.s diff: non-significant difference.</p>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table5" position="float">
<label>Table 5.</label>
<caption>
<title>Studies of IORT in extremity soft tissue sarcoma in combination with function preserving surgery and moderate doses of EBRT (40-50Gy).</title>
</caption>
<table frame="border" rules="all">
<thead>
<tr>
<th align="center" valign="top" rowspan="1" colspan="1">Author/Year</th>
<th align="center" valign="top" rowspan="1" colspan="1">Sample size</th>
<th align="center" valign="top" rowspan="1" colspan="1">Study design</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT type</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT dose Gy</th>
<th align="center" valign="top" rowspan="1" colspan="1">EBRT %</th>
<th align="center" valign="top" rowspan="1" colspan="1">Median follow-up</th>
<th align="center" valign="top" rowspan="1" colspan="1">LC 5 year</th>
<th align="center" valign="top" rowspan="1" colspan="1">DFS 5 year</th>
<th align="center" valign="top" rowspan="1" colspan="1">OS 5 year</th>
<th align="center" valign="top" rowspan="1" colspan="1">Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Edmonson
<italic>et al</italic>
. [
<xref rid="ref77" ref-type="bibr">77</xref>
] 2001</td>
<td align="left" valign="top" rowspan="1" colspan="1">39 (Recurrent-3%,
<italic>R</italic>
+:38%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT/HDR IORT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">70</td>
<td align="left" valign="top" rowspan="1" colspan="1">90
<xref ref-type="table-fn" rid="table5-fn3">
<sup>α</sup>
</xref>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">80</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR for IORT</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Azinovic
<italic>et al</italic>
. [
<xref rid="ref78" ref-type="bibr">78</xref>
] 2003</td>
<td align="left" valign="top" rowspan="1" colspan="1">45 (Recurrent-42%,
<italic>R</italic>
+:33%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">80</td>
<td align="left" valign="top" rowspan="1" colspan="1">93</td>
<td align="left" valign="top" rowspan="1" colspan="1">80
<break></break>
<italic>R</italic>
0 vs
<italic>R</italic>
1:
<break></break>
88 vs 57
<break></break>
<italic>p</italic>
= 0.04</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">64</td>
<td align="left" valign="top" rowspan="1" colspan="1">Wound complication -4
<xref ref-type="table-fn" rid="table5-fn1">
<sup>*</sup>
</xref>
<break></break>
Neuropathy-5
<xref ref-type="table-fn" rid="table5-fn1">
<sup>*</sup>
</xref>
<break></break>
Fracture-2
<xref ref-type="table-fn" rid="table5-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Kretzler
<italic>et al</italic>
. [
<xref rid="ref79" ref-type="bibr">79</xref>
] 2004</td>
<td align="left" valign="top" rowspan="1" colspan="1">28
<break></break>
(Recurrent -57%,
<italic>R</italic>
+:39%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">HDR/IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">12–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">90</td>
<td align="left" valign="top" rowspan="1" colspan="1">55</td>
<td align="left" valign="top" rowspan="1" colspan="1">84</td>
<td align="left" valign="top" rowspan="1" colspan="1">54</td>
<td align="left" valign="top" rowspan="1" colspan="1">66</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-24%
<break></break>
Neuropathy-1
<xref ref-type="table-fn" rid="table5-fn1">
<sup>*</sup>
</xref>
<break></break>
Fractures-2
<xref ref-type="table-fn" rid="table5-fn1">
<sup>*</sup>
</xref>
<break></break>
Contracture-2
<xref ref-type="table-fn" rid="table5-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Oertel
<italic>et al</italic>
. [
<xref rid="ref80" ref-type="bibr">80</xref>
] 2006</td>
<td align="left" valign="top" rowspan="1" colspan="1">153
<break></break>
(Recurrent - 38%,
<italic>R</italic>
+: 30%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">33</td>
<td align="left" valign="top" rowspan="1" colspan="1">78</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">77</td>
<td align="left" valign="top" rowspan="1" colspan="1">Wound-17%
<break></break>
Neuropathy-7
<xref ref-type="table-fn" rid="table5-fn1">
<sup>*</sup>
</xref>
<break></break>
Lymphededma-6
<xref ref-type="table-fn" rid="table5-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Niewald
<italic>et al</italic>
. [
<xref rid="ref81" ref-type="bibr">81</xref>
] 2009</td>
<td align="left" valign="top" rowspan="1" colspan="1">38
<break></break>
(Recurrent -24%,)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">HDR-IORT</td>
<td align="left" valign="top" rowspan="1" colspan="1">8–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">27</td>
<td align="left" valign="top" rowspan="1" colspan="1">63</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">57</td>
<td align="left" valign="top" rowspan="1" colspan="1">Skin-42%
<break></break>
Neuropathy-0</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Call
<italic>et al</italic>
. [
<xref rid="ref82" ref-type="bibr">82</xref>
] 2012
<xref ref-type="table-fn" rid="table5-fn2">¥</xref>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">61
<break></break>
(Recurrent -21%,
<italic>R</italic>
+:18%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">7.5–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">70</td>
<td align="left" valign="top" rowspan="1" colspan="1">91</td>
<td align="left" valign="top" rowspan="1" colspan="1">80</td>
<td align="left" valign="top" rowspan="1" colspan="1">72</td>
<td align="left" valign="top" rowspan="1" colspan="1">Wound-3.2%
<break></break>
Neuropathy-1
<xref ref-type="table-fn" rid="table5-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Calvo
<italic>et al</italic>
. [
<xref rid="ref83" ref-type="bibr">83</xref>
] 2014</td>
<td align="left" valign="top" rowspan="1" colspan="1">159
<break></break>
(
<italic>R</italic>
1-16%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective pooled</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">53</td>
<td align="left" valign="top" rowspan="1" colspan="1">82
<break></break>
<italic>R</italic>
0 vs
<italic>R</italic>
1:
<break></break>
<italic>p</italic>
= 0.009</td>
<td align="left" valign="top" rowspan="1" colspan="1">62</td>
<td align="left" valign="top" rowspan="1" colspan="1">72</td>
<td align="left" valign="top" rowspan="1" colspan="1">Acute skin/wound- 16%
<break></break>
Neuropathy-6
<xref ref-type="table-fn" rid="table5-fn1">
<sup>*</sup>
</xref>
<break></break>
Lympedema-7
<xref ref-type="table-fn" rid="table5-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Roeder
<italic>et al</italic>
. [
<xref rid="ref84" ref-type="bibr">84</xref>
] 2014</td>
<td align="left" valign="top" rowspan="1" colspan="1">34
<break></break>
(
<italic>R</italic>
1-12%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Prospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">43</td>
<td align="left" valign="top" rowspan="1" colspan="1">97
<break></break>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">66</td>
<td align="left" valign="top" rowspan="1" colspan="1">79</td>
<td align="left" valign="top" rowspan="1" colspan="1">Neuropathy-1
<xref ref-type="table-fn" rid="table5-fn1">
<sup>*</sup>
</xref>
<break></break>
osteonecrosis-1
<xref ref-type="table-fn" rid="table5-fn1">
<sup>*</sup>
</xref>
<break></break>
Joint dysfunction-1
<xref ref-type="table-fn" rid="table5-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Roeder
<italic>et al</italic>
. [
<xref rid="ref85" ref-type="bibr">85</xref>
] 2016</td>
<td align="left" valign="top" rowspan="1" colspan="1">183
<break></break>
(Recurrent -22%,
<italic>R</italic>
1 - 32%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">8–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">64</td>
<td align="left" valign="top" rowspan="1" colspan="1">86
<break></break>
<italic>R</italic>
0 vs
<italic>R</italic>
1: 92 vs 75
<italic>p</italic>
= 0.019</td>
<td align="left" valign="top" rowspan="1" colspan="1">61</td>
<td align="left" valign="top" rowspan="1" colspan="1">77</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-19%
<break></break>
Wound-15
<xref ref-type="table-fn" rid="table5-fn1">
<sup>*</sup>
</xref>
<break></break>
Neuropathy-14
<xref ref-type="table-fn" rid="table5-fn1">
<sup>*</sup>
</xref>
<break></break>
osteonecrosis-11
<xref ref-type="table-fn" rid="table5-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>
<italic>R</italic>
+: Residual after surgery,
<italic>R</italic>
0: no residual after surgery, LC: local control, OS: overall Survival, DFS: disease-free survival, NR: not reported,</p>
<fn id="table5-fn1">
<label>
<sup>*</sup>
</label>
<p>Number of patients,</p>
</fn>
<fn id="table5-fn2">
<label>¥</label>
<p>call
<italic>et al</italic>
included only upper extremity tumours,</p>
</fn>
<fn id="table5-fn3">
<label>α</label>
<p>-crude rate</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table6" position="float">
<label>Table 6.</label>
<caption>
<title>Studies of IORT in Retroperitoneal sarcoma.</title>
</caption>
<table frame="border" rules="all">
<thead>
<tr>
<th align="center" valign="top" rowspan="1" colspan="1">Author/Year</th>
<th align="center" valign="top" rowspan="1" colspan="1">Sample size</th>
<th align="center" valign="top" rowspan="1" colspan="1">Study design</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT type</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT dose (Gy)</th>
<th align="center" valign="top" rowspan="1" colspan="1">EBRT %</th>
<th align="center" valign="top" rowspan="1" colspan="1">Median follow-up</th>
<th align="center" valign="top" rowspan="1" colspan="1">LC 5 year (%)</th>
<th align="center" valign="top" rowspan="1" colspan="1">OS 5 year (%)</th>
<th align="center" valign="top" rowspan="1" colspan="1">Toxicity grade 3 or ></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Sindelar
<italic>et al</italic>
. [
<xref rid="ref86" ref-type="bibr">86</xref>
] 1993</td>
<td align="left" valign="top" rowspan="1" colspan="1">35
<break></break>
GTR-100%</td>
<td align="left" valign="top" rowspan="1" colspan="1">RCT
<break></break>
Sx + IORT + low-dose PORT
<break></break>
Vs Sx + high-dose PORT</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">20</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">96</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT + PORT- 60%’
<break></break>
PORT-20%</td>
<td align="left" valign="top" rowspan="1" colspan="1">-</td>
<td align="left" valign="top" rowspan="1" colspan="1">Neuropathy
<break></break>
IORT + PORT-60%
<break></break>
PORT-5%
<break></break>
Enteritis
<break></break>
IORT + PORT-13%
<break></break>
PORT-50%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Alektiar
<italic>et al</italic>
. [
<xref rid="ref87" ref-type="bibr">87</xref>
] 2000</td>
<td align="left" valign="top" rowspan="1" colspan="1">32
<break></break>
Recurrent -62%, GTR-94%</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective cohort</td>
<td align="left" valign="top" rowspan="1" colspan="1">HDR-IORT</td>
<td align="left" valign="top" rowspan="1" colspan="1">12–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">78</td>
<td align="left" valign="top" rowspan="1" colspan="1">33</td>
<td align="left" valign="top" rowspan="1" colspan="1">62</td>
<td align="left" valign="top" rowspan="1" colspan="1">45</td>
<td align="left" valign="top" rowspan="1" colspan="1">GI -18%
<break></break>
Neuropathy-0%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Gieschen
<italic>et al</italic>
. [
<xref rid="ref88" ref-type="bibr">88</xref>
] 2001</td>
<td align="left" valign="top" rowspan="1" colspan="1">37
<break></break>
IORT-20
<break></break>
No IORT-17
<break></break>
Recurrent-22%
<break></break>
GTR-78%</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective cohort</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<break></break>
100
<break></break>
100</td>
<td align="left" valign="top" rowspan="1" colspan="1">38</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<break></break>
IORT-83
<break></break>
No IORT-61
<break></break>
p = 0.197
<xref ref-type="table-fn" rid="table6-fn2">¥</xref>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<break></break>
IORT-74
<break></break>
No IORT-30
<break></break>
p = 0.044
<xref ref-type="table-fn" rid="table6-fn2">¥</xref>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-20%
<break></break>
Neuropathy-1
<xref ref-type="table-fn" rid="table6-fn1">
<sup>*</sup>
</xref>
<break></break>
Fistula-2
<xref ref-type="table-fn" rid="table6-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Peterson
<italic>et al</italic>
[
<xref rid="ref89" ref-type="bibr">89</xref>
] 2002</td>
<td align="left" valign="top" rowspan="1" colspan="1">87
<break></break>
Recurrent-50%, GTR-84%</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective cohort</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">8.75–30</td>
<td align="left" valign="top" rowspan="1" colspan="1">89</td>
<td align="left" valign="top" rowspan="1" colspan="1">42</td>
<td align="left" valign="top" rowspan="1" colspan="1">59</td>
<td align="left" valign="top" rowspan="1" colspan="1">47</td>
<td align="left" valign="top" rowspan="1" colspan="1">GI-14%
<break></break>
Neuropathy- 10%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Bobin
<italic>et al</italic>
. [
<xref rid="ref90" ref-type="bibr">90</xref>
] 2003</td>
<td align="left" valign="top" rowspan="1" colspan="1">24
<break></break>
Recurrent-79%
<break></break>
GTR-92</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective cohort</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">8–22</td>
<td align="left" valign="top" rowspan="1" colspan="1">92</td>
<td align="left" valign="top" rowspan="1" colspan="1">53</td>
<td align="left" valign="top" rowspan="1" colspan="1">46</td>
<td align="left" valign="top" rowspan="1" colspan="1">56</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-8%
<break></break>
Neuropathy-2
<xref ref-type="table-fn" rid="table6-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Pierie
<italic>et al</italic>
. [
<xref rid="ref91" ref-type="bibr">91</xref>
] 2006</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT-14
<break></break>
No IORT-27
<break></break>
Recurrent-0%
<break></break>
GTR-100%</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective cohort</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">100
<break></break>
100</td>
<td align="left" valign="top" rowspan="1" colspan="1">27</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT-77
<break></break>
No IORT-45
<break></break>
<italic>p</italic>
= 0.38</td>
<td align="left" valign="top" rowspan="1" colspan="1">GI-1%
<break></break>
Neuropathy-3%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Krempien
<italic>et al</italic>
. [
<xref rid="ref92" ref-type="bibr">92</xref>
] 2006</td>
<td align="left" valign="top" rowspan="1" colspan="1">67
<break></break>
Recurrent-61%, GTR-82%</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective cohort</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">12–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">67</td>
<td align="left" valign="top" rowspan="1" colspan="1">30</td>
<td align="left" valign="top" rowspan="1" colspan="1">40</td>
<td align="left" valign="top" rowspan="1" colspan="1">64
<break></break>
<italic>R</italic>
0:87
<break></break>
<italic>R</italic>
+:50
<break></break>
<italic>p</italic>
< 0.01</td>
<td align="left" valign="top" rowspan="1" colspan="1">Fistula-3
<xref ref-type="table-fn" rid="table6-fn1">
<sup>*</sup>
</xref>
<break></break>
Neuropathy-5
<xref ref-type="table-fn" rid="table6-fn1">
<sup>*</sup>
</xref>
<break></break>
Urethral stenosis-2
<xref ref-type="table-fn" rid="table6-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Pawlik
<italic>et al</italic>
. [
<xref rid="ref93" ref-type="bibr">93</xref>
] 2006</td>
<td align="left" valign="top" rowspan="1" colspan="1">72
<break></break>
IORT-22
<break></break>
No IORT-50
<break></break>
Recurrent-25%, GTR-75%</td>
<td align="left" valign="top" rowspan="1" colspan="1">Prospective cohort</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">15</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">40</td>
<td align="left" valign="top" rowspan="1" colspan="1">60
<xref ref-type="table-fn" rid="table6-fn2">¥</xref>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">50</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Ballo
<italic>et al</italic>
. [
<xref rid="ref94" ref-type="bibr">94</xref>
] 2007</td>
<td align="left" valign="top" rowspan="1" colspan="1">83
<break></break>
IORT-18
<break></break>
No IORT-63
<break></break>
Recurrent-28%,
<italic>R</italic>
+-47%</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective cohort</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">47</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<break></break>
IORT-46
<break></break>
No IORT-51
<break></break>
<italic>p</italic>
= 0.9</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Dziewirski
<italic>et al</italic>
. [
<xref rid="ref95" ref-type="bibr">95</xref>
] 2010</td>
<td align="left" valign="top" rowspan="1" colspan="1">57
<break></break>
Recurrent -74%, GTR-85%</td>
<td align="left" valign="top" rowspan="1" colspan="1">Prospective cohort</td>
<td align="left" valign="top" rowspan="1" colspan="1">HDR-IORT</td>
<td align="left" valign="top" rowspan="1" colspan="1">20</td>
<td align="left" valign="top" rowspan="1" colspan="1">60</td>
<td align="left" valign="top" rowspan="1" colspan="1">20</td>
<td align="left" valign="top" rowspan="1" colspan="1">51</td>
<td align="left" valign="top" rowspan="1" colspan="1">55</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Sweeting
<italic>et al</italic>
. [
<xref rid="ref96" ref-type="bibr">96</xref>
] 2013</td>
<td align="left" valign="top" rowspan="1" colspan="1">18
<break></break>
Recurrent-28%, GTR-100%</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective cohort</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">94</td>
<td align="left" valign="top" rowspan="1" colspan="1">43</td>
<td align="left" valign="top" rowspan="1" colspan="1">64</td>
<td align="left" valign="top" rowspan="1" colspan="1">72</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Roeder
<italic>et al</italic>
. [
<xref rid="ref97" ref-type="bibr">97</xref>
] 2014</td>
<td align="left" valign="top" rowspan="1" colspan="1">27
<break></break>
Recurrent-15%, GTR-100%</td>
<td align="left" valign="top" rowspan="1" colspan="1">Prospective cohort</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">33</td>
<td align="left" valign="top" rowspan="1" colspan="1">72</td>
<td align="left" valign="top" rowspan="1" colspan="1">74</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-6% late toxicity</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Stucky
<italic>et al</italic>
. [
<xref rid="ref98" ref-type="bibr">98</xref>
] 2014</td>
<td align="left" valign="top" rowspan="1" colspan="1">63
<break></break>
IORT-37
<break></break>
Sx only-26
<break></break>
Recurrent-36%,GTR-89%</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective cohort</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<break></break>
100
<break></break>
0</td>
<td align="left" valign="top" rowspan="1" colspan="1">45</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<break></break>
IORT-89
<break></break>
Sx-46
<break></break>
<italic>p</italic>
= 0.03</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<break></break>
IORT-60
<break></break>
No IORT-60</td>
<td align="left" valign="top" rowspan="1" colspan="1">Ureteral stricture-1
<break></break>
No grade-3 neuropathy</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Gronchi
<italic>et al</italic>
. [
<xref rid="ref99" ref-type="bibr">99</xref>
] 2014</td>
<td align="left" valign="top" rowspan="1" colspan="1">83
<break></break>
IORT-14pts only
<break></break>
Recurrent-24%
<break></break>
GTR-84%</td>
<td align="left" valign="top" rowspan="1" colspan="1">Prospective cohort</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–12</td>
<td align="left" valign="top" rowspan="1" colspan="1">88</td>
<td align="left" valign="top" rowspan="1" colspan="1">58</td>
<td align="left" valign="top" rowspan="1" colspan="1">63</td>
<td align="left" valign="top" rowspan="1" colspan="1">59</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>RCT: randomised control trial, PORT: post-operative RT, Sx: surgery, LC: local control, OS: overall survival, DFS: disease-free survival, NR: not reported,</p>
<fn id="table6-fn1">
<label>*</label>
<p>Number of patients</p>
</fn>
<fn id="table6-fn2">
<label>
<sup>¥</sup>
</label>
<p>In GTR patients,</p>
</fn>
<p>α-crude rate</p>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table7" position="float">
<label>Table 7.</label>
<caption>
<title>Studies of IORT in various paediatric tumours.</title>
</caption>
<table frame="border" rules="all">
<thead>
<tr>
<th align="center" valign="top" rowspan="1" colspan="1">Author/Year</th>
<th align="center" valign="top" rowspan="1" colspan="1">Sample size</th>
<th align="center" valign="top" rowspan="1" colspan="1">Study design</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT type</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT dose (Gy)</th>
<th align="center" valign="top" rowspan="1" colspan="1">EBRT %</th>
<th align="center" valign="top" rowspan="1" colspan="1">Median Follow-up</th>
<th align="center" valign="top" rowspan="1" colspan="1">LC 5 year (%)</th>
<th align="center" valign="top" rowspan="1" colspan="1">OS 5 year (%)</th>
<th align="center" valign="top" rowspan="1" colspan="1">Toxicity grade 3 or ></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Haase
<italic>et al</italic>
[
<xref rid="ref102" ref-type="bibr">102</xref>
] 1994</td>
<td align="left" valign="top" rowspan="1" colspan="1">25 (neuroblastoma)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Prospective, single arm</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–17</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">51 (mean)</td>
<td align="left" valign="top" rowspan="1" colspan="1">75</td>
<td align="left" valign="top" rowspan="1" colspan="1">63</td>
<td align="left" valign="top" rowspan="1" colspan="1">No late effects at 5-year follow-up</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Nag
<italic>et al</italic>
[
<xref rid="ref106" ref-type="bibr">106</xref>
] 2003</td>
<td align="left" valign="top" rowspan="1" colspan="1">13 (5 metastatic)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">38</td>
<td align="left" valign="top" rowspan="1" colspan="1">42</td>
<td align="left" valign="top" rowspan="1" colspan="1">72
<break></break>
(3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">31
<break></break>
(3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">late morbidity-30%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Goodman
<italic>et al</italic>
[
<xref rid="ref104" ref-type="bibr">104</xref>
] 2003</td>
<td align="left" valign="top" rowspan="1" colspan="1">66 (35% recurrent)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">HDR-IORT</td>
<td align="left" valign="top" rowspan="1" colspan="1">12–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">44</td>
<td align="left" valign="top" rowspan="1" colspan="1">12</td>
<td align="left" valign="top" rowspan="1" colspan="1">56
<break></break>
(2yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">54
<break></break>
(2yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Late morbidity-12%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Oertel
<italic>et al</italic>
<break></break>
[
<xref rid="ref103" ref-type="bibr">103</xref>
] 2005</td>
<td align="left" valign="top" rowspan="1" colspan="1">18 (17% recurrent)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">8–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">54.5</td>
<td align="left" valign="top" rowspan="1" colspan="1">95
<break></break>
(3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">83
<break></break>
(3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">late morbidity-33%
<break></break>
Loss of Limb-1
<xref ref-type="table-fn" rid="table7-fn1">
<sup>*</sup>
</xref>
<break></break>
Neuropathy-1
<xref ref-type="table-fn" rid="table7-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Stauder
<italic>et al</italic>
[
<xref rid="ref107" ref-type="bibr">107</xref>
] 2011</td>
<td align="left" valign="top" rowspan="1" colspan="1">20</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">7.5–25</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">139</td>
<td align="left" valign="top" rowspan="1" colspan="1">77
<break></break>
(10yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">65
<break></break>
(10yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">No grade 3 or more late effects or second primary</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Sole
<italic>et al</italic>
[
<xref rid="ref105" ref-type="bibr">105</xref>
] 2015</td>
<td align="left" valign="top" rowspan="1" colspan="1">71 (35% recurrent)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">7.5–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">72</td>
<td align="left" valign="top" rowspan="1" colspan="1">68
<break></break>
(10yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">74
<break></break>
(10yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Late morbidity-13%
<break></break>
Neuropathy-4
<xref ref-type="table-fn" rid="table7-fn1">
<sup>*</sup>
</xref>
<break></break>
Necrosis-2
<xref ref-type="table-fn" rid="table7-fn1">
<sup>*</sup>
</xref>
<break></break>
Lymphedema-2
<xref ref-type="table-fn" rid="table7-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>LC: local control, OS: overall survival, DFS: disease-free survival, NR: not reported,</p>
<fn id="table7-fn1">
<label>
<sup>*</sup>
</label>
<p>Number of patients.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table8" position="float">
<label>Table 8.</label>
<caption>
<title>Studies of IORT in recurrent gynaecological malignancies after gross total resection.</title>
</caption>
<table frame="border" rules="all">
<thead>
<tr>
<th align="center" valign="top" rowspan="1" colspan="1">Author/Year</th>
<th align="center" valign="top" rowspan="1" colspan="1">Sample size</th>
<th align="center" valign="top" rowspan="1" colspan="1">Site</th>
<th align="center" valign="top" rowspan="1" colspan="1">Primary/Recurrent</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT type</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT dose (Gy)</th>
<th align="center" valign="top" rowspan="1" colspan="1">Prior EBRT %</th>
<th align="center" valign="top" rowspan="1" colspan="1">Present EBRT %</th>
<th align="center" valign="top" rowspan="1" colspan="1">Median follow-up</th>
<th align="center" valign="top" rowspan="1" colspan="1">LC 5yr (%)</th>
<th align="center" valign="top" rowspan="1" colspan="1">OS 5yr (%)</th>
<th align="center" valign="top" rowspan="1" colspan="1">Toxicity grade 3 or ></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Haddock
<italic>et al</italic>
. [
<xref rid="ref113" ref-type="bibr">113</xref>
,
<xref rid="ref115" ref-type="bibr">115</xref>
] 1996</td>
<td align="left" valign="top" rowspan="1" colspan="1">63</td>
<td align="left" valign="top" rowspan="1" colspan="1">Cervix-40
<break></break>
Endometrium-16
<break></break>
Others-8</td>
<td align="left" valign="top" rowspan="1" colspan="1">Primary-16%
<break></break>
Recurrent-84%</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">8–25</td>
<td align="left" valign="top" rowspan="1" colspan="1">0
<break></break>
70</td>
<td align="left" valign="top" rowspan="1" colspan="1">100
<break></break>
63</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">61</td>
<td align="left" valign="top" rowspan="1" colspan="1">27</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-17%
<break></break>
GI-5
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
<break></break>
Neuropathy-2
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Mahe
<italic>et al</italic>
. [
<xref rid="ref124" ref-type="bibr">124</xref>
,
<xref rid="ref125" ref-type="bibr">125</xref>
] 1996</td>
<td align="left" valign="top" rowspan="1" colspan="1">70</td>
<td align="left" valign="top" rowspan="1" colspan="1">Cervix</td>
<td align="left" valign="top" rowspan="1" colspan="1">Recurrent-100%</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT
<break></break>
X ray IORT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–30</td>
<td align="left" valign="top" rowspan="1" colspan="1">97</td>
<td align="left" valign="top" rowspan="1" colspan="1">42</td>
<td align="left" valign="top" rowspan="1" colspan="1">15</td>
<td align="left" valign="top" rowspan="1" colspan="1">21 (3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">8 (3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-14%Neuropathy-5
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
<break></break>
Ureteral obstruction-4
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Del carmen
<italic>et al</italic>
. [
<xref rid="ref126" ref-type="bibr">126</xref>
] 2000</td>
<td align="left" valign="top" rowspan="1" colspan="1">15</td>
<td align="left" valign="top" rowspan="1" colspan="1">Cervix-5Endometrium-3
<break></break>
Vagina-7</td>
<td align="left" valign="top" rowspan="1" colspan="1">Recurrent-93%</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–22.5</td>
<td align="left" valign="top" rowspan="1" colspan="1">60</td>
<td align="left" valign="top" rowspan="1" colspan="1">6</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">74</td>
<td align="left" valign="top" rowspan="1" colspan="1">Neuropathy-4
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
<break></break>
GU-3
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
<break></break>
Lymphedema-2
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Martinez-monge
<italic>et al</italic>
.[
<xref rid="ref116" ref-type="bibr">116</xref>
] 2001</td>
<td align="left" valign="top" rowspan="1" colspan="1">67</td>
<td align="left" valign="top" rowspan="1" colspan="1">Cervix</td>
<td align="left" valign="top" rowspan="1" colspan="1">Primary-46%
<break></break>
Recurrent-54%</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–25
<break></break>
10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<break></break>
86</td>
<td align="left" valign="top" rowspan="1" colspan="1">97
<break></break>
14</td>
<td align="left" valign="top" rowspan="1" colspan="1">58
<break></break>
19</td>
<td align="left" valign="top" rowspan="1" colspan="1">80.5
<break></break>
49</td>
<td align="left" valign="top" rowspan="1" colspan="1">58 (10yr)
<break></break>
14 (10yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-14.9%
<break></break>
Neuropathy-1
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
<break></break>
Chronic pain-8
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Gemignani
<italic>et al</italic>
. [
<xref rid="ref114" ref-type="bibr">114</xref>
] 2001</td>
<td align="left" valign="top" rowspan="1" colspan="1">17</td>
<td align="left" valign="top" rowspan="1" colspan="1">Cervix-9
<break></break>
Endometrium-7
<break></break>
Vagina-1</td>
<td align="left" valign="top" rowspan="1" colspan="1">Recurrent-
<break></break>
100%</td>
<td align="left" valign="top" rowspan="1" colspan="1">HDR-IORT</td>
<td align="left" valign="top" rowspan="1" colspan="1">12–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">82</td>
<td align="left" valign="top" rowspan="1" colspan="1">12</td>
<td align="left" valign="top" rowspan="1" colspan="1">20</td>
<td align="left" valign="top" rowspan="1" colspan="1">67 (3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">54 (3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">GI-4
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
<break></break>
Neuropathy-3
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
<break></break>
Wound-4
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Dowdy
<italic>et al</italic>
. [
<xref rid="ref126" ref-type="bibr">126</xref>
] 2006</td>
<td align="left" valign="top" rowspan="1" colspan="1">25</td>
<td align="left" valign="top" rowspan="1" colspan="1">Endometrium</td>
<td align="left" valign="top" rowspan="1" colspan="1">Recurrent-
<break></break>
100%</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–25</td>
<td align="left" valign="top" rowspan="1" colspan="1">56</td>
<td align="left" valign="top" rowspan="1" colspan="1">84</td>
<td align="left" valign="top" rowspan="1" colspan="1">34</td>
<td align="left" valign="top" rowspan="1" colspan="1">84</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<italic>R</italic>
0-71
<break></break>
<italic>R</italic>
1-47
<break></break>
<italic>R</italic>
2-0</td>
<td align="left" valign="top" rowspan="1" colspan="1">Neuropathy-8
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
<break></break>
GU-5
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
<break></break>
Fitula-5
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Tran
<italic>et al</italic>
. [
<xref rid="ref118" ref-type="bibr">118</xref>
]
<break></break>
2007</td>
<td align="left" valign="top" rowspan="1" colspan="1">36</td>
<td align="left" valign="top" rowspan="1" colspan="1">Cervix-17
<break></break>
Endometrium-11
<break></break>
Others-8</td>
<td align="left" valign="top" rowspan="1" colspan="1">Recurrent-89%</td>
<td align="left" valign="top" rowspan="1" colspan="1">X-ray IORT</td>
<td align="left" valign="top" rowspan="1" colspan="1">6–17.5</td>
<td align="left" valign="top" rowspan="1" colspan="1">72</td>
<td align="left" valign="top" rowspan="1" colspan="1">53</td>
<td align="left" valign="top" rowspan="1" colspan="1">50</td>
<td align="left" valign="top" rowspan="1" colspan="1">44</td>
<td align="left" valign="top" rowspan="1" colspan="1">47</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-27%
<break></break>
Wound-4
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
<break></break>
GI-1
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Barney
<italic>et al</italic>
[
<xref rid="ref119" ref-type="bibr">119</xref>
].2013</td>
<td align="left" valign="top" rowspan="1" colspan="1">86</td>
<td align="left" valign="top" rowspan="1" colspan="1">Cervix-100</td>
<td align="left" valign="top" rowspan="1" colspan="1">Recurrent-85%</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">6–25</td>
<td align="left" valign="top" rowspan="1" colspan="1">81</td>
<td align="left" valign="top" rowspan="1" colspan="1">71</td>
<td align="left" valign="top" rowspan="1" colspan="1">32</td>
<td align="left" valign="top" rowspan="1" colspan="1">Primary-70
<break></break>
Recurrent-61%
<break></break>
(3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">25
<break></break>
(3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">GI-4
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
<break></break>
GU-4
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
<break></break>
Neuropathy-1
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Calvo
<italic>et al</italic>
.[
<xref rid="ref120" ref-type="bibr">120</xref>
] 2013</td>
<td align="left" valign="top" rowspan="1" colspan="1">35</td>
<td align="left" valign="top" rowspan="1" colspan="1">Cervix-20 Endometrium-7 Others-8</td>
<td align="left" valign="top" rowspan="1" colspan="1">Recurrent-
<break></break>
100%</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">71</td>
<td align="left" valign="top" rowspan="1" colspan="1">46</td>
<td align="left" valign="top" rowspan="1" colspan="1">46</td>
<td align="left" valign="top" rowspan="1" colspan="1">58</td>
<td align="left" valign="top" rowspan="1" colspan="1">42</td>
<td align="left" valign="top" rowspan="1" colspan="1">Fistula-5
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
<break></break>
Ureter stenosi-2
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
<break></break>
Neuropathy-1
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Backes
<italic>et al</italic>
.[
<xref rid="ref127" ref-type="bibr">127</xref>
] 2014</td>
<td align="left" valign="top" rowspan="1" colspan="1">32</td>
<td align="left" valign="top" rowspan="1" colspan="1">Cervix-21
<break></break>
Others-11
<break></break>
IORT in 66% only</td>
<td align="left" valign="top" rowspan="1" colspan="1">Recurrent-
<break></break>
100%</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT/HDR-IORT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">0</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">PE+IORT-10Mon
<break></break>
LEER+IORT-9Mon
<break></break>
PE-33Mon</td>
<td align="left" valign="top" rowspan="1" colspan="1">PE+IORT-10Mon
<break></break>
LEER+IORT-10Mon
<break></break>
PE-41Mon</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Foley
<italic>et al</italic>
.[
<xref rid="ref121" ref-type="bibr">121</xref>
] 2014</td>
<td align="left" valign="top" rowspan="1" colspan="1">32</td>
<td align="left" valign="top" rowspan="1" colspan="1">Cervix-21
<break></break>
Endometrium-6
<break></break>
Others-5</td>
<td align="left" valign="top" rowspan="1" colspan="1">Rccurent-81%</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–22.5</td>
<td align="left" valign="top" rowspan="1" colspan="1">88</td>
<td align="left" valign="top" rowspan="1" colspan="1">20</td>
<td align="left" valign="top" rowspan="1" colspan="1">26</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<italic>R</italic>
1-73
<break></break>
<italic>R</italic>
2-71</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<italic>R</italic>
1-77
<break></break>
<italic>R</italic>
2-55
<italic>p</italic>
= 0.001</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-47%
<break></break>
GU-2
<break></break>
Lymphedema-2</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Sole
<italic>et al</italic>
. [
<xref rid="ref117" ref-type="bibr">117</xref>
] 2014</td>
<td align="left" valign="top" rowspan="1" colspan="1">61</td>
<td align="left" valign="top" rowspan="1" colspan="1">Cervix-18
<break></break>
Endometrium-32
<break></break>
Ovarian-9
<break></break>
Vagina-2</td>
<td align="left" valign="top" rowspan="1" colspan="1">Recurrent
<break></break>
Pelvic-57%
<break></break>
Para-aortic-
<break></break>
43%</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">66</td>
<td align="left" valign="top" rowspan="1" colspan="1">48</td>
<td align="left" valign="top" rowspan="1" colspan="1">42</td>
<td align="left" valign="top" rowspan="1" colspan="1">65</td>
<td align="left" valign="top" rowspan="1" colspan="1">45</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-20%
<break></break>
Fistula-5
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
<break></break>
Neuropathy-1
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
<break></break>
Wound-3
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Arians
<italic>et al</italic>
.[
<xref rid="ref122" ref-type="bibr">122</xref>
] 2016</td>
<td align="left" valign="top" rowspan="1" colspan="1">36</td>
<td align="left" valign="top" rowspan="1" colspan="1">Cervix-18
<break></break>
Endometrium-12
<break></break>
Vulva-6</td>
<td align="left" valign="top" rowspan="1" colspan="1">Recurrent-
<break></break>
100%</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–18</td>
<td align="left" valign="top" rowspan="1" colspan="1">76
<break></break>
25
<break></break>
100</td>
<td align="left" valign="top" rowspan="1" colspan="1">11
<break></break>
17
<break></break>
17</td>
<td align="left" valign="top" rowspan="1" colspan="1">14</td>
<td align="left" valign="top" rowspan="1" colspan="1">Cervix-0
<break></break>
Endometrium-40
<break></break>
Vulva-20
<break></break>
<italic>p</italic>
= 0.017</td>
<td align="left" valign="top" rowspan="1" colspan="1">Cervix-6
<break></break>
Endometrium-50
<break></break>
Vulva-17
<break></break>
<italic>P</italic>
= 0.038</td>
<td align="left" valign="top" rowspan="1" colspan="1">Wound complications-5
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
<break></break>
Neuropathy-4
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
<break></break>
Lymphedema-3
<xref ref-type="table-fn" rid="table8-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>Sx: surgery, LC: local control, OS: overall survival, NR: not reported,</p>
<fn id="table8-fn1">
<label>
<sup>*</sup>
</label>
<p>Number of patients</p>
</fn>
<p>PE: pelvic exenteration, LEER: laterally extended endopelvic resection, Mon: median survival in months.</p>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table9" position="float">
<label>Table 9.</label>
<caption>
<title>Studies of IORT in bladder and renal cancers.</title>
</caption>
<table frame="border" rules="all">
<thead>
<tr>
<th align="center" valign="top" rowspan="1" colspan="1">Author/Year</th>
<th align="center" valign="top" rowspan="1" colspan="1">Sample size</th>
<th align="center" valign="top" rowspan="1" colspan="1">Study design</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT type</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT dose (Gy)</th>
<th align="center" valign="top" rowspan="1" colspan="1">Prior EBRT %</th>
<th align="center" valign="top" rowspan="1" colspan="1">Present EBRT %</th>
<th align="center" valign="top" rowspan="1" colspan="1">Median follow-up months</th>
<th align="center" valign="top" rowspan="1" colspan="1">LC 5 year %</th>
<th align="center" valign="top" rowspan="1" colspan="1">OS 5 year %</th>
<th align="center" valign="top" rowspan="1" colspan="1">Toxicity grade 3 or ></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Hallemeier
<italic>et al</italic>
. [
<xref rid="ref128" ref-type="bibr">128</xref>
] 2013</td>
<td align="left" valign="top" rowspan="1" colspan="1">Bladder-13, Ureter-4
<break></break>
Recurrent-88%</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective cohort</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">24</td>
<td align="left" valign="top" rowspan="1" colspan="1">94</td>
<td align="left" valign="top" rowspan="1" colspan="1">43.2
<break></break>
In survivors</td>
<td align="left" valign="top" rowspan="1" colspan="1">51
<break></break>
(2 yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">16 (5 yr)
<break></break>
<italic>R</italic>
0+
<italic>R</italic>
1: 56
<break></break>
<italic>R</italic>
2-11
<break></break>
<italic>p</italic>
= 0.03 (2 yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-12%
<break></break>
Ureter stricture-4
<break></break>
Fistula-1</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Paly
<italic>et al</italic>
. [
<xref rid="ref134" ref-type="bibr">134</xref>
] 2014</td>
<td align="left" valign="top" rowspan="1" colspan="1">98-RCC
<break></break>
Recurrent-72%</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">9.5–20</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1">63</td>
<td align="left" valign="top" rowspan="1" colspan="1">42
<break></break>
In survivors</td>
<td align="left" valign="top" rowspan="1" colspan="1">76</td>
<td align="left" valign="top" rowspan="1" colspan="1">Advanced-37
<break></break>
Recurrent-55</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-5%
<break></break>
Pancreatic leak-3
<xref ref-type="table-fn" rid="table9-fn1">
<sup>*</sup>
</xref>
<break></break>
gastritis-1
<xref ref-type="table-fn" rid="table9-fn1">
<sup>*</sup>
</xref>
<break></break>
ARDS-1
<xref ref-type="table-fn" rid="table9-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Calvo
<italic>et al</italic>
. [
<xref rid="ref130" ref-type="bibr">130</xref>
] 2013</td>
<td align="left" valign="top" rowspan="1" colspan="1">25-RCC
<break></break>
Recurrent-40%</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">9–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">-</td>
<td align="left" valign="top" rowspan="1" colspan="1">60</td>
<td align="left" valign="top" rowspan="1" colspan="1">266</td>
<td align="left" valign="top" rowspan="1" colspan="1">80</td>
<td align="left" valign="top" rowspan="1" colspan="1">38</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-24%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Habl
<italic>et al</italic>
. [
<xref rid="ref132" ref-type="bibr">132</xref>
] 2013</td>
<td align="left" valign="top" rowspan="1" colspan="1">17-RCC
<break></break>
Recurrent-100%</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1">65</td>
<td align="left" valign="top" rowspan="1" colspan="1">18</td>
<td align="left" valign="top" rowspan="1" colspan="1">91 (2 yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">73
<break></break>
(2 yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">None</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Hallemeier
<italic>et al</italic>
. [
<xref rid="ref129" ref-type="bibr">129</xref>
] 2012</td>
<td align="left" valign="top" rowspan="1" colspan="1">22-RCC
<break></break>
Recurrent-86%</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">-</td>
<td align="left" valign="top" rowspan="1" colspan="1">95</td>
<td align="left" valign="top" rowspan="1" colspan="1">119
<break></break>
In survivors</td>
<td align="left" valign="top" rowspan="1" colspan="1">73</td>
<td align="left" valign="top" rowspan="1" colspan="1">40
<break></break>
<italic>R</italic>
0-80
<break></break>
<italic>R</italic>
1-29
<break></break>
<italic>p</italic>
= 0.057</td>
<td align="left" valign="top" rowspan="1" colspan="1">Total-23%
<break></break>
ARDS-1
<xref ref-type="table-fn" rid="table9-fn1">
<sup>*</sup>
</xref>
Pancreatic pseudocyst-1
<xref ref-type="table-fn" rid="table9-fn1">
<sup>*</sup>
</xref>
<break></break>
Perforated ulcer-2
<xref ref-type="table-fn" rid="table9-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Master
<italic>et al</italic>
. [
<xref rid="ref133" ref-type="bibr">133</xref>
] 2005</td>
<td align="left" valign="top" rowspan="1" colspan="1">14-RCC
<break></break>
Recurrent-100%</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">12–20</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">66
<break></break>
(mean in survivors)</td>
<td align="left" valign="top" rowspan="1" colspan="1">85
<break></break>
(crude rate)</td>
<td align="left" valign="top" rowspan="1" colspan="1">30</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Eble
<italic>et al</italic>
. [
<xref rid="ref131" ref-type="bibr">131</xref>
] 1998</td>
<td align="left" valign="top" rowspan="1" colspan="1">11-RCC
<break></break>
Recurrent-73%</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">15–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">-</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">24</td>
<td align="left" valign="top" rowspan="1" colspan="1">100</td>
<td align="left" valign="top" rowspan="1" colspan="1">47
<break></break>
(4 yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Wound-2
<xref ref-type="table-fn" rid="table9-fn1">
<sup>*</sup>
</xref>
<break></break>
None IORT related</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>RCT: randomised control trial, Sx: surgery, LC: local control, OS: overall survival, DFS: disease-free survival, NR:-not reported,</p>
<fn id="table9-fn1">
<label>
<sup>*</sup>
</label>
<p>Number of patients</p>
</fn>
<p>ARDS: acute respiratory distress syndrome.</p>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table10" position="float">
<label>Table 10.</label>
<caption>
<title>IORT studies for prostate cancers.</title>
</caption>
<table frame="border" rules="all">
<thead>
<tr>
<th align="center" valign="top" rowspan="1" colspan="1">Author/Year</th>
<th align="center" valign="top" rowspan="1" colspan="1">Sample size</th>
<th align="center" valign="top" rowspan="1" colspan="1">Study design</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT type</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT dose (Gy)</th>
<th align="center" valign="top" rowspan="1" colspan="1">Present EBRT %</th>
<th align="center" valign="top" rowspan="1" colspan="1">Median follow-up months</th>
<th align="center" valign="top" rowspan="1" colspan="1">LC 5 year %</th>
<th align="center" valign="top" rowspan="1" colspan="1">OS 5 year %</th>
<th align="center" valign="top" rowspan="1" colspan="1">Toxicity grade 3 or ></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Krengli
<italic>et al</italic>
. [
<xref rid="ref139" ref-type="bibr">139</xref>
] 2010</td>
<td align="left" valign="top" rowspan="1" colspan="1">38 (intermediate–
<break></break>
high-risk Pca,
<break></break>
Margin +ve: 71%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Prospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–12</td>
<td align="left" valign="top" rowspan="1" colspan="1">Margin +ve and/or ECE</td>
<td align="left" valign="top" rowspan="1" colspan="1">18.2</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR
<break></break>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">No grade 3
<break></break>
complications</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Rocco
<italic>et al</italic>
. [
<xref rid="ref136" ref-type="bibr">136</xref>
] 2009</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT-33
<break></break>
(intermediate–
<break></break>
high-risk Pca,
<break></break>
Margin +ve: 24%)
<break></break>
RP-100</td>
<td align="left" valign="top" rowspan="1" colspan="1">Matched pair analysis</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">12</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT-88
<break></break>
<italic>R</italic>
1, pT4, N+
<break></break>
RP-44</td>
<td align="left" valign="top" rowspan="1" colspan="1">16</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT-97
<break></break>
RP-86 (bRFS)</td>
<td align="left" valign="top" rowspan="1" colspan="1">100
<break></break>
( 2yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Acute grade ≥ 2
<break></break>
IORT vs. RP
<break></break>
GU-7% vs. 5%
<break></break>
GI-3% vs. 4%
<break></break>
Lategrade ≥ 2
<break></break>
IORT vs. RP
<break></break>
GU-3% vs. 1%
<break></break>
GI-0% vs. 1%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Saracino
<italic>et al</italic>
[
<xref rid="ref141" ref-type="bibr">141</xref>
] 2007</td>
<td align="left" valign="top" rowspan="1" colspan="1">34
<break></break>
(intermediate-risk Pca, Margin +ve: 41%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Prospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">16–22</td>
<td align="left" valign="top" rowspan="1" colspan="1">None</td>
<td align="left" valign="top" rowspan="1" colspan="1">41</td>
<td align="left" valign="top" rowspan="1" colspan="1">77.3
<break></break>
(3-yr bRFS)</td>
<td align="left" valign="top" rowspan="1" colspan="1">71
<break></break>
(3-yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">None</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Orrechia
<italic>et al</italic>
. [
<xref rid="ref140" ref-type="bibr">140</xref>
] 2007</td>
<td align="left" valign="top" rowspan="1" colspan="1">11
<break></break>
(high-risk Pca)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Prospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">12</td>
<td align="left" valign="top" rowspan="1" colspan="1">67</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">1 had acute symptomatic lymphocele</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Kato
<italic>et al</italic>
. [
<xref rid="ref138" ref-type="bibr">138</xref>
] 1998</td>
<td align="left" valign="top" rowspan="1" colspan="1">54
<break></break>
Stage B2-D1
<xref ref-type="table-fn" rid="table10-fn1">
<sup>α</sup>
</xref>
<break></break>
No RP</td>
<td align="left" valign="top" rowspan="1" colspan="1">Prospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">25–30</td>
<td align="left" valign="top" rowspan="1" colspan="1">100
<break></break>
(30 Gy)</td>
<td align="left" valign="top" rowspan="1" colspan="1">54</td>
<td align="left" valign="top" rowspan="1" colspan="1">83 (LC)
<break></break>
75
<break></break>
(bRFS)</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">Late rectal toxicity-7%
<break></break>
(No toxicity with IORT of 25 Gy)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Higashi
<italic>et al</italic>
. [
<xref rid="ref137" ref-type="bibr">137</xref>
] 1998</td>
<td align="left" valign="top" rowspan="1" colspan="1">35
<break></break>
Stage B-C
<xref ref-type="table-fn" rid="table10-fn1">
<sup>α</sup>
</xref>
<break></break>
No RP</td>
<td align="left" valign="top" rowspan="1" colspan="1">Prospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">25–30</td>
<td align="left" valign="top" rowspan="1" colspan="1">100
<break></break>
(30 Gy)</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">Stage B-92
<break></break>
Stage C-87</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>RCT: randomised control trial, Sx: surgery, LC: local control, OS: overall survival, DFS: disease-free survival, NR: not reported, *Number of patients, RP: radical prostatectomy, Pca: prostate cancer, ECE: extra capsular extension,
<italic>R</italic>
1: margin +ve,
<italic>N</italic>
+: node-positive disease, bRFS: biochemical relapse-free survival,</p>
<fn id="table10-fn1">
<label>
<sup>α</sup>
</label>
<p>Whitmore-Jewett staging system [Whitmore 1956, Jewett 1975].</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table11" position="float">
<label>Table 11.</label>
<caption>
<title>IORT studies for gastric cancers.</title>
</caption>
<table frame="border" rules="all">
<thead>
<tr>
<th align="center" valign="top" rowspan="1" colspan="1">Author/Year</th>
<th align="center" valign="top" rowspan="1" colspan="1">Sample size</th>
<th align="center" valign="top" rowspan="1" colspan="1">Study design</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT type</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT dose (Gy)</th>
<th align="center" valign="top" rowspan="1" colspan="1">EBRT (%)</th>
<th align="center" valign="top" rowspan="1" colspan="1">Type of nodal dissection</th>
<th align="center" valign="top" rowspan="1" colspan="1">Median follow-up (months)</th>
<th align="center" valign="top" rowspan="1" colspan="1">LRC</th>
<th align="center" valign="top" rowspan="1" colspan="1">OS 5 year (%)</th>
<th align="center" valign="top" rowspan="1" colspan="1">Toxicity grade 3 or ></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Sindelar
<italic>et al</italic>
. [
<xref rid="ref149" ref-type="bibr">149</xref>
] 1993</td>
<td align="left" valign="top" rowspan="1" colspan="1">Sx+IORT-27
<break></break>
Sx+/-EBRT-33</td>
<td align="left" valign="top" rowspan="1" colspan="1">RCT</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">20</td>
<td align="left" valign="top" rowspan="1" colspan="1">0
<break></break>
72</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">84</td>
<td align="left" valign="top" rowspan="1" colspan="1">37
<break></break>
8
<break></break>
<italic>p</italic>
< 0.001</td>
<td align="left" valign="top" rowspan="1" colspan="1">25 months (M.S)
<break></break>
21 months (M.S)
<break></break>
<italic>p</italic>
= 0.99</td>
<td align="left" valign="top" rowspan="1" colspan="1">Fistula:
<break></break>
IORT-4 vs. Sx-5
<xref ref-type="table-fn" rid="table11-fn1">
<sup>*</sup>
</xref>
<break></break>
Enteritis:
<break></break>
IORT-0 vs. Sx-2
<xref ref-type="table-fn" rid="table11-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Abe
<italic>et al</italic>
[
<xref rid="ref1" ref-type="bibr">1</xref>
] 1995</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT-94
<break></break>
No IORT-127</td>
<td align="left" valign="top" rowspan="1" colspan="1">NRC</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">28–35</td>
<td align="left" valign="top" rowspan="1" colspan="1">none</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">Stage II:
<break></break>
IORT-78
<break></break>
No IORT-66
<break></break>
Stage III:
<break></break>
IORT-60
<break></break>
No IORT-51
<break></break>
Stage IV:
<break></break>
IORT-33
<break></break>
No IORT-14 (all N.S)</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Avizonis
<italic>et al</italic>
.[
<xref rid="ref158" ref-type="bibr">158</xref>
] 1995</td>
<td align="left" valign="top" rowspan="1" colspan="1">27</td>
<td align="left" valign="top" rowspan="1" colspan="1">Prospective phase II</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">12.5–16.5</td>
<td align="left" valign="top" rowspan="1" colspan="1">79</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">85</td>
<td align="left" valign="top" rowspan="1" colspan="1">47
<break></break>
(2yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Acute
<break></break>
toxicity-14%
<break></break>
Late-7%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Ogata
<italic>et al</italic>
. [
<xref rid="ref152" ref-type="bibr">152</xref>
] 1995</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT-58
<break></break>
No IORT-120</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">12</td>
<td align="left" valign="top" rowspan="1" colspan="1">None</td>
<td align="left" valign="top" rowspan="1" colspan="1">D2</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">Stage II:
<break></break>
IORT-100,
<break></break>
No IORT-63 (4yr)
<break></break>
Stage III:
<break></break>
IORT-55
<break></break>
No IORT-35 (8yr)
<break></break>
Stage IV:
<break></break>
IORT-12
<break></break>
No IORT-13 (5yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">None</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Coquard
<italic>et al</italic>
. [
<xref rid="ref156" ref-type="bibr">156</xref>
] 1997</td>
<td align="left" valign="top" rowspan="1" colspan="1">63
<break></break>
(
<italic>R</italic>
0-92%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">12–23</td>
<td align="left" valign="top" rowspan="1" colspan="1">48</td>
<td align="left" valign="top" rowspan="1" colspan="1">D1-89%</td>
<td align="left" valign="top" rowspan="1" colspan="1">61 in survivors</td>
<td align="left" valign="top" rowspan="1" colspan="1">76 (crude rate)</td>
<td align="left" valign="top" rowspan="1" colspan="1">47</td>
<td align="left" valign="top" rowspan="1" colspan="1">None attributed to IORT</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Skoropad
<italic>et al</italic>
. [
<xref rid="ref154" ref-type="bibr">154</xref>
] 2000</td>
<td align="left" valign="top" rowspan="1" colspan="1">78
<break></break>
Pre-op RT+IORT+ Sx vs. Sx alone</td>
<td align="left" valign="top" rowspan="1" colspan="1">RCT</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">20</td>
<td align="left" valign="top" rowspan="1" colspan="1">100
<break></break>
(Pre-op RT-20 Gy/5
<xref ref-type="table-fn" rid="table11-fn2">
<sup>#</sup>
</xref>
)</td>
<td align="left" valign="top" rowspan="1" colspan="1">D1</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">Entire cohort:
<break></break>
IORT:21months
<break></break>
No IORT: 9months
<break></break>
(
<italic>P</italic>
= 0.311)
<break></break>
Node +ve and
<break></break>
Advanced stage: IORT vs. No IORT:
<break></break>
<italic>p</italic>
< 0.05</td>
<td align="left" valign="top" rowspan="1" colspan="1">Similar acute toxicity in both arms
<break></break>
Higher pancreatitis surgery alone.
<break></break>
No RT late toxicity</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Weese
<italic>et al</italic>
. [
<xref rid="ref159" ref-type="bibr">159</xref>
] 2000</td>
<td align="left" valign="top" rowspan="1" colspan="1">16
<break></break>
(IORT-56%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Prospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10</td>
<td align="left" valign="top" rowspan="1" colspan="1">88</td>
<td align="left" valign="top" rowspan="1" colspan="1">D2</td>
<td align="left" valign="top" rowspan="1" colspan="1">27</td>
<td align="left" valign="top" rowspan="1" colspan="1">93 (crude rate)</td>
<td align="left" valign="top" rowspan="1" colspan="1">66 (crude rate at 3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Glehen
<italic>et al</italic>
. [
<xref rid="ref160" ref-type="bibr">160</xref>
] 2003</td>
<td align="left" valign="top" rowspan="1" colspan="1">42
<break></break>
(All Node +ve,
<italic>R</italic>
0-93%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">12–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">97</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">131</td>
<td align="left" valign="top" rowspan="1" colspan="1">79</td>
<td align="left" valign="top" rowspan="1" colspan="1">45</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Miller
<italic>et al</italic>
. [
<xref rid="ref161" ref-type="bibr">161</xref>
] 2006</td>
<td align="left" valign="top" rowspan="1" colspan="1">50
<break></break>
(
<italic>R</italic>
0-42%, recurrent-26%, oesophagus-14%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–25</td>
<td align="left" valign="top" rowspan="1" colspan="1">96</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">19</td>
<td align="left" valign="top" rowspan="1" colspan="1">75</td>
<td align="left" valign="top" rowspan="1" colspan="1">15 (5 yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Acute-48%
<break></break>
Chronic-26%
<break></break>
GI-6
<xref ref-type="table-fn" rid="table11-fn1">
<sup>*</sup>
</xref>
<break></break>
Overall treatment-related mortality-6%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Qin
<italic>et al</italic>
. [
<xref rid="ref153" ref-type="bibr">153</xref>
] 2006</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT-106
<break></break>
No IORT-441</td>
<td align="left" valign="top" rowspan="1" colspan="1">NRC</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–30</td>
<td align="left" valign="top" rowspan="1" colspan="1">None</td>
<td align="left" valign="top" rowspan="1" colspan="1">D2/3</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">Stage III D2:
<break></break>
IORT- 60%
<break></break>
No IORT-36%
<break></break>
<italic>p</italic>
< 0.005
<break></break>
Stage III D3:
<break></break>
IORT-61%
<break></break>
No IORT-56%
<break></break>
<italic>p</italic>
> 0.05</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Drognitz
<italic>et al</italic>
. [
<xref rid="ref151" ref-type="bibr">151</xref>
] 2007</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT-61
<break></break>
No IORT-61
<break></break>
(
<italic>R</italic>
0-100%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">NRC</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">15–25</td>
<td align="left" valign="top" rowspan="1" colspan="1">None</td>
<td align="left" valign="top" rowspan="1" colspan="1">D2</td>
<td align="left" valign="top" rowspan="1" colspan="1">56</td>
<td align="left" valign="top" rowspan="1" colspan="1">90</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT-58%
<break></break>
No IORT-59%
<break></break>
<italic>p</italic>
= 0.99</td>
<td align="left" valign="top" rowspan="1" colspan="1">Perioperative mortality-4.9% both groups
<break></break>
Surgical morbidity:
<break></break>
IORT:44%
<break></break>
No IORT: 20%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Fu
<italic>et al</italic>
. [
<xref rid="ref148" ref-type="bibr">148</xref>
] 2008</td>
<td align="left" valign="top" rowspan="1" colspan="1">97
<break></break>
IORT-46
<break></break>
No IORT-51
<break></break>
(
<italic>R</italic>
0-90%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Prospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">12–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">100%
<break></break>
CTRT</td>
<td align="left" valign="top" rowspan="1" colspan="1">D2</td>
<td align="left" valign="top" rowspan="1" colspan="1">24</td>
<td align="left" valign="top" rowspan="1" colspan="1">77
<break></break>
IORT- 77
<break></break>
No IORT- 63
<break></break>
<italic>p</italic>
= 0.05, (3Yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">44
<break></break>
IORT-56
<break></break>
No IORT-47
<break></break>
<italic>p</italic>
= 0.20, (3Yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Late toxicity-3
<xref ref-type="table-fn" rid="table11-fn1">
<sup>*</sup>
</xref>
<break></break>
No difference among groups</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Zhang
<italic>et al</italic>
. [
<xref rid="ref150" ref-type="bibr">150</xref>
] 2012</td>
<td align="left" valign="top" rowspan="1" colspan="1">97
<break></break>
IORT-46
<break></break>
No IORT-51
<break></break>
(
<italic>R</italic>
0-90%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Prospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">12–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">100% CTRT</td>
<td align="left" valign="top" rowspan="1" colspan="1">D2</td>
<td align="left" valign="top" rowspan="1" colspan="1">37</td>
<td align="left" valign="top" rowspan="1" colspan="1">50
<break></break>
IORT-50
<break></break>
No IORT-35
<break></break>
<italic>p</italic>
= 0.04</td>
<td align="left" valign="top" rowspan="1" colspan="1">26
<break></break>
IORT-28
<break></break>
No IORT-26
<break></break>
<italic>p</italic>
= 0.4</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT vs. No IORT
<break></break>
Acute-39% vs. 37%
<break></break>
Late-.10% vs. 0%,
<italic>p</italic>
= 0.02
<break></break>
Enteritis-1
<xref ref-type="table-fn" rid="table11-fn1">
<sup>*</sup>
</xref>
<break></break>
Haemorrhage-4
<xref ref-type="table-fn" rid="table11-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Calvo
<italic>et al</italic>
. [
<xref rid="ref155" ref-type="bibr">155</xref>
] 2012</td>
<td align="left" valign="top" rowspan="1" colspan="1">32
<break></break>
(
<italic>R</italic>
0-100%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">47</td>
<td align="left" valign="top" rowspan="1" colspan="1">D2</td>
<td align="left" valign="top" rowspan="1" colspan="1">40</td>
<td align="left" valign="top" rowspan="1" colspan="1">84</td>
<td align="left" valign="top" rowspan="1" colspan="1">55</td>
<td align="left" valign="top" rowspan="1" colspan="1">Acute GI-5
<xref ref-type="table-fn" rid="table11-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>RCT: randomised control trial, NRC: non-randomised comparison, Sx: surgery, LC: local control, OS: overall survival, DFS: disease-free survival, NR: not reported,</p>
<fn id="table11-fn1">
<label>
<sup>*</sup>
</label>
<p>Number of patients,</p>
</fn>
<fn id="table11-fn2">
<label>
<sup>#</sup>
</label>
<p>fractions,</p>
</fn>
<p>Pre-op: pre-operative, M.S: median survival, N.S: non-significant.</p>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table12" position="float">
<label>Table 12.</label>
<caption>
<title>Studies of IORT in the management of pancreatic cancers.</title>
</caption>
<table frame="border" rules="all">
<thead>
<tr>
<th align="center" valign="top" rowspan="1" colspan="1">Author/Year</th>
<th align="center" valign="top" rowspan="1" colspan="1">Sample size</th>
<th align="center" valign="top" rowspan="1" colspan="1">Study design</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT type</th>
<th align="center" valign="top" rowspan="1" colspan="1">IORT dose (Gy)</th>
<th align="center" valign="top" rowspan="1" colspan="1">EBRT %</th>
<th align="center" valign="top" rowspan="1" colspan="1">Median follow-up</th>
<th align="center" valign="top" rowspan="1" colspan="1">LC 5 year (%)</th>
<th align="center" valign="top" rowspan="1" colspan="1">OS 5 year (%)</th>
<th align="center" valign="top" rowspan="1" colspan="1">Toxicity grade 3 or ></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Mohiuddin
<italic>et al</italic>
. [
<xref rid="ref178" ref-type="bibr">178</xref>
] 1995</td>
<td align="left" valign="top" rowspan="1" colspan="1">49 UR-PC
<break></break>
(Resected-0%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">100
<break></break>
(Post-op)</td>
<td align="left" valign="top" rowspan="1" colspan="1">28</td>
<td align="left" valign="top" rowspan="1" colspan="1">69</td>
<td align="left" valign="top" rowspan="1" colspan="1">7 (4yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Acute toxicity-14%
<break></break>
GI bleeding-2
<xref ref-type="table-fn" rid="table12-fn1">
<sup>*</sup>
</xref>
<break></break>
Late toxicity-19%
<break></break>
GI bleeding-3
<xref ref-type="table-fn" rid="table12-fn1">
<sup>*</sup>
</xref>
<break></break>
Obstruction-2
<xref ref-type="table-fn" rid="table12-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Nishimura
<italic>et al</italic>
. [
<xref rid="ref179" ref-type="bibr">179</xref>
] 1997</td>
<td align="left" valign="top" rowspan="1" colspan="1">Resected-157
<break></break>
IORT- 55
<break></break>
No IORT-102
<break></break>
Unresectable-175
<break></break>
IORT-71
<break></break>
No IORT-104</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">12–33 Gy</td>
<td align="left" valign="top" rowspan="1" colspan="1">Resected-
<break></break>
70
<break></break>
Unresectable-87
<break></break>
(Pre-op or post-op)</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">Resected:
<break></break>
IORT-16
<break></break>
No IORT-0 (2yr)
<break></break>
Unresectable:
<break></break>
IORT-14
<break></break>
No IORT-0
<break></break>
<italic>p</italic>
< 0.05 (2yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT:
<break></break>
Late toxicity:
<break></break>
gastric ulcer-18
<xref ref-type="table-fn" rid="table12-fn1">
<sup>*</sup>
</xref>
<break></break>
Intestinal perforation-4
<xref ref-type="table-fn" rid="table12-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Ma
<italic>et al</italic>
. [
<xref rid="ref177" ref-type="bibr">177</xref>
] 2004</td>
<td align="left" valign="top" rowspan="1" colspan="1">81 UR-PC
<break></break>
(Resected-0%)
<break></break>
IORT-18
<break></break>
IORT+EBRT-25
<break></break>
EBRT-16
<break></break>
Palliative Sx-22</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">15–25</td>
<td align="left" valign="top" rowspan="1" colspan="1">80
<break></break>
(Post-op)</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR
<break></break>
(60% complete pain relief with IORT)</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<break></break>
10.7 (M.S)
<break></break>
12.2 (M.S)
<break></break>
5.1 (M.S)
<break></break>
7 (M.S)</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT vs IORT+EBRT:
<break></break>
Delayed gastric
<break></break>
emptying: 3 vs 2
<xref ref-type="table-fn" rid="table12-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Willet
<italic>et al</italic>
. [
<xref rid="ref180" ref-type="bibr">180</xref>
] 2005</td>
<td align="left" valign="top" rowspan="1" colspan="1">150 UR-PC
<break></break>
(Resected-0%)
<break></break>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">15–20 Gy</td>
<td align="left" valign="top" rowspan="1" colspan="1">100 (Pre/post-op RT)</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">7 (3Yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Post-operative complications- 20%
<break></break>
Late toxicity- 15%
<break></break>
Upper GI bleed-16
<xref ref-type="table-fn" rid="table12-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Jingu
<italic>et al</italic>
. [
<xref rid="ref176" ref-type="bibr">176</xref>
] 2012</td>
<td align="left" valign="top" rowspan="1" colspan="1">322
<break></break>
Resected-83
<break></break>
Unresectable- 109
<break></break>
Metastatic-130 (exclude)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">20–30</td>
<td align="left" valign="top" rowspan="1" colspan="1">29 (post-op RT)</td>
<td align="left" valign="top" rowspan="1" colspan="1">38</td>
<td align="left" valign="top" rowspan="1" colspan="1">64</td>
<td align="left" valign="top" rowspan="1" colspan="1">9
<break></break>
<italic>R</italic>
2:HR-2.03,
<break></break>
<italic>p</italic>
< 0.001</td>
<td align="left" valign="top" rowspan="1" colspan="1">Late toxicity
<break></break>
GI-4
<xref ref-type="table-fn" rid="table12-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Cai
<italic>et al</italic>
. [
<xref rid="ref174" ref-type="bibr">174</xref>
] 2013</td>
<td align="left" valign="top" rowspan="1" colspan="1">194 UR-PC
<break></break>
(Resected-0%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–25</td>
<td align="left" valign="top" rowspan="1" colspan="1">97% (Pre-op CTRT)</td>
<td align="left" valign="top" rowspan="1" colspan="1">12</td>
<td align="left" valign="top" rowspan="1" colspan="1">38 (3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">6 (3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Acute toxicity- 21%
<break></break>
Late toxicity-14%
<break></break>
Haemorrhage-23
<xref ref-type="table-fn" rid="table12-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Chen
<italic>et al</italic>
. [
<xref rid="ref175" ref-type="bibr">175</xref>
]
<break></break>
2016</td>
<td align="left" valign="top" rowspan="1" colspan="1">247 UR-PC
<break></break>
(Resected-0%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">51% (Post-op CTRT)</td>
<td align="left" valign="top" rowspan="1" colspan="1">10</td>
<td align="left" valign="top" rowspan="1" colspan="1">35 (3yr)
<break></break>
Complete pain relief-70%</td>
<td align="left" valign="top" rowspan="1" colspan="1">7.2 (3yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Post-operative complications-14%
<break></break>
Fistula-11
<xref ref-type="table-fn" rid="table12-fn1">
<sup>*</sup>
</xref>
<break></break>
Haemorrhage- 7
<xref ref-type="table-fn" rid="table12-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Keane
<italic>et al</italic>
. [
<xref rid="ref181" ref-type="bibr">181</xref>
] 2016
<break></break>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">68 UR-PC
<break></break>
After NACTRT
<break></break>
Resected-41 IORT-22 (R1-73%)
<break></break>
No IORT-19
<break></break>
Unresectable-18 (IORT-17)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<break></break>
8–13
<break></break>
15–17</td>
<td align="left" valign="top" rowspan="1" colspan="1">100 % (NACTRT)</td>
<td align="left" valign="top" rowspan="1" colspan="1">21</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<break></break>
35.1 (M.S)
<break></break>
24.5 (M.S)
<break></break>
24.8 (M.S)</td>
<td align="left" valign="top" rowspan="1" colspan="1">No significant difference in post-operative complications</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Kokubo
<italic>et al</italic>
. [
<xref rid="ref172" ref-type="bibr">172</xref>
] 2000</td>
<td align="left" valign="top" rowspan="1" colspan="1">138 R/BR-PC
<break></break>
(Resected-100%,
<italic>R</italic>
1-29%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">20–30</td>
<td align="left" valign="top" rowspan="1" colspan="1">45
<break></break>
(Pre-op:13%
<break></break>
Post op-47%
<break></break>
Both-40%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<italic>R</italic>
0:19
<break></break>
<italic>R</italic>
1:4
<break></break>
<italic>p</italic>
< 0.005
<break></break>
(2-yr cause specific survival)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Acute toxicity- none
<break></break>
Late toxicity-
<break></break>
GI ulcers-20%
<break></break>
Perforation-2
<xref ref-type="table-fn" rid="table12-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Alfieri
<italic>et al</italic>
. [
<xref rid="ref165" ref-type="bibr">165</xref>
] 2001</td>
<td align="left" valign="top" rowspan="1" colspan="1">46 R/BR-PC (Resected-100%)
<break></break>
IORT-26 (R1-10%)
<break></break>
No IORT-20 (R1-13%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">NRC</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<break></break>
100
<break></break>
0
<break></break>
(Post-op)</td>
<td align="left" valign="top" rowspan="1" colspan="1">82</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<break></break>
IORT-58
<break></break>
No IORT-30
<break></break>
<italic>p</italic>
< 0.001</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<break></break>
IORT-16
<break></break>
No IORT-6
<break></break>
<italic>p</italic>
= 0.06</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT vs. No IORT
<break></break>
Acute morbidity-
<break></break>
57% vs. 43% (
<italic>p</italic>
= 0.1)
<break></break>
Perioperative mortality-
<break></break>
8% vs. 9%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Reni
<italic>et al</italic>
. [
<xref rid="ref173" ref-type="bibr">173</xref>
] 2001</td>
<td align="left" valign="top" rowspan="1" colspan="1">127 R/BR-PC
<break></break>
(Resected-82%)
<break></break>
IORT- 127
<break></break>
(
<italic>R</italic>
0-1:104,
<italic>R</italic>
2-23)
<break></break>
No IORT- 76 (
<italic>R</italic>
0-1:62,
<italic>R</italic>
2-14)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–25</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<break></break>
32
<break></break>
20
<break></break>
(Post-op)</td>
<td align="left" valign="top" rowspan="1" colspan="1">21 (in
<break></break>
survivors)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Stage I-II:
<break></break>
IORT-73
<break></break>
No IORT-40
<break></break>
Stage III-IVA:
<break></break>
IORT-50
<break></break>
No IORT-45</td>
<td align="left" valign="top" rowspan="1" colspan="1">Stage I–II:
<break></break>
IORT-22
<break></break>
No IORT-6
<break></break>
Stage III-IVA:
<break></break>
IORT-3
<break></break>
No IORT-5</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT vs. No IORT: Acute toxicity: N.S difference
<break></break>
Chronic toxicity:
<break></break>
Abdominal pain 15 vs. 22%
<break></break>
Late GI bleed-6 vs. 3%
<break></break>
Stenosis-3% vs. 0%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Messick
<italic>et al</italic>
. [
<xref rid="ref169" ref-type="bibr">169</xref>
] 2008</td>
<td align="left" valign="top" rowspan="1" colspan="1">49 R/BR-PC (Resected-100%, R1-74%)
<break></break>
IORT-22
<break></break>
No IORT-27
<break></break>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">NRC</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–12</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<break></break>
76
<break></break>
64</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<break></break>
10.1
<break></break>
13.3</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<break></break>
IORT-82
<break></break>
No IORT-88
<break></break>
(N.S)</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<break></break>
IORT-20 (M.S)
<break></break>
No IORT-13 (M.S)
<break></break>
(N.S)</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT vs. No IORT: Delayed gastric emptying-6.7 vs. 4.2%
<break></break>
Wound infection-4.5 vs. 22%
<break></break>
Pancreatic fistula 10 vs. 4.8% (N.S)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Valentini
<italic>et al</italic>
. [
<xref rid="ref171" ref-type="bibr">171</xref>
] 2008</td>
<td align="left" valign="top" rowspan="1" colspan="1">26 R/BR-PC
<break></break>
Resected-100%,
<italic>R</italic>
1-4%
<break></break>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10</td>
<td align="left" valign="top" rowspan="1" colspan="1">100
<break></break>
(Post-op: 65%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">102 in survivors</td>
<td align="left" valign="top" rowspan="1" colspan="1">57</td>
<td align="left" valign="top" rowspan="1" colspan="1">15</td>
<td align="left" valign="top" rowspan="1" colspan="1">Perioperative
<break></break>
complications-11%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Showalter
<italic>et al</italic>
. [
<xref rid="ref167" ref-type="bibr">167</xref>
] 2009</td>
<td align="left" valign="top" rowspan="1" colspan="1">R/BR-PC
<break></break>
IORT-37 (
<italic>R</italic>
1-2:43%)
<break></break>
No IORT-46 (
<italic>R</italic>
1-2: 30%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–20</td>
<td align="left" valign="top" rowspan="1" colspan="1">74
<break></break>
66
<break></break>
(Post-op RT)</td>
<td align="left" valign="top" rowspan="1" colspan="1">NR</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT-79
<break></break>
No IORT-61
<break></break>
<italic>p</italic>
= 0.19</td>
<td align="left" valign="top" rowspan="1" colspan="1">IORT-21 (M.S)
<break></break>
No IORT-19 (M.S)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Perioperative
<break></break>
complications-46% vs. 40% (N.S)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Valentini
<italic>et al</italic>
. [
<xref rid="ref168" ref-type="bibr">168</xref>
] 2009</td>
<td align="left" valign="top" rowspan="1" colspan="1">270
<break></break>
Resected-81%
<break></break>
(
<italic>R</italic>
1-27%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">ISIORT Pooled analysis</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">7.5–25</td>
<td align="left" valign="top" rowspan="1" colspan="1">64
<break></break>
(pre-op:24
<break></break>
Post-op:40)</td>
<td align="left" valign="top" rowspan="1" colspan="1">96</td>
<td align="left" valign="top" rowspan="1" colspan="1">23
<break></break>
Pre-op RT vs. post-op RT vs. IORT alone
<break></break>
<italic>p</italic>
< 0.0001</td>
<td align="left" valign="top" rowspan="1" colspan="1">18
<break></break>
IORT + Pre-op RT vs. IORT + post-op RT vs. IORT alone
<break></break>
<italic>p</italic>
< 0.0001</td>
<td align="left" valign="top" rowspan="1" colspan="1">Acute toxicity- None > G2
<break></break>
Late-NS</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Ogawa
<italic>et al</italic>
. [
<xref rid="ref170" ref-type="bibr">170</xref>
] 2010</td>
<td align="left" valign="top" rowspan="1" colspan="1">210 R/BR-PC
<break></break>
Resected-100%, R1-32%</td>
<td align="left" valign="top" rowspan="1" colspan="1">Retrospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">20–30</td>
<td align="left" valign="top" rowspan="1" colspan="1">30</td>
<td align="left" valign="top" rowspan="1" colspan="1">26</td>
<td align="left" valign="top" rowspan="1" colspan="1">84 (2yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">42 (2yr)</td>
<td align="left" valign="top" rowspan="1" colspan="1">Late toxicity
<break></break>
GI-7
<xref ref-type="table-fn" rid="table12-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Calvo
<italic>et al</italic>
. [
<xref rid="ref166" ref-type="bibr">166</xref>
]
<break></break>
2013</td>
<td align="left" valign="top" rowspan="1" colspan="1">60 R/BR-PC
<break></break>
(Resected-83%,
<break></break>
<italic>R</italic>
1-43%)
<break></break>
IORT-29
<break></break>
No IORT-31</td>
<td align="left" valign="top" rowspan="1" colspan="1">Prospective</td>
<td align="left" valign="top" rowspan="1" colspan="1">IOERT</td>
<td align="left" valign="top" rowspan="1" colspan="1">10–15</td>
<td align="left" valign="top" rowspan="1" colspan="1">100%
<break></break>
(Pre-op CTRT-32%)</td>
<td align="left" valign="top" rowspan="1" colspan="1">16</td>
<td align="left" valign="top" rowspan="1" colspan="1">58
<break></break>
No IORT:
<break></break>
HR-6.75,
<break></break>
<italic>p</italic>
= 0.01</td>
<td align="left" valign="top" rowspan="1" colspan="1">20
<break></break>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">Perioperative complications-43% (N.S)
<break></break>
Chronic-17%
<break></break>
Neuropathy-4
<xref ref-type="table-fn" rid="table12-fn1">
<sup>*</sup>
</xref>
<break></break>
GI-3
<xref ref-type="table-fn" rid="table12-fn1">
<sup>*</sup>
</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>RCT: randomised control trial, NRC: non-randomised comparison, Sx: surgery, LC: local control, OS: overall survival, DFS: disease-free survival, NR: not reported,</p>
<fn id="table12-fn1">
<label>
<sup>*</sup>
</label>
<p>Number of patients,</p>
</fn>
<p>
<sup>#</sup>
fractions, Pre-op: pre-operative, Post-op: post-operative, M.S: median survival in months, N.S: non-significant, R/BR-PC: resectable/borderline resectable pancreatic cancer, UR-PC: unresectable pancreatic cancer, NACTRT: neoadjuvant chemoradiotherapy, Resected: complete resections (R0/R1), Unresectable: R2/palliative resections.</p>
</table-wrap-foot>
</table-wrap>
</floats-group>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004979 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 004979 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Pmc
   |étape=   Corpus
   |type=    RBID
   |clé=     PMC:5493441
   |texte=   Intraoperative radiotherapy: review of techniques and results
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i   -Sk "pubmed:28717396" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1 

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024